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Abstract 
 
Introduction 
 
There are insufficient data on the epidemiology and clinical features of HIV in the 
Middle East. WHO statistics show the Kingdom of Saudi Arabia (KSA) to be one of 
the least affected countries globally. However, the Saudi National Program for HIV 
Control reported a 34.6% increase in cases in 2008 from the previous year. Jeddah 
region has the highest proportion of HIV cases in KSA (40%). Infection risk data are 
not always complete and coinfection rates have not been studied. The first part of 
these studies included a retrospective longitudinal case review of all patients 
attending the Jeddah clinic to obtain a clearer view of clinical and epidemiological 
features of that population 
 
There are few publications about resistance to antiretroviral therapy (ART) in the 
Arabian Peninsula, including KSA, and most are heavily biased towards assessment 
of patients with sequential treatment failure. Wider access to resistance testing has 
only become available recently and baseline local resistance patterns are largely 
unknown. The aim of the second part of the study was to determine patterns of 
ART resistance in a systematic fashion in treatment-naïve HIV positive Saudi 
patients and to document the presence and frequency of novel resistance HIV 
markers in Jeddah.  
 
Study Part 1. Clinical features and epidemiology of HIV and coinfection 
with TB and/or viral hepatitis in a large clinic in Jeddah, Kingdom of Saudi 
Arabia 
 
Aims: To describe demographic and clinical features of HIV infection in clinics and 
hospitals in Jeddah and to document prevalence and risks for coinfections with 
tuberculosis (TB) and/or hepatitis 
 
Methods: Retrospective study including all HIV positive Saudi adults attending the 
main treatment centre in Jeddah in the 11 years (2000-2010). Data were 
systematically collected from case files and summarised. Statistical comparisons 
included univariate analyses with a p value <5% considered significant. 
 
Results:  1383 HIV positive adults were reviewed, median (range) age 40 (18-86) 
years, of whom 1026 (74.2%) were male. Risk factors included heterosexual 
transmission in 709 (51.3%), men having sex with men (MSM) in 264 (26%), blood 
products in 148 (10.7%), injecting drug use (IDU) in 97 (7%) and not identified in 
165 (11%). The predominant clinical presentation was with respiratory symptoms 
611 (44%), followed by gastrointestinal manifestations in 312 (22%), while 29% 
(408) were asymptomatic. Past or present TB coinfection (clinical and/or radiology) 
was found in 208 (15%); 59 (5.3%) had hepatitis B serology positive (HBsAg 
positive) and 82 (7.4%) had hepatitis C coinfection (antibody positive). TB was 
associated with IDU (RR 1.67 (CI 1.13-2.41) p< 0.01) and having been in prison 
(RR 1.83 (1.18-2.85) p< 0.01) and these two risk factors were closely linked 
themselves. HBV coinfection was not linked with IDU (RR 1.89 (0.93-3.85) p=0.08) 
but was linked to being in prison (2.38 (1.25-4.54) p <0.01), while HCV was 
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strongly linked with IDU (RR 4.22 (2.71-6.57) p<0.01) and MSM but not with 
imprisonment (RR 1.94 (1.04-3.63) p=0.07)   
 
Conclusion:  
 
HIV/AIDS and related coinfections are medical problems in Saudi Arabia with many 
social challenges. The Saudi National Program for HIV Control actively addresses 
prevention of HIV and provision of high quality care for those affected. More 
detailed studies are needed on clinical patterns in outpatient and inpatient settings 
and on locally appropriate prevention programmes in high risk groups. 
 
Study Part 2. HIV resistance in ART naïve patients in a large treatment 
centre in Jeddah, Kingdom of Saudi Arabia 
 
Aims: To document the prevalence and types of ART resistance in ART naïve HIV 
patients in Jeddah, and to compare the efficacy of Next Generation Sequencing 
(NGS) with standard (Sanger) genotypic methods. 
 
Methods: Plasma samples were collected from all ART-naïve patients sequentially 
attending the HIV clinic at King Saud Hospital, the main HIV treatment centre in 
Jeddah, between November 2012 and February 2013. Plasma was saved and HIV 
protease (Prot) and reverse transcriptase (RT) regions were sequenced according to 
routine in-house diagnostic protocols (Sanger) at Liverpool Specialist Virology 
Centre. The Stanford database was used for interpretation of resistance profiles. 
Neighbour-joining phylogenetic analysis was performed on samples with adequate 
sequence data for both Prot and RT. NGS sequencing was later performed at the 
Public Health England reference laboratory in Colindale. 
 
Results: Blood samples were collected from 109/116 (94%) eligible patients 
approached to join the study. 71 (65%) were male and 52 (48%) had been 
diagnosed with HIV within the last 6 months. HIV RNA was successfully amplified 
from 96, and sequence data obtained from 93 Prot amplicons and 87 RT amplicons 
by Sanger and 105 by NGS. Mutations at putative resistance sites for NNRTI NRTI 
and PI were detected by Sanger in 9/87 (10.3%), 1/87 (1.1%) and 6/93 (6.5%) 
and 24/105 (22.9%), 6/105 (5.7%) and 34/105 (32.4%) respectively by NGS. 
Those with significant potential to confer resistance to NNRTI were found in 9/87 
(10.3%), with resistance to NRTI in 1/87 (1.1%) and PI in 6/93 (6.5%). 4.5% of 
the samples showed resistance to efavirenz and nevirapine. The most common HIV-
1 subtype was C (38%); although a cluster of CRF2_A (7%) was also prominent.  
 
Conclusion: Clinically significant resistance is emerging (16 %) in this population. 
A variety of other markers included some clustering suggesting local transmission 
of primary resistance. The results are probably generalizable in KSA and we 
recommend the introduction of routine resistance testing for all HIV positive 
patients in the region before starting ART.   
 
Overall: 
These findings provide evidence for introduction of several changes to enhance the 
National HIV/AIDS programme in the Kingdom of Saudi Arabia. 
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1. 1. Introduction: 
  
1.1.1 Global view  
 
The HIV/AIDS pandemic is one of the most important medical problems 
globally over the past 30 years. The Human Immunodeficiency Viruses 
(HIV) are retroviruses of simian origin that transcribe ribonucleic acid 
(RNA) into cell deoxyribonucleic acid (DNA) and integrate the genome 
in the human host. There are two main HIV types which cause human 
disease: HIV-1 and HIV-2. 
 
Phylogenetic sequence analysis from apes and humans suggest that 
the infection and transmission of HIV to humans started as early as 
1930. 50 years later the first case of HIV/AIDS was described in 1981 
in the US (Centers for Disease Control (U.S.) 1981). HIV/AIDS had 
been recognised in all world regions by 1985 (Peters et al. 2013). 
 
Infection is spread by sexual contact, transfusion of blood products or 
organs, by needles in healthcare practice or by injecting drug use (IDU) 
and from mother to child. Once HIV enters the host CD4+ T-
24 
 
lymphocyte, it converts its RNA to DNA by using reverse transcriptase 
enzyme. The cell is then used to produce more HIV viruses and the 
cycle continues. As infection progresses, the number and function of 
the CD4 cells decreases and the amount of HIV in the body increases. 
The person becomes increasingly susceptible to infections, some of 
which are otherwise rare, and to a variety of tumours and metabolic 
problems. This late stage of HIV infection is often known by its earlier 
title AIDS, or Acquired Immunodeficiency Syndrome (AIDS). Without 
specific treatment, AIDS is fatal although the time to progression varies 
in different people. 
 
The rates of new HIV infections affect some world regions more than 
others, predominantly in central Asia, Sub-Saharan Africa and Eastern 
Europe. Globally, Africa continues to be the most affected region, with 
increasing rates in Asia. HIV/AIDS has a strong impact on individual 
patient’s social life, economy and development and a huge social and 
economic impact on countries in which it has increased. Efforts against 
HIV/AIDS should continue and should be focused to control this global 
threat (Piot et al. 2001). 
 
The introduction of antiretroviral therapy (ART) has dramatically 
improved the clinical management of HIV/AIDS patients. Studies 
performed soon after introduction of Highly Active Antiretroviral 
Therapy (HAART) with three classes of antiretroviral drugs (ARV) in 
25 
 
1996 showed a remarkable decline in mortality and morbidity of up to 
85% in treated patients ( Palella et al. 1998; Flepp et al. 2001). 
In 2013, the World Health Organization (WHO) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) estimated that globally 
there were 35.3 million people living with HIV (PLWHIV). In the same 
year, there were  2.3 million newly diagnosed HIV/AIDS cases (UNAIDS 
2013). 
 
 
 
Figure (1-1) Global HIV/AIDS numbers in 2011 (UNAIDS 2013) 
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1.1.2 Regional view 
 
In the Middle East and North Africa (MENA) data on the epidemiology 
of HIV/AIDS and behavioural and social information are incomplete and 
need to be improved for better understanding of the situation and to 
inform quality prevention and treatment programmes. Although several 
countries have taken forward steps to improve HIV information 
systems, passive reporting remains the primary mechanism for 
obtaining evidence on epidemiological and behavioural trends in the 
region (Shawky, Soliman & Sawires 2009). This study also reflected the 
effect of social constraints on the HIV/AIDS situation in the MENA 
region. In conservative societies found in Saudi cities, men are more 
independent than women and thus, men are more able to experience 
sexual relations than women. This may explain the predominant male 
gender bias in HIV in the Region. Women face many barriers to 
accessing accurate information about HIV, because in this society they 
are not allowed to be sexually experienced. Societal ideals for relations 
between women and men may increase the risk for of infection for both 
genders. However, in the last 5 years the female to male ratio has 
increased, possibly because of improved cultural mobility and as a 
result of effective reachout of local HIV programmes. In addition, 
improvements in the systems of notification and surveillance in the 
Region have started to reflect the true local prevalence of HIV 
infections. 
27 
 
There is particularly little information about HIV in the Middle East. 
Until recently, most countries in the Region suppressed information 
about HIV. In the past this was particularly because HIV was presented 
to the population as a disease caused by bad sexual morals. In 
addition, HIV testing has been considered a very sensitive issue 
especially in monitoring high risk groups such injecting drug use (IDU) 
and men who have sex with men (MSM), which limits screening 
strategies in this region (Obermeyer 2006). His review of HIV/AIDS was 
performed in 2006 and concentrated on the whole MENA region, 
ignoring the important detail that societies in the Middle East are 
culturally very different from those in North Africa.  Furthermore, there 
are many cultural differences within the Middle East Region itself.   
With development of life-saving therapy over the past decade or more, 
some countries in the Region have acknowledged the importance of 
examining various aspects of HIV in their own setting. This includes 
identifying local risk behaviour and high risk groups, the social 
behaviour of these groups and the responses of doctors and other 
health care workers. 
 
Moussavi et al studied knowledge about HIV/AIDS in Iranian 
adolescents in 2007 and showed that they form a particularly 
important target group for primary prevention of HIV in the 
community. The study was carried out by anonymous questionnaires 
administered to 1227 Iranian students. The students reported that 
28 
 
television (84%) and school teachers (66%) were the best sources of 
HIV/AIDS information, while parents (27%) and school books (15%) 
were least informative. Most students knew that heterosexual 
intercourse (90%) and shared intravenous needles (94%) can cause 
HIV infection; however, many misconceptions were revealed. Only 
53% were aware that condoms protect against infection through 
sexual intercourse. More effective school-based HIV/AIDS education is 
needed in Iran. This study identified misconceptions about viral 
transmission and the availability of a cure that highlights the need for 
further HIV/AIDS prevention among adolescents. Descriptive results 
contribute to a larger process by which barriers of silence are broken 
and foundations provided for targeted interventions. Future studies in 
Iran must take into consideration the ways in which cultural and 
religious value systems impact on lifestyle and access to information. 
Schools are particularly useful settings for HIV/AIDS interventions 
because they provide an existing community based infrastructure, 
while reaching a sizeable target population during a critical period. 
(Moussavi et al 2007) 
In 2013 a similar study in Turkey assessed the knowledge about 
HIV/AIDS in two high schools in Kırıkkale, Turkey (Aylikçi et al. 2013). 
Most of the 473 students (92.2%) had some knowledge about 
HIV/AIDS prior to the study. 27% believed that there is a cure for 
AIDS and 64% believed that HIV can be avoided by using condoms 
during sexual contact (Aylikçi et al. 2013). 
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In 2014, Al-Malki published an interesting study looking at the 
knowledge of STI among students at Taif University, Saudi Arabia. All 
400 participants were adults aged 18-30 year old.  27.7% obtained  
their knowledge about sexually transmitted infections (STI) from the 
internet. 36.8% knew that an infected mother could transmit a sexual 
disease to her infant during labour. The vast majority of students 
(98.5%) were aware of HIV/AIDS as a STI. This study also showed 
associations of better understanding of STI with being married and 
having a good parental educational level. The study concluded that 
education and religious programmes should be given early on in 
secondary schools.  In addition, premarital screening is important for 
controlling STI in the kingdom (AL-Malki 2014). This study reflected 
the knowledge of a specific group and cannot be generalised over the 
different populations in the Kingdom. Even though this study 
examined some aspects of knowledge among these students, more 
critical questions could have been asked especially about high risk 
sexual behaviours in such a restricted and conservative society.  
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In the Kingdom of Saudi Arabia (KSA), there has been a major change 
in official attitudes. The Ministry of Health (MOH) has established a 
comprehensive programme for monitoring the epidemiology of 
HIV/AIDS and for publishing the data in an open format. Treatment 
centres and management protocols have been established in every part 
of the Kingdom.  Public information and prevention programmes have 
continuously been introduced. 
 
However, there has been little assessment of the clinical features or the 
effects of coinfection with other pathogens such as hepatitis B (HBV) or 
C (HCV) or tuberculosis (TB) and there are no published data on clinical 
audit. Very few data are available in the whole Region or the Kingdom 
about resistance to antiretroviral regimens, which is essential to guide 
treatment policies. 
     
The treatment centre with the largest population of HIV positive 
patients is in Jeddah (Kabbash et al. 2012). In addition, risk factors 
such as injecting drug use (IDU) are known to be present in Jeddah, 
although several studies have previously shown a relatively low 
prevalence of HIV in these patients (Kabbash et al. 2012).   
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1.1.3 Aims: 
The main aims of this work were to: 
1. Review the epidemiology of HIV in the Middle East and in 
particular in the Kingdom of Saudi Arabia (KSA). 
2. Review Regional and KSA data on coinfection of HIV with 
hepatitis B, C and tuberculosis. 
3. Describe the clinical presentation, demographic features and 
rates of coinfection in a large outpatient HIV clinic in Jeddah. 
4. Investigate the prevalence and types of primary resistance to 
antiretroviral therapy in HIV positive patients in Jeddah.      
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1.2. Literature Review  
 
This chapter provide a brief review of the global epidemiology of 
HIV and then detailed review of HIV in Arabian Peninsula. The 
review includes recent data on HIV epidemiology in the Region 
and in the Kingdom of Saudi Arabia. World regions were defined 
according to the WHO definition (UNAIDS 2013). 
 
WHO HIV/AIDS surveillance  
A wide range of surveillance methods and indicators have been used 
to monitor the HIV/AIDS epidemic by WHO in developing countries. 
These include measures of disease occurrence (HIV incidence and 
prevalence indicators) as well as indicators of risk and impact. 
• Passive surveillance: This is the routine reporting of cases of 
diseases reaching health care facilities for treatment or service. 
No special effort is made to find unsuspected disease incidence.  
• Active surveillance: A search is conducted to find cases in the 
community, mainly through door-to-door surveys or by 
targeting specific high risk populations. This method also 
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includes the gathering of information from institutions and 
healthcare providers. 
• Sentinel surveillance: This is a reporting system based on 
selected institutions or people who provide regular, complete 
reports on one or more diseases, ideally occurring in a defined 
attachment format. 
The WHO has promoted sentinel surveillance as the method of choice 
for monitoring the spread of HIV in developing countries (Riedner & 
Dehne 1999). In addition, the occurrence of other infections has 
occasionally been used as a surrogate indicator of HIV spread in these 
countries. Therefore, surveillance of sexually transmitted infections 
(STI) and HIV associated diseases such as TB and herpes zoster 
(HZV) have been used as HIV infection markers in some populations 
(Riedner & Dehne 1999).  
Surveillance in developing countries includes HIV and AIDS case 
reporting, sentinel sero-surveillance, and STI and behavioural 
surveillance (Riedner & Dehne 1999) 
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1.2.1 Global epidemiology. 
 
The global prevalence of HIV-1 is 0.8%, this includes 34 million 
people living with HIV/AIDS and 1.7 million AIDS deaths in 2011 
(UNAIDS 2011).  
 
 Estimate  Range  
People living with HIV/AIDS 34 million  31.4 – 35.9 million  
Newly infected patients 2.5 million  2.2 -2.8 million  
HIV/AIDS deaths  1.7 million  1.5 -1.9 million  
 
Table (1-1) Global HIV estimates for 2011 (UNAIDS 2013) 
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WHO estimates for the epidemiology of HIV/AIDS according to the 
Region are summarised in the table (1-2). 
Region PLWHIV Newly infected  Prevalence  AIDS deaths 
Sub-Saharan Africa 23.5 million 1.8 million 4.9% 1.2million 
North Africa and Middle East  300,000 37,000 0.2% 23,000 
South and South East Asia 4 million 280,000 0.3% 250,000 
East Asia 830,000 89,000 0.1% 59,000 
Oceania 53,000 2,900 0.3% 1,300 
Latin America 1.4 million 83,000 0.4% 54,000 
Caribbean 230,000 13,000 1.0% 10,000 
East Europe and Central Africa  1.4 million 140,000 0.2% 92,000 
North America  1.4 million 51,000 0.6% 21,000 
Western and Central Europe 900,000 30,000 0.2% 7,000 
Global Total 34 million 2.5 million 0.8% 1.7 million 
  
Table (1-2) Global HIV/AIDS epidemiology in 2011 (UNAIDS 2013) 
 
The heterosexual route remains the most common mode of 
transmission in addition to male to male sex (MSM) and injecting drug 
use (IDU).  The rates of new HIV infections are generally declining in 
most of the world’s Regions but are increasing in certain Regions such 
as in Eastern Europe and central Asia. 
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1.2.1.1 ASIA: 
 
Asia is the largest continent, with almost 60% of the global population. 
It has the second highest number of people living with HIV/AIDS after 
Africa. WHO UNAIDS estimated that 370,000 newly diagnosed HIV 
patients were living in East Asia in 2011 compared with 310,000 in 
2001 (UNAIDS 2013) but this number has dropped to 280,000 newly 
diagnosed patients in 2013 (UNAIDS 2013)   
 
1.2.1.2 Sub-Saharan Africa  
The largest burden of HIV has been in Sub-Saharan Africa, accounting 
for around three quarter of the global death toll so far. The epidemic 
emerged in 1980’s and in contrast to certain settings was largely 
spread by heterosexual sex and from mother to child at birth or in 
infancy. It was accompanied by a huge rise in tuberculosis cases in 
the 1990’s. Mortality was high due to poor health infrastructure and 
lack of treatment in many countries. By 2001 there were 21 million 
PLWHIV which increased to 25 million in 2012 (UNAIDS 2013). 
However, there has been a drop in the number of newly diagnosed 
patients from 2.4 million in 2001 to 1.2 in 2012 (UNAIDS 2013). 
The peak age group of diagnosis is younger in women than in men, 
and the prevalence of HIV in all young adults was estimated at 4.9% 
across the region in 2011. The incidence and epidemiology differ 
generally from North African setting, although there is an intermediate 
situation in the Sudan, close to KSA   
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1.2.1.3 East Europe and Central Asia 
Eastern Europe and Central Asia is the only region where HIV 
prevalence clearly remains on the rise. UNAIDS estimated 1.4 million 
PLWHIV in this region (UNAIDS 2013). 110,000 newly diagnosed 
cases in 2008 (UNAIDS 2008) had increased to 140,000 in 2012 
(UNAIDS 2013). 
 
1.2.1.4 Middle East and North Africa (MENA) 
 
In general the prevalence of HIV/AIDS prevalence in the Middle East 
and North Africa (MENA) Region is low. However, even in areas of low 
prevalence, at-risk populations in those countries may be heavily 
affected by the HIV epidemic (Abu-Raddad & Longini 2008). 
Up to the present there has been little dissemination of information 
about HIV in the Middle East, as many countries in the Region used to 
suppress related data about HIV within their countries. 
The most recent estimate of the number of people living with 
HIV/AIDS in the Middle East and North Africa region is about 260,000 
in 2012 (UNAIDS 2013); the accuracy of this estimate is low because 
of poor and incomplete data. Publications from this region were 
limited especially from the Middle East countries and HIV/AIDS data 
were collected by notifying the cases as a part from the official HIV 
reports to WHO. 
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Country Year Prevalence  PLWHIV AIDS 
deaths 
Reference  
Middle East & 
North Africa 
2013 0.1% 260,000 17,000 (UNAIDS 2013) 
Bahrain 2010 0.2% (2008) NA NA (UNGASS Country Progress Report 2010) 
Emirates 2012 0.2% (2008) NA NA (UNAIDS 2008) and (UNGASS Country 
Progress Report 2012) 
Iran 2013 0.2% 71,000 4,600 (UNAIDS 2013) and (UNGASS Country 
Progress Report 2012) 
Iraq 2008 0.1%  NA NA ( UNGASS Country Progress Report 2008) 
Israel 2011 0.2% 3875 832 (WHO, key facts on HIV epidemiology  in 
Israel and progress  2011) 
Jordan 2011 0.2% 8,500 25 (WHO, KEY FACTS ON HIV EPIDEMIC IN 
ISRAEL AND PROGRESS  2011) 
Kuwait 2010 0.1% 600 500 (UNGASS Country Progress Report 2010) 
Lebanon 2013 0.1% NA NA (UNAIDS 2013) 
Oman 2012 0.1% 3,000 200 (UNGASS 2012) 
 2013 0.1% 1,371 200 (UNAIDS 2013) and (UNGASS Country 
Progress Report 2012) 
Qatar 2013 0.1% NA NA (UNAIDS 2013) 
Saudi Arabia 2014 0.1% 20,539 NA (UNGASS Country Progress Report 2014) 
Syria 2008 0.1% 500 200 (UNGASS Country Progress Report 2008) 
Yemen 2013 0.1% 19,000 NA (UNAIDS 2013) 
Other  Islamic Countries 
Egypt 2013 0.1 9,200 500 (UNAIDS 2013) 
Sudan 2010 1.4 77,000 
(2013) 
25,000 (UNGASS Country Progress Report 2010) 
and (UNAIDS 2013) 
Turkey 2010 0.1 N.A N.A (UNGASS Country Progress Report 2010) 
 
Table (1-3) HIV data in the Middle East and selected neighbouring countries 
(various sources) 
PLWHIV: People live with HIV 
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The HIV-related literature in the Region is patchy, emphasising the 
paucity of systematic surveillance efforts and the difficulty of 
enhancing activities that reduce risks, together with the challenges to 
measuring the HIV/AIDS epidemic in societies in this Region. There is 
also a need to ensure that diagnostic and therapy strategies are 
following best international practice. 
In order to obtain a clearer picture of the epidemiology and clinical 
presentation of HIV and antiretroviral resistance in the Region a 
systematic literature review was performed. Large databases 
(PubMed, Scopus, Google Scholar and CINAHL) were investigated 
using a wide search strategy for the period 1981 to 2014.  
Combinations of keywords included HIV, AIDS, drug misuse, ART, 
ARV, coinfections, TB, hepatitis, HIV treatment naïve, resistance 
together with geographical terms such as Middle East, Saudi Arabia 
and each country in the Middle East and North Africa (MENA) WHO 
Region. The WHO website and UNAIDS websites were also consulted 
for any references to HIV and to ART resistance. Abstracts were 
initially reviewed, the relevant papers and reviews were obtained and 
the reference lists were consulted to identify further sources. The 
content indexes of regional scientific journals were also reviewed 
including the Saudi Medical Journal, Annals of Saudi Medicine and 
Journal of Infection and Public Health. Furthermore, the websites of 
the Ministry of Health (or equivalent) for each country were reviewed 
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to obtain reports related to HIV epidemiology or treatment. These 
reports were then reviewed.   
The review started at the beginning of work and was repeated in 
March 2015 to include more recent publications. 
1493 results were found in the following databases: PubMed (749), 
Google Scholar (482), Scopus (213) and CINAHL (49). 1365 of the 
total results were excluded after reading the abstract mostly because 
they were individual case reports or did not contain relevant 
epidemiological or virological data. Of the remaining 78, 37 were not 
suitable or relevant to this review study. Suitable results from 41 
studies were included (Table 1-4). 
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1943 total review results 
 
 
 
 
 
 
 
 
 
 
 
PubMed (749) , Google  
Scholar (482) Scopus (213)  
and CINAHL (49) 
 
 
 
 
 
 
 
 
1365 of the total results were 
excluded 
 
 
 
 
 
 
 
 
 
 
1365 of the total results were  
excluded after reading the  
abstract mostly because they  
were individual case reports 
or did not contain relevant  
epidemiological or virological 
data 
 
 
 
 
 
78 remaining results  
 
 
 
 
 
 
 
37 were not suitable or 
relevant to  
this review study 
 
 
 
41 studies were included 
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Country or region Year of 
publication 
Authors 
Bahrain 1994 Al-Haddad et al 
Bahrain 1997 Al-Haddad et al. 
Bahrain 2002 Ehrahim et al 
Bahrain 2014 Saeed et al. 
Iran 2009 Fallahzadeh et al. 
Iran 2012 Rahimi-Movaghar et al. 
Israeli Arab 2005 Chemtob et al. 
Israel (Palestine) 2004 Chemtob et al. 
Israel (Palestine) 2013 Mor 
Israel (Palestine) 2014 Zohar et al. 
Jordan 2010 Bakri et al. 
Kuwait 2000 Al-Owaish et al. 
Kuwait 2012 Akhtar et al. 
Lebanon and Suadi Arabia 2005 Al-Mazrou et al. 
Lebanon and Suadi Arabia 2006 Traboulsi et al. 
Lebanon 2010 Naba et al. 
MENA 2004 Sufian 
MENA 2006 Obermeyer 
MENA 2009 Shawky et al. 
MENA 2011 Mumtaz et al. 
MENA 2014 Bozicevic et al. 
Morocco 2008 Ministry of Health HIV Report 
Oman 1999 Scrimgeour et al. 
Oman 2012 Balkhair et al. 
Oman 2004 Al Dhahry et al. 
Saudi Arabia 1993 Ellis et al. 
Saudi Arabia 2004 Alrajhi 
Saudi Arabia 2004 Madani 
Saudi Arabia 2004 El-Hazmi 
Saudi Arabia 2005 Al-Mazrou et al. 
Saudi Arabia 2010 Al-Jabri et al. 
Saudi Arabia 2010 Alothman et al. 
Saudi Arabia 2010 Jamjoom et al. 
Saudi Arabia 2012 Kabbash et al. 
Syria 2013 Seal 
Turkey 2009 Alim et al. 
Turkey 2013 Aylikçi et al. 
Turkey 2014 Agacfidan 
UAE, Dubai 2011 Al-Dabal et al. 
Yemen 2007 Lambert 
Yemen 2014 Mirzazadeh et al. 
 
Table 1-4 Publications used in this review of epidemiology of HIV in MENA 
region 
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In 2011, 14 countries from the MENA region reported 4263 new HIV 
cases of which 66.8% were men. Heterosexual sex was the most 
common reported route of transmission. This could be due to under 
reporting of male-to-male transmission and more frequent testing of 
men than women (Bozicevic, Riedner & Haghdoost 2014). This paper 
reviewed the country reports to WHO about HIV/AIDS overview from 
the countries in the Eastern Mediterranean Region (WHO EMR). Most 
of these countries depend on passive surveillance for HIV data 
reporting to WHO. However, the Saudi National AIDS Programme 
(NAP) enhanced active surveillance, targeting high risk groups and 
certain populations in the community (NAP 2014).    
 
 
HIV/AIDS transmission in the region is also recognised in certain high 
risk groups such as injecting drug users (IDU) and in men having sex 
with men (MSM),  but heterosexual transmission is still the most 
common route of infection reported in the MENA WHO region 
(Obermeyer 2006). 
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Country Year IDU MSM  Prisoners  Reference  
Bahrain 2011 0.3% NA NA (UNAIDS 2011) 
Egypt 2013 6.7% 4.1% NA (UNAIDS 2013) 
Emirates 2013 NA NA NA (UNAIDS 2013) 
Iran 2013 13.6% 15.9% 2.0% (UNAIDS 2013) and (UNGASS Country Progress 
Report 2012) 
Iraq 2013 NA NA NA (UNAIDS 2013) 
Israel 2011 10.2% 36.7% NA (WHO, KEY FACTS ON HIV EPIDEMIC IN ISRAEL 
AND PROGRESS  2011) 
Jordan 2010 2.0% NA NA (UNGASS Country Progress Report 2010) 
Kuwait 2013 NA NA NA (UNAIDS 2013) 
Lebanon 2012 5.7% 20.0% NA (UNGASS 2012) 
Oman 2013 1.1% 
(2013) 
14.1% NA (UNAIDS 2013) and (UNGASS Country Progress 
Report 2012) 
Qatar 2013 NA NA NA (UNAIDS 2013) 
Saudi 
Arabia 
2014 NA NA 1.6% (UNGASS Country Progress Report 2014) 
Syria 2013 0.5% NA NA (UNAIDS 2013) 
Turkey 2014 NA 8.9% NA (Agacfidan 2014)   
Yemen 2013 NA 5.9% NA (UNAIDS 2013) 
 
Table (1-5) Prevalence of high HIV in risk groups in some Middle East and North African 
countries (IDU, Injecting drug users, MSM, men who have sex with men) 
 
 
There are usually two known epidemiological patterns of HIV/AIDS 
transmission in the Middle East and North Africa. First, patients are 
infected with HIV while they are travelling out of the country and they 
then transmit to their sexual partner. The second is transmission 
within high risk populations, which also leads to sexual partner 
infection. In the early years of HIV epidemic in the region, 
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transmission occurred in recipients of blood products including renal 
patients, haemophiliacs and others (Madani 2004).   
 
Most countries in the MENA region are still slow to develop optimal 
HIV/AIDS strategies and treatment programmes. Although 
antiretroviral therapy (ART) is provided at low cost or even in some 
countries free of charge, only about 5% of those who needed the 
therapy in MENA region were actually receiving it by the late 2005 
(Obermeyer 2006).  Only 14% of those needing antiretroviral therapy 
had received treatment during 2008 and treatment coverage in the 
region was less than 50% of the international  average for low and 
middle income countries (WHO, UNCF, UNAIDS, 2009). However, this 
does not apply in all countries of the MENA Region especially in 
resource rich countries like Saudi Arabia and the Arabian Gulf states. 
ART is provided to all diagnosed HIV patients free of charge in 
addition to providing full medical care. It is, therefore, important to 
differentiate between resource rich countries and resource poor 
countries in the Region.     
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But there have been some improvements in some parts of the Region. 
For example, HIV counselling and testing in Yemen had increased 18 
times in 2006 compared to the previous year (UNGASS country 
progress report 2007). In the Morocco also counselling and testing for 
HIV had increased according to Morocco Health Ministry HIV report in 
2008, increasing about 24 times from 1500 people in 2001 to 35458 
people in 2007.  
 
 
 
Figure (1-2) Reported HIV cases in MENA (new, AIDS cases and deaths) 
from 2001-2012 (UNAIDS 2013) 
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No country in the MENA Region has performed fully systematic 
surveys of HIV prevalence and incidence. In 2003 the World Bank 
reported that the assumed data of low rates of HIV/AIDS in the 
Middle East and North Africa led to underestimation of the real state 
of the problem. As a result, authorities in these countries gave a lower 
priority to HIV/AIDS. It was recommended that efforts should be 
made to improve HIV data and studies to reflect the actual situation, 
in order to achieve the best for the HIV population in this area (Sufian 
2004) 
In addition, data and literature on HIV/AIDS in Arab populations is 
very limited. Discussion of subjects related to HIV/AIDS is highly 
sensitive in this society and this is considered to be the main cause of 
the data shortage in this region.  However, in the past 5 years, the 
quantity and quality publications of HIV/AIDS data in the region have 
improved. Moreover, many national plans and international 
cooperations have been initiated to improve medical strategies in 
fighting HIV. 
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1.2.2.1 Bahrain 
 
Al-Haddad et al reviewed 241 male IDU patients followed at the drug 
rehabilitation clinic of the Psychiatric Hospital in Manama, Bahrain for 
a year (Al-Haddad et al. 1994). They looked at the risk factors for HIV 
infection among the IDU. Patients provided demographic and 
behavioural information based on a questionnaire. 21 % of IDU 
patient were HIV positive (Al-Haddad et al. 1994), much higher than 
the 0.3%reported in 2011 (UNAIDS 2011) 
 
Three years later, Al-Haddad et al reviewed all HIV patients in Bahrain 
within the period from 1986 to 1996. There were 378 HIV diagnosed, 
of which 51% were foreign nationals. 38.8% of Bahraini HIV patients 
were IDU and the heterosexual route of transmission found in 45.7%. 
The male to female ratio for Bahraini nationals was 10:1 (Al-Haddad, 
Baig & Ebrahim 1997).  
 
Pneumocystis jirovecii pneumonia was the commonest (50%) 
opportunistic infection (OI) , followed by tuberculosis (21%). This was 
one of the earliest OI reviews of HIV in Bahrain and in the whole 
Region. Only 378 patients were included and more than half were 
non-nationals (Al-Haddad, Baig & Ebrahim 1997). 
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Ehrahim et al from the Arabian Gulf University, Manama, Bahrain 
studied the microbial infections most commonly found in Bahraini HIV 
patients. They reviewed 67 HIV positive Bahraini patients seen 
between May 1997 and November 1998 retrospectively. 31.3% of 
patients had a CD4 count less than 100 cells/mm3, 7.5% had CD4 
100-200 cells/ mm3, 37.3% had 201-500 cells/ mm3 and 23.9% had 
counts greater than 500 cells/ mm3. Staphylococcus epidermidis was 
found in 14.3%, Pseudomonas aeruginosa infection in 9.5% and 
Haemophilus influenzae infection found in 9.5%.  Pneumocystis 
jirovecii was found in 9.5% and herpes simplex in 4.8 % (Ehrahim et 
al. 2002). 
 
In 2014 Saeed et al reviewed opportunistic infections in HIV positive 
patients in Bahrain over 4 years. This retrospective study was based 
on laboratory records from a major hospital in Bahrain, from January 
2009 to May 2013. Staphylococcus aureus was the commonest 
infections (9.8%) and TB infection was present in 3.6%. Pneumocystis 
jirovecii pneumonia (PCP) was observed in 5.1% (Saeed, Farid & 
Jamsheer 2014).  
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1.2.2.2 Iran 
 
In another neighbouring Islamic country, Iran, considerable data have 
been published, including especially data on high risk groups such as 
prisoners and IDU. Fallahzadeh et al reviewed the HIV/AIDS data in 
Iran between 1986 and 2006, stating that “surveillance of HIV/AIDS in 
Iran has faced many challenges, such as under-reporting and 
difficulties in reaching high-risk groups, leading to an inaccurate and 
incomplete epidemiological profile” (Fallahzadeh, Morowatisharifabad 
& Ehrampoosh 2009). 
 
Rahimi et al reviewed many studies in Iran and estimated the 
HIV/AIDS prevalence in IDU over the period of ten years starting from 
1998. 22 studies were reviewed and this included a total of 3916 IDU. 
10 studies were done in prisons and the other 12 studies were 
conducted in medical centres. The systematic review found that 
HIV/AIDS prevalence among IDU had increased after 2005 to 18.4% 
compared to 8.7% before 2005. They recommended improving HIV 
reduction strategies for such patients (Rahimi-Movaghar et al. 2012). 
However, this study, like many others in Iran, concentrated on one 
high risk group (IDU). Therefore the results cannot be generalised for 
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all HIV patients in Iran and more studies are needed to include all risk 
groups for HIV infection.  
 
In 2013 the prevalence of HIV in Iran was 0.2% with 71,000 PLWHIV 
and 4,600 deaths due to HIV infection (UNGASS Country Progress 
Report 2012; UNAIDS 2013) 
 
1.2.2.3 Jordan 
 
There are few data on HIV in Jordan, UNAIDS has estimated that 
there were about 2000 people liveing with HIV/ (UNAIDS 2010). 
Figure 1-3 summarises the modes of HIV transmission in 194 patients 
in Jordan 1996-2008 (Bakri et al. 2010). This study showed the most 
common route of HIV transmission to be heterosexual, in keeping 
with other countries in the Region. Transmission by transfusion of 
blood or blood products was found in about 30% of the cases from 
1996 to 2008. This proportion has fallen since then, as in the recent 5 
years all blood donors in Jordan and other Middle East countries are 
tested for HIV before donation. The proportion of MSM in this study 
may be underestimated or hidden for various social and religious 
reasons. Further studies were recommended with a large and more 
representative sample size to reflect the actual prevalence and routes 
of transmission of HIV/AIDS in this country.      
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Figure (1-3) Modes of HIV transmission among 194 Jordanian patients (Bakri 2010) 
HT, heterosexual; MHSM, men having sex with men; IVD, intravenous drugs; PN, perinatal 
 
 
 
1.2.2.4 Kuwait 
 
In 2000 Al-Owaish et al found that of 1984 HIV patients in Kuwait, 
76% were in the age group 15-34 years. Their study indicated that 
reported HIV/AIDS cases in Kuwait had increased over the time. 
They also showed that 53% of those patients were married and that 
most were illiterate (Al-Owaish, Anwar et al. 2000). 
 
In 2012, Akhtar and Mohammad found that the prevalence of HIV 
among migrant workers in Kuwait was 21 in 100 000, and that TB 
affected 198 patients in 100 000 (Akhtar & Mohammad 2012). 
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However, the study covered the previous 10 years and only included 
migrant workers coming to Kuwait and did not reflect HIV in Kuwaiti 
citizens. However, it is one of very few studies in the Region to 
report on migrants and expatriates as these are usually deported as 
soon as their HIV status is diagnosed. There was no description of 
the clinical conditions or hospital admissions in this study. There are 
no data on clinical features or the epidemiological situation of HIV in 
Kuwait. It has been estimated that Kuwait still has a low HIV 
prevalence of 0.1%. The cumulative reported HIV diagnoses from 
1986 to 2011 was 206 cases (UNAIDS 2013).  
 
1.2.2.5 Lebanon 
 
HIV/AIDS cases were first diagnosed in Lebanon in the early 1980’s, 
and this nearby country has similar features of HIV/AIDS to  Saudi 
Arabia, with the most common route of transmission being 
heterosexual (Al-Mazrou et al. 2005). There are similarities in the high 
risk groups and in the high male to female ratio. All those similarities 
are believed to be a reflection of the similar social and cultural 
behaviour in those countries (Traboulsi et al. 2006).  
 
89 HIV patients in the period from 1984 to 2008 were managed and 
received their care at the American University of Beirut Medical Centre 
(AUBMC) in Lebanon. The average age for HIV patients was  
35.4 years and male to female ratio was 6.4:1. Cerebral 
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toxoplasmosis was the most commonly diagnosed opportunistic 
infection (21%) reflecting late presentation of patients to medical 
service. There are few other clinical data about the OIs and AIDS 
deﬁning illnesses in Lebanon. The lack of studies about the 
epidemiological proﬁle of AIDS patients in Lebanon makes it difﬁcult 
to implement effective clinical strategies and programs (Naba et al. 
2010). Data concerning HIV/AIDS in Lebanon are limited and this is to 
be expected considering the political instability with the civil war in the 
past 10-15 years.  
 
1.2.2.6 Oman 
 
Oman had a cumulative report of 1,539 cases of HIV between 1986 
and 1999. Most of these cases were males, and almost half were 
infected through heterosexual contact (Scrimgeour, Mehta & Suleiman 
1999). 
 
More recent data published in 2014 by Oman Ministry of Health 
(country progress) reported that 2394 people have been diagnosed 
with HIV infection up to the end of 2013. (Country Progress Report 
Oman 2014) 115 people were diagnosed in 2013. The most common 
routes of infection were heterosexual (50.6%), homosexual-bisexual 
(13.8%), Mother to child (5.7%), IDU (3.8%), blood transfusion (3%) 
and unknown mode of transmission (23.1%).  
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Balkhair et al studied the different opportunistic infections in a cohort 
of hospital admissions of HIV/AIDS patients in Muscat, Oman.  This 
study was published in 2012 and collected data retrospectively from 
1998 to 2008 and included 77 HIV/AIDS patients. The results showed 
that 58% (45) of the patients had one or more OI. The commonest 
was infection with Pneumocystis jirovecii pneumonia (25%), followed 
by cryptococcal meningitis (22%), cytomegalovirus (CMV) retinitis 
(17%), disseminated tuberculosis (15%) and cerebral toxoplasmosis 
(12.5%). This study concluded that there is wide range of OIs in 
Oman and subsequently in the Gulf region and that the most common 
OI in Oman were P. jirovecii pneumonia and cryptococcal meningitis. 
(Balkhair et al. 2012) 
 
Apart from Saudi Arabia, Oman is the only country from which there is 
a report on resistance to ARV’s. This study was performed in patients 
heavily exposed to ARV’s and failing regimens and showed high 
resistance rates (Al Dhahry, Scrimgeour et al. 2004). This is discussed 
in more detail in Chapter 5. 
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1.2.2.7 Palestine (Israel) 
 
Between 1985 and 2002, Chemtob and Srour collected 
epidemiological data for Arabs in Palestine (Israeli Arabs) and they 
found notifications of 80 patients with HIV/AIDS. The cumulative 
prevalence rate of HIV/AIDS was 10.1 per 100,000 population 
(Chemtob & Srour 2005).The study showed that prevalence in Arab 
Israelis was less than in non-Arab Israelis and neighbouring Arab 
countries. However, the modes of transmission remained similar to 
the rest of the Middle East and surrounding countries (Chemtob & 
Grossman 2004). 
 
For the period of 20 years (1980-2000) retrospective data were 
collected for 2886 patients with HIV. The overall prevalence of 
infection was 61/100 000. More than half were males (65.2%) with an 
average age of 35 years for males and 31 years for females. As in 
other countries in the region, heterosexual transmission was the most 
common route, accounting for 68% of cases. Men who have sex with 
men (MSM) was the second most common mode of transmission in 
Israel at 18.4% and injecting drug users (IDU) were 8.7%. About 
0.6% of HIV/AIDS patients were infected secondary to blood 
transfusion or after organ transplantation (Chemtob & Grossman 
2004). 
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In 2011 the WHO key data on the HIV epidemic in Israel showed that 
the prevalence of HIV was 0.2%, with 8500 PLWHIV. At that time, 
10.2% of HIV cases were in IDU and MSM accounted for 36.7% 
(WHO 2011). In 2013 the prevalence of TB coinfection was reported 
to be 5.8% among HIV positive Israeli patients (Mor 2013).  
 
A more recent review of HIV over the 30 years from 1981-2010 
emphasized that 41.3% of all 6579 HIV/AIDS cases in the period were 
in immigrants from high prevalence countries such as Ethiopia and 
this group accounted for most of the heterosexual transmission (Zohar 
et al. 2014). The proportion of MSM in HIV positive men rose from 
20.4% in 2000 to 50.9% a decade later. Overall, 13.4% of all cases 
were related to IDU (Zohar et al. 2014)     
These publications emphasize the differences in epidemiological 
patterns in immigrants, Israeli Arabs and other Israelis. Israel is the 
only country to have consistently reported on the rapidly increasing 
HIV related to MSM, and slow but significant increase of IDU use as a 
risk factor for HIV.   
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1.2.2.8 Syria 
Qualitative interviews were done by Seal and his colleagues in 21 
HIV/STI service providers in Damascus and Aleppo in Syria (Seal 
2013) . They aimed to evaluate HIV/STI related education, testing, 
and treatment and to obtain clinical care information. This study also 
explored the possible barriers to treatment and good medical care for 
HIV patients.  The study aimed to reduce these barriers especially for 
HIV/STI high risk groups in Syria.  
 
Interviews were performed in early 2011. Most of the physicians 
questioned  thought that HIV patients suffered from more stigma than 
other STI patients. The physicians said that they rarely asked about a 
patient’s sexual behaviour in detail to avoid embarrassment  (Seal 
2013).  
 
Therefore, improvement of physician knowledge and attitude towards 
HIV/STI patients was of key importance. Treatment protocols and 
standard treatment and management care should be provided. In 
addition privacy and avoiding patient stigma are essential components 
of HIV/STI care. There is a need for increased collaboration between 
HIV and STI services. No clinical descriptions or epidemiological 
studies about HIV/AIDS were found in Syria apart from the UNAIDS 
reports which estimate HIV/AIDS prevalence of 0.1% (Seal 2013). 
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1.2.2.9 Turkey 
 
According to the Turkish Ministry of Health in 2012 there were 5137 
HIV cases in Turkey. Most were between ages 20-59, the majority 
were males (72%) and MSM accounted for 8.9% of cases. 
Heterosexual transmission is the most common route, accounting for 
48% of all HIV cases in Turkey (Agacfidan 2014)   
 
In a Turkish pre marriage programme Alim et al. performed a cross-
sectional study of 1,332 pre marriage samples in 2005. The results 
showed 0.1% to be HIV positive. The study did not specify the 
difference between the gender, age or mode of transmission (Alim et 
al. 2009). In 2013 a study was done by Aylikçi, et al to assess 
knowledge about HIV/AIDS in two high schools in Kırıkkale, Turkey. 
Most of the 473 students (92.2%) had some knowledge about 
HIV/AIDS prior to the study. 27% believed that there is a cure for 
AIDS and 64% believed that HIV can be avoided by using condoms 
during sexual contact (Aylikçi et al. 2013). 
 
This study reflects the importance of improving young people’s 
knowledge as a key component of HIV/AIDS prevention programmes 
and destroys the social negative effect on these strategies especially 
in developing countries.   
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Table 1-6 summarised the common route of transmission in Turkey 
from 1985 to 2011 (Mutlu 2014) 
 
Years  1985-1996 1997-2001 2002-2006 2007-2011 
Route of transmission N (%) N (%) N (%) N (%) 
Heterosexual 254 (41.2%) 421 (59.5%) 668 (54.8%) 1410 (52.6%) 
MSM 65 (10.5%) 40 (5.6%) 105(8.6%) 240 (9%) 
IDU 71 (11.5%) 26 (3.7%) 25 (2.1%) 27 (1%) 
Blood transfusion  44 (7.1%) 6 (0.8%) 4 (0.3%) 14 (0.5%) 
 
(Table 1-6)  The common routes of transmission in Turkey from 1985 to 2011 (Mutlu 2014) 
 
 
1.2.2.10 United Arab Emirates 
As in neighbouring countries, the prevalence of HIV in United Arab 
Emirates (UAE) is estimated to be low. Al-Dabal et al reviewed the 
pattern of pulmonary infections in 92 HIV positive persons in Dubai 
over the 2 years January 2009 to January 2011. They found that 
42.2% patients had active pulmonary TB. 77.7% of them had CD4 
counts < 200/mm3 but no patient was receiving ART. 31.1% of 
reviewed patients had community acquired pneumonia (CAP) and 
8.8% had Pneumocystis jirovecii . 
This study showed that pulmonary TB was most frequently diagnosed 
illness followed by CAP (Al-Dabal et al. 2011). This study included only 
one city of the UAE and only a few patients were reviewed. There are 
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insufficient epidemiological or clinical reviews published from UAE; 
another report suggested only 1% of HIV patients had TB (UNAIDS 
2014)  
  
1.2.2.11 Yemen 
 
UNAIDS has estimated the adult prevalence of HIV in Yemen to be 
about 0.1%, with the number of HIV/AIDS infected patients 
increasing from 4000 patients to 12000 in 2004 (UNAIDS 2004). The 
WHO suggested that a hidden epidemic was on-going in Yemen at 
that time. The male to female ratio changed considerably in a few 
years, as in 1995 the male to female ratio for HIV/AIDS infected 
patients was 4:1, changing to 2:1 in 1999 and 1:1 in 2000 (UNAIDS 
2004). 
 
The most common mode of transmission in Yemen was found to be 
heterosexual in about 77% of all cases, followed by homosexual 
transmission (16%), blood products (6.8%), and IDU in about 2% 
(Lambert 2007).  
 
In 2014 Mirzazadeh et al published a study of high risk HIV MSM. The 
epidemic has not been well explored among this population in most 
Arab countries. 261 HIV positive men with a history of having sex with 
men in the previous 6 months from different cities of Yemen were 
included. 
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20% (95 % CI 15.8–25.0) reported condom use and 31.4 % (95 % CI 
25.9–37.3) reported that they or their sexual partner had a sexually 
transmitted disease symptom. Injecting drug use was only reported 
by 0.8 % (95 % CI 0.1–9.2) of this population (Mirzazadeh et al. 
2014).  
 
This is an important study concerning very sensitive issues. These 
could not have been tackled or discussed before in such a 
conservative society and reflects a very important improvement in 
overcoming the social barriers in the Region.   
 
1.2.3.1 Saudi Arabia 
 
The first case of HIV in Saudi Arabia was diagnosed in 1984 (Ellis et 
al. 1993). However, 20 years later, there was still no reasonable 
estimate of the real statistical and epidemiological state of HIV 
infections in the country and there were few peer reviewed 
publications. Only two countries in the MENA region did not provide 
estimates of the number of HIV/AIDS patients to the Joint United 
Nations Programme on HIV/AIDS and the WHO Regional Office of the 
Eastern Mediterranean: these were the Kingdom of Saudi Arabia 
(KSA) and Afghanistan (Alrajhi 2004).  This was because of the nature 
and the different social understanding of the disease. It is difficult in 
such a conservative society to address the real HIV/AIDS situation, 
which is wrongly directly linked to illegal sexual behaviour.  
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Furthermore, In the UNAIDS/WHO Epidemiological Fact Sheet on KSA 
2002 update, none of the parameters for HIV epidemiology could be 
estimated (Alrajhi 2004). However, the situation has changed 
continuously over the past decade with improved surveillance, 
discussion about HIV and publication of data about HIV in the 
Kingdom. 
 
A more comprehensive review of cases in KSA up to 2001 was 
published by Madani et al in 2004 (Madani, Al-Mazrou et al. 2004) and 
showed that heterosexual mode of transmission accounted for 40% of 
the cases. However, no route of transmission could be identified for 
42% of cases (Madani 2004). The study also showed that HIV cases 
were continuously rising in the Kingdom (figure 1-4). 
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Figure (1-4) HIV/AIDS cases in KSA between 1984 and 2001 (Madani 2004) 
 
Al-Mazrou et al. published a study of the epidemiological data on 
HIV/AIDS available in Saudi Arabia in 2003 (Al-Mazrou, Al-Jeffri et al. 
2005). They found that there had been 1743 HIV positive Saudi 
patients and 6064 non Saudi HIV positive patients identified in the 
Kingdom. Moreover, 872 (50%) of the Saudi HIV patients had AIDS 
and 77% were males, with a male to female ratio of 3:1. Most of the 
cases (about 67%) were reported in Jeddah, Riyadh and Dammam. 
No recent cases were reported to be infected through infected blood 
transfusion. 46% of the cases were infected through sexual routes. 
 Finally, the report concluded that Saudi HIV/AIDS cases were 
increasing significantly every year. The three year survival rate for 
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AIDS patients had increased by more than 100% from 27% in 1984 to 
72% in 2000 and the availability of antiretroviral therapy was 
assumed to have played a major role in that improvement (Al-Mazrou 
et al. 2005). 
At that time, a survey of 20423 Saudi blood donors in the Central 
region of KSA showed no cases of HIV, while hepatitis B ( HBV) 
prevalence was 1.5% and hepatitis C (HCV) 0.4% (El-Hazmi 2004). 
Subsequently, A-Jabri et al showed that rates had increased slightly in 
pregnant women by 2010. Tests in 11553 pregnant women showed a 
HIV prevalence of 0.13%, with 1.5 positive cases in 100 000 per year 
(Al-Jabri et al. 2010).  
There were 505 newly diagnosed cases of HIV in Saudi Arabia in 
2008, a 34.6% annual increase from previous year. The Jeddah region 
had the highest proportion of HIV cases in the country (37%) (Madani 
2004). 
Since 2001 the Saudi Ministry of Health (MOH) has published an 
annual report specifically for HIV/AIDS in the country.  This report 
included good quality statistics and data about HIV/AIDS in the 
Kingdom.  By 2009, the official MOH reports indicated there have 
been a total of 3538 HIV/AIDS cases in Saudi (Alothman, Altalhi et al. 
2010). In 2012 a retrospective study concerning HIV notifications at 
Saudi MOH for the ten years (2000 to 2009) was performed. This 
review showed that a total of new HIV cases of 10217 of which 2958 
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(29%) were Saudi nationals (Kabbash, Felemban et al. 2012).  The 
discrepancy from the 3538 patients described by Al-Othman et al 2 
years previously emphasized problems with data consistency in the 
Kingdom. The incidence was 1.5 cases per 100 000 for Saudi national 
patients. Case notifications were increasing yearly until 2009 when 
they levelled off (Figure 1-6). 
In addition the male to female ratio was 4.4:1 in Saudi HIV patients. 
The study concluded that even though HIV/AIDS reported cases are 
stabilised from 2006, HIV/AIDS was still considered one of the 
challenging and important public health problems in KSA (Kabbash, 
Felemban et al. 2012). 
 
 
Figure (1-5) Saudi HIV cases annual reports through 2003 -2008 (Kabbash et 
al. 2012) 
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Figure (1-6) Increasing annual HIV/AIDS cases in KSA  (Kabbash et al. 2012) 
 
 
According to the most recent case report statistics from the National 
Programme for HIV/AIDS Control, there had been 12000 HIV positive 
people diagnosed in the Kingdom. Almost half of all cases have been 
found in Jeddah, the main Saudi west coast city (NAP 2014).  
 
The National Saudi AIDS Programme (NAP) is one of the most 
effective programmes under the General Administration of Infectious 
Diseases Control, unit of Deputy of Public Health, Ministry of Health, 
Kingdom of Saudi Arabia. It was established in 1994 and included 
plans to modernise approved treatment centres after around 10 years, 
using the latest international guidelines and recommendations for HIV 
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treatment with ART. The programme supports HIV prevention, care 
and treatment (NAP 2014).  
The NAP is multi-sectorial and has strategies to help in preventing HIV 
infection and supporting HIV patients around the Kingdom. The NAP is 
aiming to prevent HIV in Saudi society, especially in those at high risk 
in order to maintain a low prevalence of HIV in the Kingdom. In 
addition, the NAP aims to improve the quality of life for HIV/AIDS 
patients.  One of the important roles of the Saudi NAP is to ensure 
easy access to antiretroviral therapy and comprehensive HIV 
treatment programmes with appropriate care (NAP 2014). 
 
At the end of 2011, the Ministry of Health (MOH) and the National 
AIDS Programme (NAP) developed a five-year National Strategic 
HIV/AIDS Plan (NSP) for the period of 2013-2017. 
NAP launched its website (http://www.napksa.com/) and developed a 
mobile application to disseminate HIV/AIDS related information. 
 
In Saudi Arabia HIV surveillance is integrated into the national 
communicable disease surveillance system and the national 
monitoring and evaluation framework. Modes of transmission analysis 
and data triangulation have not been carried out. There is a national 
protocol for HIV case reporting. In 2011, 394 HIV new cases were 
reported and 81.2% of these were in men (WHO 2013).  
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An HIV test is not routinely offered to pregnant women, and there is 
no mandatory testing of pregnant women.  However, tuberculosis and 
STI patients are routinely tested for HIV without asking for 
permission. 
In 2012, the national AIDS  programme  reported  that  facility based  
surveys  would  be  conducted  in  pregnant  women,  prisoners, STI 
and tuberculosis patients  and in injecting drug users  in 2013. Female 
sex workers and men who have sex with men remain “non-applicable 
groups” in the official country data for HIV surveillance in Saudi Arabia 
(WHO 2013).  
 
Since the eighties when the first HIV case was reported in Saudi 
Arabia, HIV/AIDS has become an important issue from a medical point 
of view and even more so as a social issue. For many years just 
talking about HIV has generally considered been an extremely 
embarrassing, due to the assumption of a direct link with immoral 
sexual relations.  This assumption prevents many individuals from 
admitting that they are infected and therefore, patients may avoid 
seeking medical care. 
 
Fortunately, there has been more openness and better understanding 
in the last 5 years and Saudi society has begun to change these old 
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barriers. In addition, there is now full support from the government 
which provides free antiretroviral therapy. 
 
Since the eighties when HIV infection was reported in KSA, there have 
been few systematic clinical descriptions of HIV cases were 
insufficient. Only two studies had been published in the whole region 
on the use of antiretroviral therapy (ART) and the emergence of ART 
resistance, in Oman in 2004 (Al Dhahry, Scrimgeour et al. 2004) and 
in Saudi Arabia in 2010 (Jamjoom, Azhar et al. 2010). 
 
1.2.3.2 HIV clinic protocols 
 
HIV services are often provided for persons who have challenges 
because of factors such as discrimination, poverty or IDU. The context 
of HIV care still is one of persistent stigma regarding HIV infection 
itself and discrimination against racial, ethnic, and sexual minorities 
who constitute the groups with the highest HIV prevalence and 
incidence. Because of these circumstances HIV clinics should follow 
certain guidelines to ensure the best possible practice and best use of 
resources.    
For example in the UK, National Institute for Health and Care 
Excellence (NICE) guidelines and British HIV Association (BHIVA) 
guidelines recommend that anyone testing HIV positive is seen by a 
specialist at the earliest possible opportunity, ideally within 48 hours 
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and at the most within 2 weeks of diagnosis. Similar guidelines are 
produced by International AIDS group and European AIDS Clinical 
Society. Diagnosed individuals are usually referred and seen at the 
HIV clinic in Jeddah within 2-3 weeks in order to join the national 
AIDS programme.  People living with HIV have the right to expect that 
their care is provided in a safe environment and that everyone is 
treated with no discrimination. 
 
NICE and BHIVA guidelines also recommend that HIV tests should be 
routinely requested in GUM, antenatal, drug dependency, TB, viral 
hepatitis B/C and lymphoma services and to all patients at high risk 
groups. People attending health care services (primary, secondary and 
tertiary care) should be offered diagnostic tests for HIV. In Saudi 
Arabia HIV tests are usually requested in these clinics but this is not 
yet uniformly followed.  
According to Western HIV clinical care guidelines (CDC, NICE, BHIVA), 
all individuals diagnosed with HIV should be offered a full assessment 
and treatment at the earliest possibility.  In addition they should have 
their infection monitored regularly and treated safely in accordance 
with national guidance, and be able to access a comprehensive range 
of required services. 
Essential investigations should be routinely used in the care of people 
living with HIV; including CD4, lymphocyte counts, HIV viral load 
measurement and HIV genotype analysis, and results should be 
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available within 2 weeks of specimen collection. All these essential 
investigations are routinely done at the HIV clinic in Jeddah for all 
newly diagnosed HIV individuals apart from HIV genotypic analysis. 
However, this can be specially requested by the treating physician.   
 
However, when this study started, there was no clear operational 
clinic guideline about best practice in selecting what test to perform 
routinely in new patients, such as syphilis, hepatitis and other 
serology and there was no standard proforma for note keeping. 
Antiretroviral therapy (ART) and treatment for opportunistic infections 
are offered free of charge through HIV centres in the Kingdom.  
Regular follow up services are offered, including clinical follow-up and 
monitoring of CD4 counts and HIV viral load testing. In HIV-1 infected 
adults and adolescents, ART is now initiated when the CD4 cell count 
falls below 500 cells/mm3. The North American Department of Health 
and Human Services (DHSS) guidelines are now followed for 
treatment, available at: 
http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolesc
entgl.pdf (NAP 2014). 
 
However, ART resistance tests are not routinely done. There is 
evidence that between 20% and 40% of people receiving ARVs in 
Europe and the USA are at risk of clinically significant drug 
interactions (BHIVA 2013). However, there are no data or national 
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guidelines available concerning assessment or monitoring drug 
interactions in patients receiving ART in the Kingdom, or in the whole 
Region. 
It has been shown that people living with HIV experience significantly 
higher rates of depression (BHIVA 2013). The Saudi National AIDS 
Programme follows guidelines of HIV care in the West, providing 
continuous emotional and mental health care including psychiatric 
consultations for HIV patients as required.      
A healthy sexual lifestyle is strongly recommended for HIV patients 
and all patients in the national AIDS programme are educated about 
sexual health for themselves and their partners, including education 
about protection of themselves (and others) from acquiring new 
sexually transmitted infections. In addition they are offered support 
from qualified staff regarding their sexual contacts and partner 
notification. 
The quality of life for HIV Saudi patients under the national AIDS 
programme has been improved through economic support and help in 
finding employment. Health education, treatment and counselling 
services are given to all HIV individuals within the programme. The 
NAP has helped to minimize stigma and discrimination of HIV 
individuals in Saudi society (NAP 2014). 
 
Even though the National AIDS programme in Saudi Arabia is playing 
an important role in maintaining high quality standard for HIV clinics, 
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specific operational protocols and guidelines for HIV care and 
improvement of HIV clinics audit should be developed and used 
ensure the optimal effectiveness of HIV clinics in the kingdom.       
 
 
1.2.3.3 Links between Islam and HIV prevalence 
 
Many authors believe that there is a strong link between low 
HIV/AIDS prevalence in Middle East countries and the religion of Islam 
(figure 2-6), as Islam prohibits homosexuality and also prohibits extra 
marital sexual activities. In addition, Islamic rules and values support 
HIV/AIDS preventive strategies such as prohibiting injecting drug use 
(IDU) and controlling sexual activities. Moreover, marriage 
encouraging programmes among youth are of much value in 
controlling sexual behaviour and for promoting safe sex. Therefore, 
those strategies were easy to implement in the society as they already 
believe in the same concept in Islam. But the real practice of these 
Islamic principles and values are extremely dependant on individual 
persons and commitment to these Islamic rules varies from one 
person to another (Gray 2004).    
 
However, some believe that HIV/AIDS cases are generally under 
reported and that, as reporting systems improve, the data will reveal 
a higher prevalence of HIV/AIDS in Islamic countries than is currently 
apparent.  
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Research about the relationship between HIV and religion is limited 
because of sensitivity of this subject in all societies. Muula et al in 
2012 compared different religious background and HIV prevalence in 
Malawi, where Christianity is the main religion and Islam is the 
second. They found no differences among Protestants and Catholics, 
Muslims, and all Christians combined or between Catholics compared 
with individual religions (Muula et al 2012).  
 
The situation is skewed in the most countries in the Middle East, 
where the majority of newly diagnosed HIV individuals are foreign 
workers (Madani 2004; Gray 2004).  
Such individuals are usually deported immediately after diagnosis, 
which reduces the overall reported incidence and prevalence in these 
Muslim societies. Muslim countries in the Middle East are in urgent 
need of improved HIV/AIDS surveillance and more enhanced 
epidemiological studies in collaboration with national and international 
prevention programmes (Hasnain 2005; Abu-Raddad et al 2010; 
Akhtar and Mhamed 2012).     
 
Six out of seven studies have shown a strong relation between a low 
HIV/AIDS prevalence and Islam. Those studies were done in Sub–
Saharan Africa Muslim countries (Gray 2004).  
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One possible reason for this link is the requirement for circumcision, 
which is more common in Muslims, in addition to the ritual washing 
which may play a rule in decreasing transmission.  Circumcision has 
been shown to reduce the risk of HIV transmission (Gray 2004). 
However, in some Islamic countries, advice not to use condoms by 
some religious authorities has had a negative effect not only on 
HIV/AIDS but on transmission of all sexually transmitted diseases in 
the region (Gray 2004). 
 
 
 
 
 
Figure (1-7) HIV/AIDS prevalence in relation to Islam (Gray 2004) 
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Sexual actions outside marriage are greatly offensive in the Muslim 
societies, even more than illicit drug use. This can lead to severe 
discrimination against HIV positive Muslim individuals.  
 
Discrimination starts with the surrounding family and close contacts of 
the patient and may lead to dramatic isolation of the HIV positive 
person. In turn, this can deter individuals from notifying themselves to 
medical authorities and getting necessary medical attention. In 
addition, it is increasingly recognized that men who have sex with 
men represent an important hidden source of new HIV infections in 
several countries in the Region (Shawky, Soliman et al 2009, Mumtaz 
et al. 2011). 
 
In most societies in the Middle East region including Saudi Arabia, it is 
commonly known that there is a significant power imbalance between 
males and females. Females are usually economically dependent on 
males and in some extreme cases they are not aware of their legal 
and sexual rights. Therefore, women are more likely to lose their 
chance of having equal health care than men and are less likely to be 
tested for HIV. This is may explain why females in such societies are 
more likely to get infected with HIV without being notified and to have 
a lower access to health care than males. 
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There are many especially challenging factors affecting HIV/AIDS 
transmission and prevention in countries in the MENA region. These 
include poverty, poor education, wars, social conflicts, refugees, 
influence of religious leaders, and decreased levels of standard 
medical care and poor health information. 
 
Further efforts will be needed at both individual and community levels 
to improve prevention plans and decrease the rising prevalence of 
HIV/AIDS in Muslim countries (Hasnain 2005). Despite efforts in some 
politically and economically stable countries in the region, more is 
needed to overcome these serious barriers. This, includes more health 
education, particularly sex education, which remains one of the 
hardest topics to discuss in the region.      
 
To overcome the barriers in prevention plans in such countries, 
Muslims must recognize there is a big difference between the ideal 
concepts of Islam which may help in HIV/AIDS prevention, and the 
situation in real life which really depends on individual practice and 
behaviours. In addition, full cooperation between religious scholars 
and public health educators should strive to develop successful and 
effective prevention plans that are acceptable to society in Muslim 
countries (Abu-Raddad et al 2010). 
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1.3. HIV Coinfections: 
 
This section will review the general epidemiology of hepatitis C (HCV), 
Hepatitis B (HBV), TB and STI infections in the Middle East and in the 
Kingdom of Saudi Arabia.  
There are few data about coinfection with HIV in the whole Middle East 
Region, illustrated by summary data in Table 1-7 below.  
 
Country Year HBV 
Coinfection 
HCV 
Coinfection   
TB 
 Coinfection  
Reference  
Bahrain   NA NA NA  
Iran 2009 
2011  
2013 
36.3% (2011) 
 
78% (2009) 10.7% (2013) 
 
11.4% (2011) 
Davarpanah et al 
2009; Alipour et al 
2013 
SeyedAlinaghi et 
al. 2011 
Iraq 2006 NA 66% 
(haemophilia HIV 
patients) 
NA Al-Kubaisy et al 
2006 
Israel 2013 NA NA 5.8% Mor et al 2013 
Kuwait  NA NA NA  
Oman 2012 NA NA 15% Balkhair et al 
2012 
Qatar   NA NA NA  
Saudi Arabia 2014 3% (Alhuraiji et 
al 2013) 
12% (Alhuraiji et 
al 2013) 
2.16% UNGASS Country 
Progress Report 
2014 
UAE 2014 NA NA 1% (only 85 cases 
were tested)  
UNGASS country 
progress report 
2014 
 
 
Table (1-7) Prevalence of HBV, HCV or TB in in patients with HIV in the Middle East 
(various sources) 
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1.3.1 Syphilis and STI in Saudi Arabia: 
 
In a conservative country like Saudi Arabia, it is extremely hard to 
discuss sexually related infections. Therefore, the data are usually of 
poor quality.  
In 1952 a combined national and international venereal disease team 
started activities in Saudi Arabia.  In the Asir region in the south, 
309/3000 patients were diagnosed with syphilis. In Abha they noticed 
a variation of syphilis prevalence among different tribes and different 
villages but positivity was more common in females than males (El 
Ghoroury 1954) 
A subsequent survey showed that in Saudi Arabia there are two 
different groups at risk of syphilis infection. These are the nomadic 
Bedouins who have a high incidence of endemic non-venereal syphilis 
(bejel), and the people born and bred in towns who were no longer 
acquiring endemic syphilis but may develop venereal syphilis. This 
study suggested that bejel accounted for most positive serological 
reactions found in nomadic communities and probably outweighed 
venereal syphilis in the population as a whole. The most common late 
manifestation noted was painful osteoperiostitis of the legs (Pace & 
Csonka 1984) 
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These infections are important and increase the likelihood of HIV 
transmission, especially ulcer casing infections such as syphilis and 
HSV. 
 
Sexually transmitted infections (STIs) are usually hard to follow and 
many of infected patients are asymptomatic and diagnosis is therefore 
missed. Furthermore, if these diseases had been diagnosed they 
remain unreported especially in developing countries. A total of 39049 
STIs were reported to the Ministry of Health (MOH) between 1995 
and 1999. These included nongonococcal urethritis (14557 infections, 
37.3%), trichomoniasis (10967 infections, 28.1%), gonococcal 
urethritis (5547 infections, 14.2%), syphilis (3385 infections, 8.7%), 
HIV (2917 infections, 7.5%), genital warts (1382, 3.5%), genital 
herpes (216 infections, 0.6%), and chancroid (78 infections, 0.2%). 
Nongonococcal urethritis, trichomoniasis, and gonococcal urethritis 
were the most commonly reported STIs in Saudi Arabia (Madani 
2006). 
Fageeh conducted a study on patients infected with genital herpes 
simplex (HSV) at King Abdulaziz University Hospital in Jeddah, Saudi 
Arabia in the period 2003-2011. 343 patients were included in this 
study and 13.1% were HIV coinfected. 12.5% of the HSV infected 
patients were coinfected with chlamydia and 12.8% were also 
infected with gonorrhoea. Genital ulcer disease was diagnosed in 
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57.9% and HBV serology (HBsAg) was positive in 2.3% (Fageeh 
2013). 
 
In 2014 a more recent study reported on the sexual behaviour and 
knowledge about HIV/AIDS and sexually transmitted infections (STI) 
in women inmates of Briman Prison, Jeddah, Saudi Arabia. 204 
women aged 16-60 years (mean, 33.3 years) were interviewed.  
Overall, 83% were not aware of STI and HIV infections. 57% had not 
been screened for HIV or STI before sexual intercourse or marriage. 
42.6% of the interviewed women were not sure about the importance 
and the role of using condoms in protection from infections. Among 
the 204 interviewed women, only 10 (4.9%) were using condoms 
during sexual intercourse to protect themselves from possible 
infections. The study concluded that efforts should be made to 
overcome this poor knowledge about STI, HIV infection and risky 
sexual behaviours (Fageeh et al. 2014).   
 
1.3.2 Hepatitis A (HAV): 
Hepatitis A (HAV) is transmitted by oro-faecal routes and infection in 
childhood used to be universal in most parts of the tropics and also in 
the Middle East including Saudi Arabia (Asghar 2014). The incidence of 
HAV is increased in some groups at risk of HIV including men who have 
sex with men and in Western settings, such risk groups are 
recommended to be immunised (Crum-Cianflone et al. 2010). It is 
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mostly a self-limiting disease but it may cause serious liver injury which 
can leads to fulminant hepatic failure and death. The WHO estimates 
that HAV infection causes nearly 1.4 million new cases worldwide yearly 
(Asghar 2014). 
 
Similarly, it has been estimated that HAV serology prevalence in Saudi 
Arabia was 18.6%, a considerable reduction from the 90-100% rates 
reported only two decades ago in the adult population. A serial 
comparative study of HAV antibody positive patients in Saudi adults 
between 1989 and 2008 found a significant decrease from 53% in 1989 
to 25% in 1997, and finally to 18.6% in 2008 (Alhetheel et al 2014).  
 
The epidemiology of hepatitis A has changed in much of the Middle 
East, partly due to improvement of water supply and in other countries 
due to immunization (Bawazir et al. 2010). In neighbouring Yemen, the 
prevalence of positive hepatitis A serology in adults was 86% in 2010. 
The improvement in prevalence of HAV infection from the past in Aden 
could be related to the quality of water supply (Bawazir et al. 2010). 
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1.3.3. Hepatitis B Viral Infection (HBV): 
About one third of the world's population have been infected with 
hepatitis B. Most of the cases occur in the tropics and in the Middle 
East. Saudi Arabia was one of the first countries to including hepatitis B 
vaccine in the national vaccine programme and recent data show that 
Saudi Arabia is now classified by the WHO as an intermediate endemic 
region for hepatitis B  (Andre 2000).  
   
Hepatitis B is a DNA virus. It has direct oncogenic effects as well as 
those due to chronic hepatitis in carriers, leading to clinically significant 
chronic liver disease, liver failure and liver cancer in about 25% of 
carriers (Bawazir et al. 2010; El-Serag 2012). It is one of leading 
causes of the preventable cancer in the tropics, now being reduced due 
to global effects to vaccinate children (El-Serag 2012) 
The virus is transmitted from mother to infant at birth, to children in 
early childhood by unknown reasons, probably mostly related to unsafe 
injections (Kermode 2004), blood transfusion and sex. In most non 
Western settings, including the Middle East, transmission in infancy and 
childhood is the most important mode of transmission. However, 
presence of HIV coinfection in the mother probably enhances perinatal 
HBV transmission.  
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Adults with HIV are at increased risk of HBV due to similar patterns of 
transmission (Chang et al. 2014). While high risk HIV populations in 
Western settings have higher risks of HBV exposure, the situation is 
less clear in tropics. In Sub Saharan and West Africa, prevalence of 
HBsAg carriage varies from intermediate (2-7%) and high (8% or 
more)(WHO 2012). 
The serological picture of HBV co infection in HIV/AIDS patient may be 
different from HBV infection in other individuals. For management 
purposes it is important to establish a diagnosis of chronic HBV 
infection in HIV patients, as some antiretroviral drugs (lamivudine, 
emtricitabine, tenofovir) also have activity against HBV.  HIV/HBV 
coinfected patient are likely to develop drug resistant mutations of HBV 
if given ART regimens containing only one agent effective against HBV, 
so ART regimens for coinfected patient usually contain at least two 
ARVs which also act against HBV, typically tenofovir and emtricitabine 
(BHIVA 2013).  As with hepatitis C, patients with HIV/HBV coinfecton 
may have a hepatic “flare” 2-3 months after starting ARV’s, due to 
immune reconstitution inflammatory response  (IRIS) (Chang et al. 
2014). 
 Identification of HBV coinfection is, thus, important for patient 
management and non-immune HIV positive individuals should be 
vaccinated against HBV (Kottilil, Jackson & Polis 2005).  
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HBV is used to be a highly endemic in the Kingdom in the late 1980’s 
with a prevalence of up to 7% for HBsAg and more than 70% for the 
presence of any hepatitis marker. In 1989 the Saudi government 
started a compulsory vaccination programme to all children and 
healthcare workers. The latest statistics from blood donors showed that 
the expected prevalence of HBV (HBsAg) ranges from 1.5% to 2.6% in 
the adult Saudi population (Abdo et al 2012).   
 
No data have been available until recently for HBV coinfection in HIV 
positive individuals in Saudi Arabia, but data from some neighbouring 
countries are summarised in Table (1-7). Data from Sub-Saharan Africa 
are available from a few studies. In general most of those studies in 
Sub-Saharan Africa showed an increase of about two folds or less, 
whereas in non-African countries most of the studies showed an 
increase of at least four fold for HBV co infection in HIV/AIDS patients 
(Burnett et al. 2005). More recent studies in Malawi show only a slight 
increase in HBV infection in HIV positive individuals compared to non 
HIV positives (Chasela et al. 2014), whereas in Ghana, where there is a 
high background of prevalence of HBV carriage serology, the risks were 
greater in HIV positive patients (Geretti et al. 2010).The only study of 
HBV coinfection in HIV patient individuals in Saudi Arabia does not 
show substantially high rates of HBV coinfection, being present in 3% 
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of a cohort reviewed from January 1985 to December 2010 (Alhuraiji et 
al. 2013). 
 
1.3.4. Hepatitis C Viral Infection (HCV): 
The WHO estimates that 3% of the global population are currently 
infected with hepatitis C (HCV) with 3-4 million patients newly infected 
every year, and that HCV infection is equating to >185 million 
infections worldwide (Messina et al. 2015) . About 80% of chronic 
liver disease (CLD) is secondary to infection with hepatitis C. In 
studies of 653 CLD patients in the Western region of Saudi Arabia, 
35.4% of Saudi patients were positive for HCV antibody. Moreover, 
39.5% of 223 patients with hepatoma were HCV antibody positive 
(Akbar 2004). 
Despite the importance of HCV infection there were poor data on the 
prevalence or incidence of the infection in the KSA. 
The Saudi blood donation protocol is strict in providing HCV antibody 
testing for all donors. In 1997, 2.7% of blood donors were infected 
with HCV (Akbar 2004) and more than 500,000 Saudis are already 
HCV positive. A subsequent study in 2002 showed different rates of 
HCV in Saudi blood donors in different regions of the country as 
follows: the Western region was the most affected region with a 
prevalence of 1%, then the Southern region at 0.9%, then Eastern 
region with a prevalence of 0.6%, the Northern region with 
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prevalence of 0.7% and the lowest prevalence was 0.4% in the 
Central region (Akbar 2004). 
 
 
 
Figure (1-8) Annually reported hepatitis 
C virus cases in Saudi Arabia (1995-2005) (Madani 2009). 
  
 
Conversely, HCV prevalence was later calculated in each Saudi 
administrative provinces and found to be highest in Al Baha and 
Jeddah (32%) and the lowest in Jizan (1.6%) during the period 
1995 to 2006 (Abdo et al  2012). 
The prevalence of HCV infection in most neighbouring and 
Islamic countries was similar to that in Saudi Arabia but ranges 
from 0.2% in Algeria to 7.9% in Libya. Table (1-8) shows the 
different prevalence rates in each country.  
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No. Country HCV Prevalence 
1 Algeria 0.2% 
2 Egypt 18.1% 
3 Indonesia 2.1% 
4 Iraq 0.5% 
5 Jordan 2.1% 
6 Kuwait 3.3% 
7 Libya 7.9% 
8 Malaysia 3.0% 
9 Mauritania 1.1% 
10 Morocco 1.1% 
11 Oman 0.9% 
12 Pakistan 2.4% 
13 Palestine 2.2% 
14 Qatar 2.8% 
15 Somalia 0.9% 
16 Sudan 3.2% 
17 Tunisia 0.7% 
18 Turkey 1.5% 
19 United Arab Emirates 0.8% 
20 Yemen 2.6% 
 
Table (1-8) HCV prevalence in some Islamic and Neighbouring countries 
around Saudi Arabia (Madani 2009) 
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The prevalence of HCV in Saudi Arabia is markedly higher in adult age 
groups than the children (figure 3-2). In older adults, this is may be 
related to past blood transfusions, and in younger adults substance 
injecting misuse plays a major role in both HCV and HIV transmission 
(Madani 2009).    
 
 
 
Figure (1-9) HCV infection according to age group in Saudi Arabia 
(1995—2005) (Madani 2009) 
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Transmission by blood and blood products are common transmission 
routes for both HCV and HIV. Alzahrani et al. examined detection of 
HCV and HIV seropositivity rates in expatriates in Dammam city in the 
Eastern region of Saudi Arabia in 2009.  This study included 875 non-
Saudi citizens who were tested for HCV antibodies, showing two 
positive and two equivocal results. On testing for HCV RNA and also 
using a HCV antigen-antibody combination assay the equivocal results 
were confirmed to be positive ie 4/875 samples were positive. Only one 
sample was positive for HIV. The authors concluded that addition of 
antigen detection assays to the screening of HCV and HIV may improve 
detection and lowering transmission for both viruses in Saudi Arabia 
(Alzahrani et al. 2009). 
 
HCV co infection is one of the important and emerging infections which 
may have a serious effect on HIV/AIDS patients and will lead to 
increase of mortality and morbidity. In particular HIV coinfection greatly 
accelerates the prognosis of hepatotoxicity and fibrosis and cirrhosis 
due to HCV (Kottilil, Jackson & Polis 2005).  
 
HCV coinfection is now considered to be an indication for starting ART 
in HIV positive individuals, irrespective of CD4 count or clinical staging 
(BHIVA 2013). 
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There may be drug interactions between antiretrovirals especially 
protease inhibitors, pattern of various therapies for HIV may interacts 
with directly acting agents for HCV (Karageorgopoulos et al. 2014)    
 
Until recently, no epidemiological data have been available about  
coinfection of HCV and HIV in the Kingdom of Saudi Arabia. There are 
two series of studies in the Region considering HCV coinfection in HIV 
patients. In Iran, Davarpanah et al in 2009 found that the prevalence 
of HCV infection in HIV positive injecting drug users was 78% 
(Davarpanah et al 2009). In Iraq a study of haemophiliac HIV positive 
patients in Baghdad found that 66% were coinfected with HCV. 
 
In late 2013 a study looked at HIV patients in Saudi Arabia and 
coinfections with HCV or HBV. This study collected data from HIV/AIDS 
patients who had been followed at King Faisal Specialist Hospital in 
Riyadh between 1985 and 2010.  Coinfection with HCV was found in 
12% of the cases. 88% of those were haemophiliac patients or 
receiving blood or blood products for other reasons (Alhuraiji et al 
2013). 
In the same cohort, hepatitis B was found in 3% of patients. The most 
common risk factor for HBV infection among HIV patients in this study 
was heterosexual transmission in 73% patients (Alhuraiji et al 2013). 
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Summary of hepatitis (A, B and C) serology interpretations are listed in 
Table (1-9) 
Hepatitis A Antibody 
(ant-HAV IgG or IgM) 
Screen for immunity to 
hepatitis A; vaccinate those 
not immune  
Negative  Offer hepatitis A vaccine if indicated  
Positive  IgG: Immun, no vaccine necessary 
IgM : Acute infection  
Hepatitis B Surface 
Antigen (HBsAg) 
Indicates active hepatitis B 
infection 
negative 
HBsAg  
 
Most likely, no chronic infection (may be falsely negative) 
Vaccinate if anti-HBcAb and anti-HBsAb negative (not 
immune)  
positive  
HBsAg  
Indicates chronic or acute hepatitis B infection; requires 
further evaluation (check HBV DNA) 
Hepatitis B Surface 
Antibody (Anti-HBs) 
Indicates immunity status, 
due to past infection or 
immunization 
 
negative  
anti-HBs  
 
The patient is not immune to hepatitis B; consider vaccination, 
unless patient has active hepatitis (HBsAg positive or HBV DNA 
positive)  
positive  
anti-HBs  
 
The patient is immune to hepatitis B either by previous 
infection or by immunization; may be negative in acute 
hepatitis B infection 
Hepatitis B Core 
Antibody (Anti-HBc 
IgG) 
Indicates past infection or 
ongoing infection 
Not affected by 
immunization  
negative 
Anti-HBc  
The patient most likely has not been infected with hepatitis B; 
consider vaccination if anti-HBsAb negative and anti-HBsAg 
negative 
positive 
Anti-HBc  
 
The patient most likely has been infected with hepatitis B; this 
test alone does not distinguish past exposure and active 
infection  
In rare cases, may be falsely negative in some patients with 
chronic infection, although positive anti HB-IgM is significant in 
acute or very active chronic infection   
If anti-HBsAb negative and sAg negative check HBV DNA to 
rule out active infection; vaccinate if HBV DNA is not detected.  
If anti-HBsAb is positive, patient is immune 
Hepatitis Be antigen 
HBeAg and  
Determining infectivity of 
hepatitis B virus (HBV) 
carriers and monitoring 
infection status of chronically 
infected patients 
positive 
HBeAg  
Presence of hepatitis Be (HBe) antigen and absence of HBe 
antibody usually indicate active hepatitis B virus (HBV) 
replication and high infectivity. 
negative 
HBeAg 
Absence of HBe antigen with appearance of HBe antibody is 
consistent with loss of HBV infectivity. 
Hepatitis Be antibody 
anti –HbeAb 
 positive 
anti-HBeAb 
Absence of HBe antigen with appearance of HBe antibody is 
consistent with reduced of HBV infectivity. 
negative 
anti-HBeAb 
Although resolution of chronic HBV infection generally follows 
appearance of HBe antibody, the HBV carrier state may 
persist. 
HBV DNA PCR Indicate level of virus 
infection 
Negative HBV 
DNA PCR 
Negative or weakly positive  (below detection limit) 
Positive HBV 
DNA PCR 
High levels positive in present of HBeAg carrier with high 
infectious state and progression to chronic liver disease  
Hepatitis C Antibody 
(HCV IgG) 
Hepatitis C negative  
anti-HCV Ab 
Patient is not infected with hepatitis C 
Screen at baseline; consider annual screening for high-risk 
patients, and if clinically indicated. May be false negative in 
HIV patient (check PCR in this situation) 
positive  
anti-HCV Ab  
Patient has chronic hepatitis C infection or past infection with 
spontaneous clearance (no protective immunity); confirm 
positive results with HCV RNA. 
HCV PCR Detection of acute hepatitis 
C virus, confirmation of 
chronic HCV and 
quantification of HCV  
 
Undetected HCV is absent in the patient’s serum specimen 
Detected  HCV RNA level indicates HCV viral replication in the patient. It 
is important to assess response to therapy.  
 
 
Table (1-9) Interpolation of hepatitis (A,B and C) virus serology 
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1.3.5. Tuberculosis Infection (TB): 
Tuberculosis (TB) remains one of the most important global health 
problems. This importance has increased dramatically in association 
with the HIV epidemiology especially in low and middle income 
countries (Tanimura et al. 2014). 
 
Tuberculosis is considered to be the most common co infection in HIV 
positive individuals and one of the leading causes of mortality in 
HIV/AIDS patients in high TB endemic countries. The WHO estimated 
that about 13% of HIV/AIDS cases died from TB coinfection (WHO 
2007). 
 
About 9.3 million new TB cases were reported in 2007, of which about 
15% (1.4 million) were newly HIV diagnosed patients. There were 1.7 
million deaths due to TB were, of which 0.46 million were HIV positive 
patients (WHO 2009). 
 
TB was a major problem in countries in Africa even before the 
HIV/AIDS endemic and escalated in the late 1990’s with HIV. In some 
African countries, more than three quarters of TB notifications were in 
HIV positive patients (WHO 2013). Similar but less dramatic 
associations are seen in other regions (Figure 1-10). 
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(Figure 1-10) Percentage of TB patients with HIV (WHO 2013) 
 
Most TB coinfections with HIV are due to reactivation of latent TB, and HIV 
positive people who have latent TB are about 50 times more likely to have 
active TB coinfection (Antonucci et al. 1995). Therefore, the incidence of TB 
infection in HIV positive people is significantly higher than the general 
population (Antonucci et al. 1995; El-Sadr & Tsiouris 2008). However, it is 
now recognised that HIV positive individuals in highly endemic regions for 
TB, such as Sub-Saharan Africa, are very susceptible to both reactivation or 
new infection and thus guidelines recommending prolonged 
chemoprophylaxis against TB in HIV positve patients in this setting (Golub et 
al. 2015) 
96 
 
 
This has gained further impact with the emergence of multidrug 
resistance and extreme drug resistance in TB in parallel with HIV. Rapid 
TB diagnostics and TB drug susceptibility testing for all patients remain 
a priority in this region (Post et al. 2014) 
 
In the Middle East and Eastern Mediterranean region the WHO 
estimated in 2009 that 20,517 (about 1.5% of global cases) new cases 
of HIV/TB coinfection are found in this region, but the impact of HIV on 
increasing TB infection was not thought be very significant. However, in 
the same report, 30.5% of TB cases in the Eastern Mediterranean 
region were found in HIV/AIDS patients (Zarocostas 2009). 
 
In Israel TB coinfection was found in 5.8% of HIV positive patients in 
2013 (Mor 2013). Iran had TB coinfection rates of 10.7% in 2013 
(Alipour et al 2013). Balkhair et al in 2012 showed that about 15% of 
HIV Omani patients were coinfected with TB (Balkhair et al 2012). 
 
Unfortunately the Saudi Ministry of Health yearly report did not show 
the TB reported cases among HIV/AIDS patients until recently. A study 
done in 2010 by Omair et al showed that the incidence of TB 
coinfection in HIV positive individuals is at least 30 times higher than it 
is in the general Saudi population. This study concluded that the 
incidence of TB coinfection in HIV/AIDS patients in Saudi Arabia is 
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significantly higher than in the general Saudi population and that 
mortality is also high despite early diagnosis and treatment (Omair, Al-
Ghamdi & Alrajhi 2010).  
 
In the latest Saudi Arabian UNGASS country progress report in 2014 
the Saudi Ministry of Health (MOH) reported that 2.16% of HIV Saudi 
patients are coinfected with TB (UNGASS Country Progress Report 
2014). Until recently there were no specific guidelines in the Kingdom 
about tuberculosis testing or isoniazid prophylaxis against TB for HIV 
positive individuals attending services of TB patients for HIV infection.  
 
Case notification for TB has improved over the past two decates in 
Saudi Arabia, along with treatment and TB control strategies. In 
comparison to neighbouring countries Saudi Arabia has a moderate rate 
of TB infection (Al-Hajoj 2009) (Table 1-10). This situation might be 
expected in a large country with around 6 million expatriates mostly 
coming from countries where TB is more endemic, and the annual 
pilgrimage (Hajj) season, when millions of multinationals come to the 
holy Muslim places.     
Infection rates in Saudi Arabia are different from region to region. 
Jeddah, the west coast and the main port to pilgrimage (Hajj) has the 
highest infection rate with 64 per 100,000 cases. In comparison in 
Riyadh, the capital and central region of Saudi Arabia, the infection rate 
is 32 per 100,000 cases (Al-Hajoj 2009). 
98 
 
 
 
 
 
# Country Infection  rates                                   Reference 
1 USA 5.2 per 100,000 (Broekmans et al. 2002) 
2 UK                                             35 per 100,000                                     (Broekmans et al. 2002) 
3 Saudi Arabia                             32—64 per 100,000                              (Maguire et al. 2002) 
4 India                                          180 per 100,000 (Porco et al. 2006) 
5 Sub-Saharan Africa                   290 per 100,000                                    (Corbett et al. 2003) 
6 South Africa                              509 per 100,000                                    (Corbett, Watt et al. 2003) 
 
 
 
 
Table (1-10) TB Infection rate in Saudi Arabia compared with 
other countries (Al-Hajoj 2009). 
 
 
 
Data collected in a retrospective study in King Abdulaziz Hospital, 
Jeddah over 3 years from medical records showed that from a total of 
157 cases diagnosed with pulmonary TB, 36% were Saudi patients and 
the majority (64%) were non Saudi patients.  The mean age was 33 
years (+/- 15.3). This study suggested that the majority of TB cases in 
Saudi Arabia especially those cases in Western region (Jeddah) are 
including imported by visitors to the Kingdom (Al-Hajoj 2009).  
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TB infection rates of 60 per 100,000 were reported by the Saudi 
Ministry of Health in 2007 and total number of TB cases has increased 
slightly from 3854 cases in 2006 to 3878 cases in 2007 (Al-Hajoj 2009). 
Data from the same study found that Saudi TB patient was 52.7% 
while non-Saudi TB cases were 47.3%.  This changing picture reflects 
the urgent need for better plans and strategies to fight and control TB 
in Saudi Arabia, and emphasised the need for reporting and 
furthermore, frequent studies on TB in Saudi Arabia (Al-Hajoj 2009). In 
addition, collaboration between local and international health 
organizations to provide the best management and control for TB 
patient in the country was highly recommended (Al-Hajoj 2009).         
Saudi Arabia remains a moderate TB burden country with an incidence 
rate of 18/100,000 (Al-Hajoj & Varghese 2015). 
 
Few studies have been conducted to explore the real situation of first 
line TB treatment resistance and MDR-TB in the Kingdom, with various 
results ranging from 14% to 20% for the first line treatment and from 
1% to 44% for MDR-TB. Until 2013, the true burden of drug-resistant 
TB was unknown, as there were no representative national surveys to 
measure levels and patterns of anti-TB drug resistance. In 2013, Al-
Hajoj et al. reported the results of 1902 TB patients and showed first 
line treatment resistance of 23% and MDR-TB of 4 % (Al-Hajoj & 
Varghese 2015)  
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1.3.6 IDU and HIV infection 
Injecting drug use is one of the most important risk factors for HIV 
transmission in many countries, but the prevalence of IDU among HIV 
positive individuals varies from one region to another. Even within a 
same country, there are marked differences in estimated HIV 
prevalence. Countries in Southeast Asia are of particular concern, as 
are Eastern Europe and Latin America, where HIV prevalence is 
estimated to be over 40% in IDU. Only 8 countries out of 148 reported 
zero prevalence of HIV patients in IDU populations (Mathers et al. 
2008) 
The transmission of HIV and other blood borne viruses leads to 
increases the significant morbidity and mortality associated with drug 
misuse and the life style of many injecting drug users reduces their 
access to success of ART (Vallecillo et al. 2014).  In the last 10 years, 
reporting of IDU and HIV rates in this population has improved. 
(Mathers et al. 2008)  
Previous estimates suggested that worldwide there were around 16 
million (range 11–21 million) IDU, and the patchy data then available 
suggested that about 3 million (range 1–7 million) IDU were living with 
HIV (Ball, Rana & Dehne 1998). There were few data to support the 
effectiveness of HIV preventions which targeted IDU in developing 
countries. However, there is evidence to support HIV prevention 
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programmes implemented in many other sociocultural settings (Ball, 
Rana & Dehne 1998). 
Malekinejad et al. conducted a cross-sectional survey in Iran to obtain 
HIV prevalence and risk behaviour in injection drug users in Tehran. 
HIV prevalence was 26.6% and was higher specifically in IDU who 
were sharing needles (Malekinejad et al. 2015). 
Injecting drug use is illegal in most countries and is particularly difficult 
to deal with in most Arabic countries. The reported importance of IDU 
as a risk factor for HIV varies from country to country, and is 
particularly important in Iran Bahrain and Oman (Malekinejad et al. 
2015; Mathers et al. 2008). 
In the Kingdom of Saudi Arabia, IDU is probably underestimated for 
social reasons but the proportion of IDU to HIV has varied from 0.14% 
in 1996 (Njoh & Zimmo 1997) to 10% in 2010 (Alshomrani 2014). The 
drug services in Jeddah, Saudi Arabia have been established for many 
years and in the past have not shown high rates of HIV in IDU. 
A study was performed in Al-Amal Hospital in Jeddah in 1996 to 
determine the prevalence of HIV among drug users, including patients 
visiting the hospital in 1995 - 1996. Only 3/2101 of the cases were HIV 
positive and the overall prevalence for HIV in drug users was 0.14% 
(Njoh & Zimmo 1997) 
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A more recent study examined of the inpatient records of admitted 
heroin addict to Al-Amal Hospital in Riyadh, KSA between 2006 and 
2009. 247 of 379 inpatients were IDU and included in the study. All the 
patients were males. The prevalences of HBV, HCV and HIV were 9%, 
82% and 10%, respectively. The study concluded that HCV infection is 
20 times higher in Saudi heroin addicts than in the general population 
while HIV infection is more than 600 fold higher, and the infection with 
HBV was not much different from that in the general population 
(Alshomrani 2014). 
Country  Year  IDU+HIV (n/N) 
Australia  2006 1.5%  (2243 /149591) 
Bahrain  2000 0.3%  ( NA ) 
Israel  2006 2.94% ( NA ) 
Italy  1996 12.1%  (39120 /326000 ) 
Iran  2015 26% (449/1726) 
Kuwait  NA 
Oman 2005 11.8% ( NA) 
Qatar  NA 
Saudi Arabia 1997 0.14%  (3 /2101 ) 
2014 10%  ( 24/247) (Alshomrani 2014) 
Spain  1998 39.7%  (33336/ 83972) 
Thailand  2001 42.5% (68224 /160528 ) 
Turkey  2005 2.6% ( NA ) 
UK 2006 2.3% (3597/156398 ) 
USA 2002 8.7% (161589/1857354) 
 
Table (1-11) Prevalence of HIV infection in IDU  (Mathers et al. 2008, Malekinejad et al. 2015)  
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1.3.7 Summary  
As in the rest of the Region, Saudi Arabia has an obvious deficit in data 
about the epidemiology and dedicated clinical information about many 
features of HIV infection. Coinfections with TB, HCV and/or HBV are 
important in this patient group but the available data are patchy and 
not always consistent. 
Simultaneously, there are no systematic reviews or data series about 
the epidemiological and socio-behavioural issues affecting high risk and 
hard to reach groups of patients, who may pose a particular risk for 
transmission of HIV in the kingdom.   
Therefore, this study aimed to improve these data gaps and increase 
the quality of data for HIV/AIDS patients in the Kingdom. The primary 
aims were to provide data on the clinical features, associated with risk 
factors and operational aspects of patient management in the largest 
HIV clinic in in the kingdom, in Jeddah. 
The aims were:  
1. Review the epidemiology of HIV in the Middle East and in 
particular in the Kingdom of Saudi Arabia (KSA). 
2. Review Regional and KSA data on coinfection of HIV with 
hepatitis B, C and tuberculosis. 
3. Describe the clinical presentation, demographic features and 
rates of coinfection in a large outpatient HIV clinic in Jeddah. 
4. Investigate the prevalence and types of primary resistance to 
antiretroviral therapy in HIV positive patients in Jeddah.       
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1.4. Antiretroviral Therapy (ART): 
The introduction of antiretroviral therapy (ART) and in particular 
combined highly active antiretroviral therapy (HAART), has dramatically 
changed the management and prognosis for people live with HIV, such 
that a normal or near normal life expectancy is predicted (Williams et 
al. 2014)  
There are several different classes of ART, each of which targets a 
phase of the HIV live cycle. These main classes include (Figure 1-11)  
 
i. Nucleoside Reverse Transcriptase Inhibitors (NRTIs). 
ii. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). 
iii. Protease Inhibitors (PIs). 
iv. CCR5 receptor blocker.  
v. Integrase inhibitors. 
 
There are many factors which may affect the clinical effectiveness of 
ART, including the importance of combining drugs from different 
classes.   Adherence to ART is also one of the most important factors in 
control of infection and prevention of the emergence of resistance to 
ART. 
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Figure (1-11) ARV and HIV life Cycle (Gebremaryam 2014) 
 
Over time HIV/AIDs treatment has been developed and improved from 
using a single ARV medication to the use of combinations of several 
classes of ARV therapy (Fischl, Richman et al. 1987, Enanoria, Ng et al. 
2004). The use of HAART has become the standard of care in modern 
clinical practice and detailed protocols of best practice are available 
internationally and frequently updated (Williams et al. 2014).  The 
introduction of triple highly active antiretroviral therapy (HAART) has 
dramatically improved the clinical management of HIV/AIDS patients. 
Studies performed soon after HAART became available in 1996 showed a 
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remarkable decline in mortality and morbidity of up to 85% in treated 
patients (Palella, Delaney et al. 1998, Flepp, Schiffer et al. 2001).  
 
However, about 2 years after the FDA approval of the use of zidovudine 
(ZDV), the first available NRTI, the first drug resistance was discovered in 
1992 (Erice, Mayers et al. 1993). Resistance to ART medication is an 
important and crucial issue in management of HIV/AIDS patients. 
Reporting of resistance to ARV’s has been increasing since the first 
discovery in 1992 and gradually included all ART classes (Johnson, Brun-
Vezinet et al. 2006). 
Further experience has shown that patients must adhere rigorously to the 
full treatment regimen, with considerable loss of efficacy and the risk of 
emergence of drug resistance if the medication is taken less than 90% of 
the time (Romanelli & Pomeroy 2000). Poor adherence is encouraged by 
the frequent side-effects caused by the medication, logistic difficulties in 
drug supply or clinic attendance, and more complex psychosocial issues. 
Interruptions of treatment are clearly associated with increased risk of 
drug resistance and subsequent failure of treatment (Romanelli & 
Pomeroy 2000). In resource poor settings, access to antiretroviral therapy 
is increasing due to the development of extensive international HIV/AIDS 
organization collaborations as the UNAIDS Estimation and Projection 
Package (EPP) (Brown et al. 2010). 
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Figure (1-12) Adherence and ART resistance (Bangsberg, Moss & Deeks 2004) 
 
A meta-analysis of the efficacy of ART in HIV/AIDS programmes in 
resource poor settings concluded that ART programmes in such 
countries may have similar results and may be just effective as in well 
developed countries (Ivers, Kendrick & Doucette 2005). However even 
with these organization and input of international panels such the 
International AIDS Society-USA, this is not universal and such roll-out 
programmes are vulnerable to interruptions in drug supplies (Hirsch et 
al. 2008). 
Therefore, it is helpful to have ART sensitivity tests to assess the 
effectiveness of ART in individuals with HIV infection. This is a crucial 
management tool to help to determine the best ART combination 
therapy for patients with HIV and to guide changes if resistance 
emerges (Johnson, Brun-Vezinet et al. 2006). 
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1.4.1 Types of ART resistance testing: 
When ART resistance testing was first introduced, there were few standard 
definitions for the role of ARV resistance testing. In clinical practice ARV 
testing is used to predict the failure of treatment rather than measuring 
success. There were several ARV resistance assays (genotypic and 
phenotypic) already in use in the clinical field and these have evolved over 
the time (Mayers 1996). Currently, the most common form of resistance 
testing is genotypic resistance testing. Mutations are known to be associated 
with certain ARV resistance (Lessells, Avalos & de Oliveira 2013). 
Resistance usually occurs because HIV has a very rapid replication and HIV 
reverse transcriptase has no proofreading function. Therefore, mutations 
may occur even before ART is started. The resistant virus is usually present 
at low concentrations in the absence of treatment. However, once the 
patient starts on ART, the low numbers of mutated virus rapidly becomes 
higher.  Very low concentrations of mutated virus population can be missed 
by either resistance testing method, due to sampling errors in a population 
of HIV that is predominantly sensitive to ARV’s.   
There are two main types of measuring ARV resistance. Phenotype and 
genotype test. 
Phenotypic ARV resistance testing is an in vitro measurement of the 
concentration of ARV drug needed to inhibit 50% of growth (IC50) or 90% 
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(IC90) of growth of HIV culture in the laboratory (Rodriguez-Rosado, Briones 
et al. 1999). It is performed by growing the virus in culture media with 
various amounts of drugs added. This allows direct measure of viral 
resistance but it does not explore nature of the underlying mutations, just 
their effect on the ability of the drug to stop the virus from replication. 
Figure (1-13) summarising the relationship between drug concentration and 
viral inhibition (Loi, Modlinski & Ptak 2011).  
  
 
Figure (1-13) Phenotypic Susceptibility: the resistance shifts the inhibition of in vitro HIV growth by 
ARV to the right  (Loi et al. 2011) 
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Phenotypic resistance testing is easy to interpret, but it is expensive and 
time consuming with a high degree of variability (2.5 to 4 fold). It cannot 
identify trends or small changes and does not take into effect 
pharmacokinetics: some drugs may be clinically ineffective if this is only a 2x 
change in phenotypic resistance, while for others a 10x change may be 
needed before a clinically important effect is noted (Perez-Elias et al. 2003). 
Virtual phenotypic testing is a way of interpreting genotypic test results. 
After the sample is tested by genotypic method, phenotypic test results for 
other virus samples with a similar genotypic pattern are taken from a 
database. Matched samples inform how the virus is likely to behave. The 
virtual phenotype is faster and less expensive than a phenotypic test (Perez-
Elias et al. 2003). 
In 2003 a study by Perez-Elias et al. compared ART choices depending on 
phenotypic or virtual phenotypic tests, which were compared in a 
prospective, randomized, double-blind, multicentre, controlled clinical trial. 
They found that virtual phenotypic testing is at least as effective as 
phenotypic testing when used to select an optimized treatment for patients 
who have failed one or more antiretroviral regimens (Perez-Elias et al. 2003). 
The virtual phenotype procedure is a computerised method characterized by 
a simple laboratory experiment that yields complex information on the 
patient, which is interpretable in terms of the relevant disease phenotype 
(Lengauer, Pfeifer & Kaiser 2014). 
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Genotypic resistance refers to the mutations that are selected for by drugs 
when a patient has virological failure. Genotypic resistance testing looks for 
the genome sequences in HIV RNA virus that have mutations conferring 
resistance to specific antiretroviral drugs. This is performed by isolating virus 
from serum/plasma of the patients and directly sequencing the viral nucleic 
acid coding for reverse transcriptase and protease. Resistance to specific 
drugs is predicted based on known point mutations in genetic sequences in 
each location (Tisdale et al. 1993, Loi et al.2011). 
Such tests aim to provide more accurate information at the genome level 
about mutations that may lead to ART resistance.  This helps clinicians as 
well as patients to have the best ART choice and hence to improve therapy 
plans and treatment outcomes (MSAC 2009) 
Results from viral RNA sequencing are compared to a large database of wild 
type HIV sequencing. The Stanford HIV Drug Resistance Database hosts a 
freely available online genotypic resistance interpretation system called 
HIVdb. This system is available to help clinicians and laboratories interpret 
HIV-1 genotypic resistance tests including resistance and susceptibility of 
NRTI, NNRTI and PI. The HIVdb genotypic resistance system gives the 
results as an XML report (Liu & Shafer 2006) and can be accessed through 
the website http://hivdb.stanford.edu/pages/webservices/.  Examples are 
shown in (Figure 1-14)  
Genotypic resistance testing is relatively fast and inexpensive. However, in 
relation to the interpretation of results, phenotypic resistance testing is 
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easier to interpret, and the contribution of some mutations to phenotypic 
resistance is controversial. Occasionally, certain combinations of mutations 
can interact to restore ART sensitivity although individually they act to confer 
resistance (Mayer et al.2001). ARV resistance in the Region is reviewed in 
chapter 5.  
Metzner et al. tested 4 patients who experienced early virological failure of a 
first-line regimen of lamivudine for ART resistance. Before treatment no drug 
resistance was noted by the standard genotype analysis. A few weeks after 
of starting ART, most of the minority quasispecies were rapidly selected and 
represented the major virus population. The study concluded that minority 
mutations of drug-resistant viruses, can rapidly become the major virus 
population and lead to ART resistance in naïve patients  when the start 
treatment (Metzner et al. 2009). This explains the need to monitor HIV viral 
load after starting treatment, and to test for resistance if viral load 
suppression is suboptimal (BHIVA 2013)   
The current prevalence and patterns of HIV drug-resistance in treatment-
naïve and treatment-experienced patients in KSA are unknown. In line with 
initiatives taken internationally, the National authority in the Kingdom is 
supporting this study as part of the Saudi policy of supporting medical 
research to inform national treatment programmes. 
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. 
Figure 1-14  Significant mutations IAS-USA  (Wensing et al. 2014) 
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Figure 1-14 Significant mutations IAS-USA  (Wensing et al. 2014) 
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Chapter 2 
Methodology 
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2.1 Clinical and laboratory features of HIV/AIDS in the Kingdom 
of Saudi Arabia:  
 
This is a descriptive, retrospective cohort study, performed in the HIV 
outpatient clinics at King Saud Hospital (Infectious Disease Hospital) in 
Jeddah, KSA. 
These clinics are part of the national Saudi programme for HIV patients 
under Ministry of Health (MOH) supervision. Primary contact was 
established with the coordinator of the Saudi AIDS national programme 
in Jeddah region, Dr. Felmban and the Hospital Director General, Dr. 
Shikhon, for the study plans and methods. Initially it was thought that 
other hospitals might be included in the study according to availability of 
patients and data follow up, but this was not logistically possible. 
During the planning phase, contact was made with Dr. Mohamed Baksh, 
general director of King Abdulaziz (Red Sea) Hospital in South Jeddah 
(MOH), which had up to 120 admissions with HIV a year but relatively 
little outpatient activity. However, the study finally focused on the clinics 
of King Saud Hospital North Jeddah (Programme Director, Dr. Sana 
Filmban), which provide the main clinics for patients in Jeddah in the 
Saudi programme for HIV prevention.  
This hospital has 150 beds with up to 60 admissions a year for HIV and 
120 admissions for other infectious diseases. In the year of the study in 
2012 there were 3 clinics a week for a cohort of about 800 adults with 
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HIV, run by 3 doctors (specialist and 2 consultants) and 6 specialist 
nurses. 
Patients are referred from all other clinics and hospitals in Jeddah and 
ART is provided free from the hospital pharmacy. Patients typically 
attend every 2-3 months for follow up.  
There is no specific community outreach.  There was no comprehensive 
management protocol but usually the same protocols recommended and 
used by the developed Western countries such as BHIVA guidelines are 
followed by the treating physician at the clinic. The most commonly 
prescribed ART is a three drugs regimen containing 2 NRTI (usually 
tenfovir/emtricitabine or abacavir/lamivudine and formerly zidovudine 
and a third agent (NNRTI, PI or more recently INI). For treatment naïve 
patients the most prescribed combination is tenofovir, emtricitabine and 
efavirenz, with nevirapine as an alternative NNRTI. The usual protease 
inhibitors at that time included ritonavir boosted lopinavir or darunavir.   
Enzyme-linked immunosorbent assay (ELISA) HIV test is the main 
screening test for Saudi Arabian Ministry of Health which is usually 
confirmed by Western-Blot (WB) test or more recently, a second ELISA 
test. A compulsory HIV screening test is required in case of clinical 
suspicion, preoccupation screening, before marriage and routine HIV 
blood test for hospitalized patients or those followed in clinics. 
HIV tests are compulsory before getting married and before taking up 
several occupations. This is the rule for all governmental careers and 
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occupations in the Ministry of Labour in Saudi Arabia. They are also 
performed routinely on inpatients and patients attending general 
outpatient clinics. They also may be requested on clinical suspicion of 
HIV.       
All HIV related special tests in Jeddah are centralized. CD4+ counts and 
HIV viral load are available in King Saud Hospital (Infectious Disease 
Hospital), King Abdulaziz University Hospital Lab and Jeddah Central Lab 
by MOH in Jeddah. HIV resistance test and HLA B*5701 test are not 
routinely available for HIV patients,  but can be done at the King 
Abdulaziz University Hospital Lab. Records of patients with resistance to 
ART are available in the HIV lab records and individual patient files from 
which data can been extracted. 
All patient data are created in computer and individual clinical records. 
These records are stored confidentially in the hospital record department 
with access only to authorized persons. As a registered Saudi doctor I 
was permitted to attend the clinics and permission was obtained to allow 
me to access to the medical records department, where the clinical 
patient records are kept safely in computers and hard drives. 
 
 
 
 
119 
 
2.2 Data collection and anonymising  
A list of all patients who had ever attended the clinic in the years 2000-
2010 was provided and I extracted the computerized case records of 
each patient within the same records area of the hospital. 
Required data (detailed in appendix B) included patient’s code, age or 
date of birth, sex, education level and marital status, duration of 
infection, age at diagnosis. Clinical data from the patient’s history in the 
records included presenting history, how HIV was diagnosed, risk factors 
and history of coinfections.  
Laboratory data included WBC, Hb, lymphocytes and absolute CD4+ cell 
count. CD4 percentage was not routinely recorded for all patients, 
however it was available for some patients as was CD8+ cell count. 
Serology for common viruses and other infections were not available for 
all patients and I recorded each result as positive, negative or not done. 
Viral load was also recorded in copies/mm3  
Data required for study were copied manually from the primary source 
on a standardized paper record form designed for the study (Appendix 
A). Data were stored anonymously, using a code labelled to specific 
patients in a log listing designed for the study (Appendix B). Anonymized 
individual records were transferred into a secure excel spreadsheet on 
the investigator’s laptop and stored as password encrypted data and 
password protected laptop. No case records or identifiable patient data 
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left the records area of the hospital or clinic. Access to the anonymized 
data was for myself and my supervisor only.       
2.3.1 Important definitions: 
HIV/AIDS patients: this included all HIV positive patients seen at King 
Saud Hospital (Infectious Disease Hospital) outpatient clinics in the 11 
year period 2000-2010 inclusive. 
HIV cases were staged according to WHO criteria (WHO 2007)(Table 2-1)  
2.3.2 TB co infection:  
 
This followed the World Health Organization (WHO 2007) definition for 
TB diagnosis depending on sputum smear positive for acid fast bacilli 
(AFB). This definition has been also confirmed by joint publication of the 
WHO, the International Union against Tuberculosis and Lung Disease 
and the Royal Netherlands Tuberculosis association (KNCV) (WHO 2007).  
International policy for TB case detection: 
1- Tuberculosis in a patient with at least two initial sputum smear 
examinations positive for acid fast bacillus (AFB+), or 
2- Tuberculosis in a patient with one sputum examination positive for AFB+ 
and radiographic abnormalities consistent with active pulmonary 
tuberculosis as determined by the treating medical officer, or 
3- Tuberculosis in a patient with one sputum specimen positive for AFB+ 
and culture positive for AFB+.          
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The revised definition of a new sputum smear-positive pulmonary TB 
case is based on the presence of at least one acid fast bacillus (AFB+) in 
at least one sputum sample in countries with a well-functioning external 
quality assurance (EQA) system. 
 
2.3.3 HCV co infection: 
 In this study HCV coinfection was defined as HIV patients who have a 
positive HCV antibody test. Unfortunately there were no HCV PCR tests 
available in the vast majority of the patients, which was one of the 
limitations of this study. Interpretation of HCV serology is summarised in 
table (1-9) 
 
2.3.4 HBV co infection: 
In this study HBV coinfection was defined as HIV patients who have 
positive HBV surface antigen test (HBsAg). There were no anti-HBV 
antibody tests, which was a limitation of the study. Detailed 
interpretation of HBV serology is summarised in table (1-9)  
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2.4.1 WHO AIDS Staging  
Clinical 
Stage 
Clinical Conditions or Symptoms 
Primary HIV 
Infection 
• Asymptomatic 
• Acute retroviral syndrome 
Clinical 
Stage 1 
• Asymptomatic 
• Persistent generalized lymphadenopathy 
Clinical 
Stage 2 
• Moderate unexplained weight loss (<10% of presumed or measured body weight) 
• Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis) 
• Herpes zoster 
• Angular cheilitis 
• Recurrent oral ulceration 
• Papular pruritic eruptions 
• Seborrheic dermatitis 
• Fungal nail infections 
Clinical 
Stage 3 
Unexplained severe weight loss (>10% of presumed or measured body weight) 
• Unexplained chronic diarrhoea for >1 month 
• Unexplained persistent fever for >1 month (>37.6°C, intermittent or constant) 
• Persistent oral candidiasis (thrush) 
• Oral hairy leukoplakia 
• Pulmonary tuberculosis (current) 
• Severe presumed bacterial infections (e.g., pneumonia, empyema, pyomyositis, bone 
or joint infection, meningitis, bacteraemia) 
• Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis 
• Unexplained anaemia (haemoglobin <8 g/dL) 
• Neutropenia (neutrophils <500 cells/µL) 
• Chronic thrombocytopenia (platelets <50,000 cells/µL) 
Clinical 
Stage 4 
• HIV wasting syndrome 
• Pneumocystis pneumonia 
• Recurrent severe bacterial pneumonia 
• Chronic herpes simplex infection (orolabial, genital, or anorectal site for >1 month or visceral herpes at any 
site) 
• Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs) 
• Extrapulmonary tuberculosis 
• Kaposi sarcoma 
• Cytomegalovirus infection (retinitis or infection of other organs) 
• Central nervous system toxoplasmosis 
• HIV encephalopathy 
• Cryptococcosis, extrapulmonary (including meningitis) 
• Disseminated no tuberculosis mycobacteria infection 
• Progressive multifocal leukoencephalopathy 
• Candida of the trachea, bronchi, or lungs 
• Chronic cryptosporidiosis (with diarrhoea) 
• Chronic isosporiasis 
• Disseminated mycosis (e.g., histoplasmosis, coccidioidomycosis, penicilliosis) 
• Recurrent nontyphoidal Salmonella bacteremia 
• Lymphoma (cerebral or B-cell non-Hodgkin) 
• Invasive cervical carcinoma 
• Atypical disseminated leishmaniasis 
• Symptomatic HIV-associated nephropathy 
• Symptomatic HIV-associated cardiomyopathy 
• Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis) 
 
Table (2-1) WHO Clinical staging (WHO 2007) 
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Data were processed and analysed using double entry into Excel 
(Microsoft office 2010) and SPSS V22 programs (IBM 2013). Statistical 
analysis included quantitative descriptive analysis and summary statistics 
(means, median, percentages, standard deviations, etc) with comparisons 
of demographic and other features.  
 
The sample size required according to the statistical power calculations 
were as follows: 
The expected rate of hepatitis C co-infection was about 3.5%. A sample 
size of 2000 is thus expected to produce 70 co-infected and 1930 non 
coinfected HIV positive patients. These numbers would provide 80% 
power to detect factors potentially related to co-infection with odds ratios 
(OR) of between 2.1 and 2.6, and 90% power to detect factors potentially 
related to co-infection with odds ratios of 2.3 to 3.0 (assuming the risk 
factor is present in 10% to 50% of the non-co-infected group). 
The expected rate of TB co-infection was about 7.4%.  A sample size of 
2000 is thus expected to produce 148 co-infected and 1852 non co-
infected HIV positive patients.  These numbers will provide 80% power to 
detect factors potentially related to co-infection with odds ratios of 
between 1.65 and 2.0, and 90% power to detect factors potentially 
related to co-infection with odds ratios of 1.8 to 2.2 (assuming the risk 
factor is present in 10% to 50% of the non-co-infected group). 
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At the time of data collection the total number of patients found officially 
registered in the Jeddah clinic was 1383 patients. All these were included 
in the retrospective study, as a preliminary for more focused prospective 
data collection in the second study later. 
Data collection was performed in 2011. Prior ethical permissions were 
obtained from the Research Ethics committee of Liverpool School of 
Tropical Medicine (LSTM) (ref. 10.66) and approved in 6 November 2010. 
Permission was obtained from the local authorities in KSA (Appendix E). 
2.5. Antiretroviral resistance in treatment naïve HIV 
patients in Jeddah  
The study included HIV positive Saudi patients who were attending 
the clinics or had been admitted to King Saud Hospital in Jeddah. 
The study has several sequential phases.  
These clinics are part of the national Saudi programme for HIV patients 
under Ministry of Health (MOH) supervision. As described in detail in 
chapter 5, 1383 patients attended the clinic from 2000 to 2010, of whom 
25% had never received ART.  
Laboratory work for genotypic resistance testing by Sanger method took 
place at the Liverpool Virology Centre at the Royal Liverpool University 
Hospital.  I have participated in basic laboratory techniques but 
advanced techniques and advanced sequencing analysis were done by 
professional virology lab staff. Samples were then sent to the Public 
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Health England laboratory in Colindale London, UK for genotypic 
resistance testing by next generation sequencing (NGS) method. 
2.5.1 Patient recruitment  
Over the period of 3 months (November 2013 – February 2014) blood 
samples were collected from HIV treatment naïve cases attending King 
Saud Hospital in Jeddah. All 664 patients attending in this period were 
approached and screened for eligibility for inclusion.  
Patients attending the clinic routinely provide consent for blood samples 
to be taken for their routine care. ART resistance testing is not routinely 
available in KSA, although it is essential for best practice. Testing is 
currently only available as a special request in KSA. 
For this study, patients were asked to provide an extra 10-15 ml of blood 
as part of their clinical management as well as for research purposes. It 
was explained that part of the sample would be used primarily for 
research purposes to inform about patterns of new HIV infections in the 
Kingdom.  
All patients were informed in detail and in their native language about 
the procedure and the test. The blood sample was taken by a well-
trained and authorised medical doctor and the WHO guideline for blood 
drawing in HIV patients was strictly followed (WHO 2010). Storage and 
transportation of the samples were performed according to CDC 
guidelines (CDC 2010). 
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Participants gave informed written consent (Appendix C) and coded data 
were recorded at the clinic visit including basic demographic and clinical 
features and details of ART exposure. These were collected anonymously 
onto a standardised anonymised data form, using a study code to link 
the data with the blood sample taken at the visit (Appendix A). Results 
were coded and the code list was known only to the treating clinician at 
KSH clinics in Jeddah to ensure confidentiality.  
Minor patients (under age of 18 years) and patients who refused to 
participate were excluded from the study.  
Primary contact had been established with the coordinator of the Saudi 
AIDS national programme, Assistant Deputy Minister for Preventive 
Medicine and the Hospital Medical Director study plans and methods 
The contacts are summarised in the table (2-2) below. While this is an 
overall description (anonymised) of the whole clinic population, patients 
who provide clinical data and blood samples had improved medical care, 
as data on ARV resistance were sent back to the treating physician with 
code numbers.  
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Hospital 
name  
Address Contacted person  
Ministry of 
Health 
Saudi Arabia 
Riyadh 
(MOH) 
Dr.Ziad Memish 
(Infectious Disease Consultant & Assistant Deputy Minister for 
Preventive Medicine) 
King Saud 
Hospital  
Jeddah 
(KSH)  
Dr.Batool Ali  
(Infectious Disease Consultant & Hospital Medical Director) 
 
Table (2-2) main Jeddah contacts 
 
2.6 Samples storage and transport  
 
Samples were sent initially to King Saud Hospital Laboratory  in 10ml 
EDTA tubes and processed according to the manufacturer’s 
guidelines. Whole blood was centrifuged and serum and plasma 
separated within 8 hours of blood withdrawal. The minimum plasma 
sample volume required is 6 ml, which was shipped in three vials each 
contain 2ml in addition to serum vial which contain at least 2ml. 
Blood samples were collected from all newly diagnosed patients seen 
during the study period and all patients who were not on ART. The 
original estimated sample size was 100-150 patients.  
Plasma and serum samples were stored at KSH laboratory. Under a 
Transport Agreement (MTA) and International Air Transport 
Association (IATA) regulations, collected blood samples were 
refrigerated and stored in -70 oC according to CDC guideline for 
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collection and transportation of human specimen. They were 
transported to the Liverpool Virology Centre by approved international 
courier. The samples underwent sequencing of the HIV-1 RNA 
genome to detect drug resistance and determine the HIV-1 subtype. 
 
2.7. Lab work methodology: 
 
The in-house HIV resistance test in Liverpool was used for partial 
sequencing of the pol region of the HIV genome for detection of anti-
retroviral resistance mutations.  
2.7.1 Principles of examination:  
 
This is a one-step real time-polymerase chain reaction (RT-PCR) which 
amplifies a 1284bp segment of the HIV pol region. PCR is then used 
to generate two overlapping products to cover protease codons and 
codons 1-235 of the reverse transcriptase gene. These products are 
sequenced in both directions and interpreted using the Stanford 
University HIV Drug Resistance Database (SDRD) version 6.31 20th 
September 2013. 
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2.7.2 HIV drug-resistance testing/nucleic acid sequencing: 
 
HIV RNA plasma was isolated the by automated extraction, 
amplification of  the viral genetic region of interest by PCR, and 
subsequently sequencing the amplified product by population (Sanger 
sequencing) and next-generation sequencing with deep sequencing 
for the sensitive detection of rarer mutations and cloning for an in-
depth characterisation of novel viral strains of interest. NGS method 
was performed at the PHE Colindale laboratory in London.  
2.7.3 Specimen requirements, means of identification and 
collection procedure:  
 
EDTA plasma samples were extracted as soon as possible or aliquoted 
into sterile 2ml ampoules stored at -70 oC, as previously discussed.  
Universal precautions were applied to all specimens. Personal 
protective equipment is worn when handling samples and Class 1 
biosafety cabinet used where appropriate.  
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2.7.4. Instrumentation, equipment and special supplies:  
 
 Pipettes  Qiasymphony  
 
 9700 and 2720 
thermalcyclers  
 3130 genetic 
analyzer 
 Sterile tips 
with filters  
 
 PCR reaction 
tubes  
 
 pack 
 
 Geneflow gel tank 
and Consort 
electrophoresis 
power 
 Vortex   Plate centrifuge   Qiacube  GeneSeq software 
for gel analysis 
 
Table (2-3) Instrumentation, equipment and special supplies for Sanger method. 
 
2.7.5. Reagents:  
 
New Qiagen RT-PCR and HotStart Taq master mix kits which are 
stored at (-20oC) were used. 
New primers are kept at +4oC. Once re-hydrated with nuclease-free 
water to a stock concentration of 100µM, further dilutions are made 
to 10µM and aliquots of the 10µM primer mixes along with the 
100µM stock solutions are stored at -20oC. 
 
 
 
 
 
 
 
 
 
 
131 
 
 
2.7.6. HIV-RNA extraction (purification): 
 
RNA was purified from aliquots (1.2 ml) of plasma using the DSP 
Virus Cell-Free 1000 protocol instructions on the automated 
QIAsymphony® extraction platform (Qiagen, Crawley, UK) 
according to the manufacturer’s description. RNA was eluted into 
110 µl volume of elution buffer. 
2.7.7. PCR: 
 
A nested PCR protocol was used to amplify HIV-1 protease and 
reverse transcriptase regions. 
The Qiagen One-Step RT-PCR kit was used for first round 
amplification. 20µl of extracted RNA was added to a PCR containing 
1 µl primers Pin16 and Prot3 in a final volume of 50µl. Reactions 
were desiderated at 95 oC for one minute and cooled to 50 oC for 
five minutes before addition of the reverse transcriptase enzyme. 
Then the following thermocycle conditions were used. 
1 cycle of 40 cycles of 1 cycle of   
95  oC   1 min  
50 oC   35 min  
95 oC 15 min  
 
94  oC  30 sec  
54 oC  30 sec  
72 oC 1 min 20 sec  
 
72 oC 10 min  
4 oC hold 
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2.7.8 Nested Protease and Reverse Transcriptase PCRs  
 
2ul of primary RT-PCR product has been used as template in 2 
second round PCRs using primers Pin 3 and Pin 4 to amplify 
protease region and primers Pin 18 and Pin 2 to amplify the HIV-1 
reverse transcriptase region. Second round thermo cycle conditions 
were as follow: 
1 cycle of 40 cycles of 1 cycle of   
95  oC  15 min 
  
 
94  oC  30 sec  
54  oC  30 sec  
72  oC  1 min  
72  oC  10 min  
4    oC  hold 
 
 
2.7.9. PCR Product Quantification :  
 
PCR products for protease (457 bp) and reverse transcriptase (804 
bp) were visualised using a 1.5% agarose gel on a gel 
documentation (gel doc) system and GeneSeq software Figures 2-1 
and 2-2.   
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2.7.10. Big Dye Cycle Sequencing PCR:  
 
Primers Pin4, Pin4B and Pin3 were used to primer protease 
sequencing resistance, whilst primers Pin18, Pin2, Pin9 and Pin8 for 
the reverse transcriptase. The primer sequences are available upon 
request from Liverpool Specialist Virology centre. Then 19µl of each 
master mix (MM) were added into a 96-well PCR reaction plate in a 
rack. Secondary PCR product (1µg) was added to Big Dye V1.1 
(Life Technologies, Paisley, UK) sequencing reactions in a final 
volume of 20µl using the amplification thermaocycle conditions 
below: 
 
1 cycle of 25 cycles of 1 cycle of   
95  oC  1 min  
 
96  oC  10 sec  
50  oC  5 sec  
60  oC  4 min 
4    oC  hold 
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Figure (2-1) Band intensities for Reverse transcriptase (804 bp) all 
channels showed protein band of RT samples 1-36  
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Figure (2-2) Band intensities for Protease (457 bp) all channels showed 
protein band of Protease samples 58-88 
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2.8. Data Collection Software and Data Analysis: 
 
SA3500 data Collection software V3.0 (2009) was used for sequencing 
data collection and SeqScape software V2.7 (2009) was used for 
sequencing data analysis.  
2.9. Sample size and ethics: 
 
Currently, 1383 patients have attended the HIV clinic at King Saud 
Hospital, the main centre of the Saudi programme for HIV/AIDS patients 
in Jeddah region in the past decade. The proportion of patients currently 
receiving antiretroviral therapy is about 75%.  
This sample size has been calculated by using the national statistical 
services (NSS) sample size calculator in the World Wide Web (NSS 
2012).  
The estimated rate of ARV resistance in ART naïve HIV patients is about 
6.4 %, based on a single publication from Oman (Al Dhahry et al. 2004).  
The sample size was calculated, aiming for 95% confidence and a 
precision of +/- 0.02. A sample size of 109 treatment naïve HIV positive 
patients is thus expected to include about 8 ARV resistant and 101 non-
ARV resistant patients.  These numbers will allow the true ARV 
resistance prevalence rate to be estimated with an exact binomial 95% 
confidence interval of 0.09 (0.46 to 0.59).  
The study was approved by the Research and Ethics Committee of the 
Liverpool School of Tropical Medicine (reference 12-15, Appendix E) and 
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the Institutional Review Board of King Fahd Medical City, Riyadh for the 
Ministry of Health (reference 12-159, Appendix E). 
 
2.10. Next Generation Sequencing methodology: 
Samples were processed for deep sequencing by Next Generation 
Sequencing (NGS) at the Public Health England Laboratory in Colindale 
London, UK. Samples were processed according to the following 
protocol: 
 
2.10.1 RNA extraction 
  
200 l of each sample was extracted using QIAamp UltraSens Virus Kit 
(QIAGEN) as per the kit instructions and eluted into 60l.  
 
 
 
2.10.2 PCR amplification 
 
1.3kb region of the HIV pol gene was amplified by single-step reverse 
transcription (RT) first round PCR followed by a nested PCR.  RT-first 
round PCR was carried out using One-Step RT PCR kit (QIAGEN) using 
10µl of extract in 50µl reactions containing 0.3µM of each primer, 
according to the manufacturer’s instructions (forward primer, P1: TGA 
ARG AIT GYA CTG ARA GRC AGG CTA AT; reverse primer, R2: CCT CIT 
TYT TGC ATA YTT YCC TGT T). 
The cycling conditions were 50C for 40 minutes, 95C for 15 minutes 
followed by 35 cycles of 94C for 30 seconds, 53C for 30 seconds, 72C 
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for 1 minute and then 4 minutes at 72C.  One µl of first round products 
were carried forward into 50µl nested PCR reactions containing 0.3µM of 
each primer using Platinum Taq (Life Technologies).  
 
 
Nesting primers were P7: CTT TAR CTT CCC TCA GAT CAC TCT, R8: 
GGC TCT TGA TAA ATT TGA TAT GTC CAT. The cycling conditions used 
were 95C for 5 minutes then 35 cycles of 90C for 30 seconds, 50.3C 
for 30 seconds, 72C for 1 minute followed by a further 2 minutes at 
72C.  
 
2.10.3 Library preparation for sequencing 
 
PCR products were visualised using agarose gel electrophoresis and then 
purified using QIAQuick kit (QIAGEN).  DNA was quantified using both 
Qubit® dsDNA Broad Range and High Sensitivity Assay Kits and the 
Qubit® 2.0 Fluorometer (Life Technologies).  One ng/µl of the amplified 
DNA was used for library preparation with the Nextera XT DNA sample 
prep kit (Illumina) as per the kit protocol.  Next generation sequencing 
was performed on the MiSeq system (Illumina).  
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2.10.4 Bioinformatic analysis.   
 
Following the generation of the paired end reads, a subset of the reads 
from each fastq file was compared to a local database of HIV reference 
sequences using BLAST in order to identify an optimum reference 
sequence in preparation for mapping. Reference mapping was then 
performed using BWA-MEM version 0.7.5.  Utilising SAMTools the 
resulting files were then converted into BAM format in preparation for in-
house developed software, QuasiBAM which generates consensus 
sequences of the protease and reverse transcriptase regions and 
produces detailed information on the frequencies of minority variants 
present within each sample. These procedures were all automated using 
a computational pipeline developed in-house using Python and C++. 
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2.11. Definitions: 
 
2.11.1. Primary HIV drug resistance: 
Drug resistant HIV that results from becoming infected with a virus that 
is already resistant to one or more drugs (Geretti & Easterbrook 2001) 
 
2.11.2. Treatment emerging HIV Drug Resistance 
Drug resistant HIV that develops during ART treatment 
 
2.11.3. Recruitment and tests 
During the 3 month study period  (November 2013 – February 2014), 
664 different Saudi patients attended the clinic and 116 were identified 
as having never received ART. Of these 116, 109 (94%) agreed to take 
part in the study. The remaining 7 were not processed because 4 
patients refused to join the study and 3 samples had a low viral load 
and we could not process the genotypic resistance test. Paired data 
and blood samples were obtained from these 109 and ultimately 
genotypic resistance testing was successful in 96 (88%) of patients and 
results were obtained by next generation sequencing in 105 (96%) 
patients. Resistance tests were only completely unobtainable from 4 
(3.7%) patients (Figure 2-3). 
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Figure (2-3) Patient selection for ART resistance testing (VL= insufficient viral load 
for testing) 
 
 
 
diagnosed ≤1 year (157) Follow up patients ≥1 year(507)
Total number of HIV patients  664 (Nov. 2013- Feb. 2014) 
Duration of infection
<6 month 6-12 month 
Selected patients (109)
74 patients
No treatment
71
On treatment
3
83 patients
No treatment
24
On treatment
59
Duration of infection 
≥ 1 year
507 patients
No treatment
21
On treatment
486
Refused 3  ↓↓ VL  1 
Processed 
67 
Refused 1 ↓↓ VL 2
Processed 
21 
Refused 0  ↓↓ VL 0   
Processed 
21  
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Chapter 3 
Clinical features and epidemiology of 
HIV in Jeddah 
 
 
 
 
 
 
 
 
143 
 
 
3.1. Introduction 
As discussed in chapter 1, there are few systematic descriptions of HIV 
in Arabic countries including the Kingdom of Saudi Arabia, although a 
preliminary clinical report was published in 1993 (Ellis et al) and in 
2004 (Madani, Al-Mazrou et al. 2004) and more recently there have 
been publications on updated epidemiology in the Kingdom (Kabbash, 
Felemban et al. 2012). There had been no studies on prevalence of 
coinfection with TB or hepatitis and risk factors for such condition and 
no assessment of ART use. 
The aims of this study were to: 
1. Describe the demographic and clinical profile and laboratory features 
of a large cohort of HIV positive Saudi adults. 
2. Describe the prevalence of coinfections and the risk factors in the 
same cohort. 
3. Describe the use of ART and resistance tests in the cohort. 
The setting for the study is the largest HIV clinic in the Kingdom, at 
King Saud Hospital, Jeddah. 
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3.2. Results: 
Data were collected for all 1383 HIV/AIDS patients who were followed 
at King Saud Hospital under the Saudi Ministry of Health HIV/AIDS 
programme in Jeddah, between 2000 and 2010. Three quarters 
1026/1383 (74.2%) of the patients were males. 
 
3.2.1. Age and features of HIV infection 
 
The youngest patient was 18 years old and the oldest was 86 years, 
while the oldest age at diagnosis of HIV infection was 80. The mean 
(SD) age of patients was 41 (11.9) years and the median (range) was 
40 (18-86) years. The mean (SD) age at HIV/AIDS diagnosis was 36.7 
(11.4) years and the median (range) 35 (18-80) years. 
The patients were divided into five main categories according their 
age group. The first age category contains patients aged 18-25 years, 
the second 26-35 years, the third age category aged 36-45 years, 
patients aged 46-59 years and finally patients aged 60 years or older. 
Most of the patients (64%) fall in the middle two categories i.e 25-45 
years old.  Only 0.1% out of the total patients were older than 60 
years. About 9% of the patients were young (18-25 years) males. 
HIV infection duration was categorised into 4 groups which included a 
recent infection group 1-2 years, 2-5 years, 6-10 years and lastly 
patients who had HIV for more than 10 years. 
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Most of the patients included in this study were within the second and 
third groups. This means that most of the patients (93%) had been 
infected with HIV for 2-10 years. Only 1% of patients had HIV 
infection for more than 10 years and 6% were recently diagnosed 
(Table 3-1). 
HIV  
duration of 
infection  
 Female  Male  Total  
 n/N % N/n % n/N % 
1-2 years 26/357 7.3% 60/1026 5.8% 86/1383 6.2% 
2-5 years 159/357 44.5% 386/1026 37.6% 545/1383 39.4% 
6-10 years 168/357 47.1% 570/1026 55.6% 738/1383 53.4% 
10+ years 4/357 1.1% 10/1026 1% 14/1383 1% 
Total 357 100% 1026 100% 1383 100% 
Total  357  1026  1383 100% 
 
Table (3-1) HIV infection duration (n=1383) 
 
3.2.2. Educational level: 
Data on educational level were obtained for most of the patients but 
was not available for about 20% (286/1383).  
Poor education level was relatively common among these patients. 
More than quarters of the patients were illiterate, 27.4% (300/1097). A 
smaller proportion can read and write but have not achieved high 
school level. This was almost equally distributed between the two 
genders. More than half of the patients, 56% (620/1097), had at least 
a high school certificate. University degree holder or equivalent 
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composed about 5% (55/1097) of all HIV/AIDS patients with no 
significant gender difference (Table 3-4). 
 
3.2.3. Marital status:  
Over a third of the patients 488/1383 (35.3%) were single and most of 
these were men 435/488 (89%). The difference between single males 
and females was highly significant (P<0.001, OR 0.24, 95% CI 0.17-
0.33). 52.6% (727/1383) of the patients were married with significantly 
more married women (65.3%) than men (48.1%). 6% of all patients 
were divorced with no significant gender difference. More women 
(13.2%) have been widowed than men (3%) (Table 3-4) 
 
3.2.4. Reasons for HIV testing: 
The reasons for testing were not mutually exclusive, so results were 
reported and differences were analysed individually (Table 3-3). 
More than 57% (795/1483) were tested after being clinically suspected 
to have HIV infection after a visit to a medical centre. There was no 
significant difference between the two genders, in males 56% 
(578/1026) and in females 60% (217/357) (P= 0.14, OR 1.2, 95% CI 
0.93-1.5). 
3% (47/1383) of the patients were discovered to have HIV infection 
through premarital testing. 4% (37/1026) of males had a positive HIV 
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premarital test, twice as many as females 9/357 (2%), (p=0.3, OR 
0.69, 95% CI 0.33-1.44), although numbers are too small to reach 
significance (Table 3-3). 
More than half of the patients 51% (705/1383) were found to be HIV 
positive as part of routine blood tests, with equal proportions of males 
(52%) and females (46%), (P= 0.06, OR 0.8, 95% CI 0.62-1.02).  
8% (110/1383) of patients were found to be HIV positive after they 
had preoccupation medical tests, with no gender difference. 
 
3.2.5 Risk Factors for HIV: 
Probable heterosexual transmission was the most likely route in over 
half of the patients (709/1383). (Table 3-3, Figs 3-1A to 3-1C). 
Homosexual transmission, male to male (MSM) was the main route in 
26% of men (264/1026).  
23% (301/1288) were known to have unprotected sex with an HIV 
positive partner. 44% (133/301) of patients with a history of not using 
protection during sexual activity were men and women accounted for 
66%, although only 24% of the whole cohort were females (Table 3-2). 
Most of the females admitted to direct sexual contact with HIV positive 
patients. This was reported in the past medical history of 70% 
(210/301) of the women.  
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Around 7% (97/1329) of patients had a history of recent (in past 5 
years from the time of data collection) use of injecting drug (IDU) and 
most of these were males ie 81% (79/97).  
10% (148/1383) had a previous history of blood transfusion. About 
13% (46/357) of the females had received blood transfusion in 
comparison to 10% (102/1026) of the male HIV/AIDS patients, with no 
significant gender difference (Table 3-2).  
 
 About 7% (98/1383) of the patients had previously (in past 5 years 
from the time of data collection) been in prison. Again, those were 
predominantly males 73/98 (75%). 
A past medical history of having sexually transmitted infections (STI) 
was recorded in 6.4% (88/1383) of patients, with similar gender 
distribution, in about 6.5% (67/1026) of the males and 5.9% (21/357) 
in females. 
A past medical history of mental illness was found in 4% (55/1383) of 
all patients. A history of overseas travel was recorded in about 13% 
(179/1383) of patients. The proportion was similar in males and female 
(Table 3-2). 
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Table (3-2) HIV Risk factors in Jeddah, Saudi Arabia. Data on risk factors are not 
mutually exclusive, so totals are more than 100%  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sex  
Female Male Total  
n / N % n / N % n / N % No data  
(Missing) 
X2 P OR 95%CI 
Heterosexual  71/357 19.9% 638/1026 62.2% 709/1383 51.3% 0 189.63 0.00 0.1 0.1-0.2 
MSM 0 0% 264/1026 26% 264/1026 26% 0 - - - - 
IDU 18/330 5% 79/999 7.9% 97/1329 7% 54/1383 
(4%) 
2.2 0.13 0.6 0.3-1.1 
Blood products 46/357 12.9% 102/1026 10% 148/1383 10.7% 0 2.4 0.12 1.3 0.9-1.9 
Unprotected  
sex 
168/310 54% 133/978 13% 301/1288 23% 95/1383 
(7%) 
216.6 0.00 7.5 5.6-10 
Contact with 
HIV 
210/361 58.8% 91/997 9% 301/1358 22% 25/1383 
(2%) 
369.5 0.00 13.8 10.2-18 
History of  
prison 
25/357 7% 73/1026 7.1% 98/1383 7.1% 0 0.01 0.94 0.9 0.6-1.6 
History of   
STI 
21/317 6.6% 67/985 6.8% 88/1302 6.7% 81/1383 
(6%) 
0.01  0.91 0.97 0.5-1.6 
Overseas travel  39/357 10.9% 140/1026 13.6% 179/1383 12.9% 0 1.74 0.18 0.7 0.5-1.1 
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  n/N % 
Education level Illiterate 300/1097 27.4% 
Read and write 122/1097 11.1% 
High school  620/1097 56.5% 
University 55/1097 5% 
PG 0 0 
Missing Data 286/1383 20.7% 
Marital status  Single 488/1383 35.3% 
Married 727/1383 52.6% 
Divorce 89/1383 6.4% 
Widow 79/1383 5.7 % 
Reasons for HIV testing Clinical suspicion 795/1383 57.5% 
Routine serology 705/1383 51% 
Premarital test 46/1383 3% 
Preoccupation 110/1383 8% 
Presenting history  Respiratory 611/1383  44.2% 
Asymptomatic 408/1383 29.3% 
GI 312 /1383 22.6% 
 Skin & MS 45/1383 3.3% 
CNS 4/1383 0.3% 
Genitourinary 4/1383 0.3% 
CVS 2/1383 0.1% 
Risk factors  Heterosexual 709/1383 51.3% 
MSM 264/1026 26% 
IDU 97/1383 7% 
Blood Transfusion 148/1383 10.7% 
Unprotected sex 301/1383 21.8% 
Contact with HIV 301/1383 21.8% 
History of  prison 98/1383 7.1% 
STI 88/1383 6.4% 
Overseas travelling 179/1383 12.9% 
HIV  duration of infection 1-2 years 86/1383 6.2% 
2-5 years 545/1383 39.4% 
6-10 years 738/1383 53.4% 
10+ years 14/1383 1% 
Total 1383 100% 
 
Table (3-3) Demographic and clinical features results summary 
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Figure (3-1A) HIV main risk factors (males, n=1026) 
 
     
 
 
Figure (3-1B) HIV main risk factors (females, n=357) 
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Figure (3-1C) HIV main risk factors (whole cohort, n=1383) 
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3.2.6. Presenting history: 
Patients were divided in this study according to their main presenting 
symptoms at the time of diagnosis table (3-4). The most common was 
respiratory symptoms (44%). 29% (408/1383) of patients were 
asymptomatic. Patients who presented with gastrointestinal (GI) 
symptoms made up the third most common presenting group (22%).  
All other presenting symptoms including central nervous system 
(CNS), skin and musculoskeletal system, cardiovascular system (CVS), 
and genitourinary system (GUS) were present in a minority of the 
patients with total percentage less than 4% (56/1383). 
  Sex  
Female Male Total  
n/N % N/n % n/N % X2 * P * OR 95%CI 
Education Illiterate 61/287 21.3% 239/810 29.5% 300/1097 27.4% 7.2 0.007 0.64 0.4-0.88 
R&W 37/287 12.9% 85/810 10.5% 122/1097 11.1% 1.3 0.3 1.26 0.83-1.9 
high school 174/287 60.8% 446/810 55% 620/1097 56.5% 2.67 0.1 1.27 0.9-1.6 
University 15/287 5.2% 40/810 4.9% 55/1097 5% 0.04 0.84 1.06 0.55-2.02 
PG 0 0 0 0 0 0 - - - - 
Missing Data 70/357 19.6% 216/1026 21% 286/1383 20.7% - - - - 
Reasons for HIV 
testing 
Clinical suspicion 217/357 60.8% 578/1026 56.3% 795/1383 57.5% 2.14 0.14 1.2 0.93-1.55 
Routine serology 167/357 46.8% 538/1026 52.4% 705/1383 51% 3.39 0.065 0.8 0.62-1.02 
Pre-marital test 9/357 2% 37/1026 4% 46/1383 3% 0.97 0.3 0.69 0.33-1.44 
Preoccupation 25/357 7% 85/1026 8% 110/1383 8% 8.2 0.004 0.64 0.46-0.88 
Marital status Single 53/357 14.8% 435/1026 42.4% 488/1383 35.3% 88.04 0.00 0.24 0.17-0.33 
Married 233/357 65.3% 494/1026 48.1% 727/1383 52.6% 31.12 0.00 2.02 1.5-2.6 
Divorce 24/357 6.7% 65/1026 6.3% 89/1383 6.4% 0.07 0.79 1.07 0.6-1.7 
Widow 47/357 13.2% 32/1026 3.1% 79/1383 5.7 % 49.6 0.00 4.7 2.8-7.7 
presenting 
history at 
diagnosis  
asymptomatic 118/357 33.1% 287/1026 28% 408/1383 29.3% - - - - 
GI 81/357 22.6% 231/1026 22.5% 312 /1383 22.6% - - - - 
Resp. 141/357 39.5% 470/1026 45.8% 611/1383 44.2% - - - - 
CNS 0 0 4/1026 0.4% 4/1383 0.3% - - - - 
CVS 1/357 0.3% 1/1026 0.1% 2/1383 0.1% - - - - 
Skin & MS 14/357 3.9% 31/1026 3% 45/1383 3.3% - - - - 
Genitourinary 2/357 0.6% 2/1026 0.2% 4/1383 0.3% - - - - 
 
Table (3-4) HIV features in Jeddah, Saudi Arabia (n=1383) 
*(Uncorrected X2 and two tailed P)  
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Toxoplasma serology (IgG) serology was positive in 45% of the tested patients 
(311/684) but was missing in more than half of the patients. The difference 
between males (238/495, 48%) and females (73/189, 38.66%) was significant 
(P= 0.03, OR 0.68, 95% CI 0.48-0.97).  Cytomegalovirus (CMV) infection was 
tested in 65% (897/1383) of the patients and 70% (634/897) were positive 
with no significant difference between genders. Only 44.5% (616/1383) of 
patients were tested for Varicella Zoster Virus (VZV) antibodies. 33.4% 
(205/616) were positive with no difference between males at 34.6% (158/457) 
and females at 29.6% (47/159) (P =0.24, OR 0.79, 95% CI 0.53-1.2). Epstein - 
Barr virus (EBV) infection was tested in about 57% (788/1383) patients and was 
positive in 67% (531/788).  
 
60% (830/1383) of patients were tested for syphilis using the Venereal Disease 
Research Laboratory (VDRL) test and 15% (128/830) were positive. This 
included 16.5% (100/605) of males and 12.4% (28/225) of females (P>0.14, 
OR 0.72, 95% CI 0.45-1.15). Missing data and summary data are detailed in 
(Table 3-5).  
Although the proportion of males and females with positive VDRL were similar, 
there was significantly higher VDRL positivity rate in MSM (24.2%, 41/170) 
compared to other men (15%, 129/856) (X2=8.3, P=0.003, OR 1.79, CI 95% 
1.2-2.6) 
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 Sex  
 Female Male Total Missing Data  
 n/N 
(%) 
n/N 
(%) 
n/N 
(%) 
n/N 
(%) 
X2 P OR 95%CI 
 
Toxo. 
 
73/189 
 
(38.6%) 
 
238/495 
 
(48%) 
 
311/684 
 
(45.5%) 
 
699/1383 
 
(50.5%) 
 
4.93 
 
0.03 
 
0.68 
 
0.48-0.97 
 
CMV 
 
159/242 
 
(65.7%) 
 
475/655 
 
(72.5%) 
 
634/897 
 
(70.7%) 
 
486/1383 
 
(35%) 
 
3.96 
 
0.05 
 
0.73 
 
0.52-1.01 
 
EBV 
 
142/220 
 
(64.5%) 
 
389/586 
 
(66.4%) 
 
531/788 
 
(67.4%) 
 
595/1383 
 
(43%) 
 
1.12 
 
0.28 
 
0.84 
 
0.6-1.18 
 
VZV 
 
47/159 
 
(29.6%) 
 
158/457 
 
(34.6%) 
 
205/616 
 
(33.3%) 
 
767/1383 
 
(55.5%) 
 
1.34 
 
0.24 
 
0.79 
 
0.53-1.2 
 
VDRL 
 
28/225 
 
(12.4%) 
 
100/605 
 
(16.5%) 
 
128/830 
 
(15.4%) 
 
553/1383 
 
(40%) 
 
2.1 
 
0.14 
 
0.72 
 
0.45-1.15 
 
Table (3-5) past and recent infections in HIV patients (denominators 
vary for each test) Toxo= Toxoplasmosis 
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3.2.7. Laboratory results: 
 
The mean haemoglobin (Hb) was 12.9 mg/dl. The mean (SD) count 
lymphocyte count was 41(8)% and the median count 43%.The mean 
(SD) absolute CD4+ cell count was 438 (339) cells/mm3 and the 
median was 374 cells/mm3, and the mean (SD) absolute CD8+ cell 
count was 1166(699) cells/mm3. The median was 1052 cells/mm3.  
 
 
 Mean SD 
Age 40 11.8 
Age at diagnosis 35 11.4 
Duration of HIV infection  6 2.6 
Baseline Hb 13 12.1 
Baseline CD4+ 374 339 
Baseline Lymphocyte % 43 8.2 
Baseline Viral Load (log) 3.3 1.5 
 
Table (3-6) Haemoglobin and virology results at presentation of 
all HIV patients (n=1383) 
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Table (3-7) summarise the CD4+ cell count and HIV viral load  results in HIV 
patients in relation to presenting symptoms, showing lower CD4+ counts and 
high viral load in those with cardiovascular presentation and lower CD4+ counts 
with CNS disease and GU symptoms (all small numbers of cases). The 
relationships of CD4+counts and viral load to coinfections is presented in 
Chapter 4. 
 
 Absolute CD4+ VL(log) 
Mean SD Mean SD 
Sex Female 471 316 3.18 1.47 
Male 427 346 3.41 1.52 
presenting Hx Respiratory 396 276 3.33 1.53 
GI 431 416 3.45 1.53 
Skin&MS 428 306 3.18 1.50 
CNS 270 77 3.61 1.25 
CVS 149 97 4.67 0.039 
Asymptomatic 513 354 3.29 1.46 
GU 240 229 3.11 1.62 
 
Table (3-7) CD4+ cell count and HIV viral load (VL) in relation to presenting 
symptoms 
 
3.2.8. Viral load: 
 
The mean (SD) log HIV viral load was 3.35 (1.5) copies/ml. The 
minimum observed log viral load was 1.3 and the maximum was log 
6.8 copies/ml.  
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3.2.9. IDU and History of prison: 
12% (12/97) of IDU patients also had history of being in prison, the 
results showed a significance different in IDU imprisonments to non-
IDU patients (P= 0.03, OR 1.9, 95% CI 1.03-3.74). 
 History of prison Total 
Yes No 
IDU  Yes Count 12/97(12.4%) 85/97(87.6%) 97 
 No Count 86/1286 (6.7%) 1200/1286 (93.3%) 1286 
 
Table (3-8) IDU and history of prison (n=1383) 
 
3.3. IDU and STI: 
About 10% STI patient had a history of IDU, of 97 STI patients 9 
patients were injecting drug users (9/97, 9.3%)  
 
3.4. Patients taking ART: 
 
Overall, 75% of patients had received ART (1049/1383).  
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3.5. WHO classification: 
 
Most of the patients (60%) presented to the clinic in WHO stage (1). 
The second common presenting stage was (2) with 32%. Only 8.5% 
(118/1383) were in stage (3) and 0.4% (5/1383) in stage 4 at 
presentation. 
Almost half of the females were presented to HIV clinics when they 
were in stage 1 and 40% (143/357) presented while they in stage 2. 
Only 8.9% (34/357) were in stage 3 or 4 at the time of presentation. 
Most of the males presented to HIV clinics while they are in stage 1 
(62%), then stage 2 with about 30% (298/1026) of male patients. 
About 8.6% were in stage 3 or 4  
 Sex Total 
female Male 
WHO staging at 
presentation 
1 n/N (%) 180/357 
(50.4%) 
639/1026 
(62.3%) 
819/1383 
(59.2%) 
2 n/N (%) 143/357 
(40.1%) 
298/1026 
(29%) 
441/1383 
(31.9%) 
3 n/N (%) 32/357 
(8.9%) 
86/1026 
(8.4%) 
11/1383 
(8.6%) 
4 n/N (%) 2/357 
(0.6%) 
3/1026 
(0.3%) 
5/1383 
(0.4%) 
 
Table (3-9) WHO staging at presentation 
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3.6. Discussion 
3.6.1 HIV/AIDS in the Kingdom of Saudi Arabia: 
Because of many religious and social concerns in the Kingdom, HIV had 
been difficult to tackle or even to discuss. This study is the first to look 
comprehensively at both epidemiology and clinical features in a cohort of 
HIV patients in the Kingdom of Saudi Arabia. The first part of this study 
was carried out retrospectively using case notes and patient details from 
their files, which varied in accuracy from case to case depending on case 
note quality. This was a significant limitation during the data collection 
period (secondary data limitations), although, I attempted to overcome 
this by reviewing all available medical notes to pick up missing or 
deficient data for each case.    
 
The median (range) age for the cohort was 41 (18 – 80) years. 
Predominance of male gender was expected and matches previous 
studies in the Region and in the Kingdom. One possible explanation is 
that Saudi males are more exposed to risk factors including travel and 
they have less social pressure to seek for medical advice and treatment. 
Similar to this study,  about two thirds of all HIV patients in a review in 
Saudi Arabia from 2000 to 2009 were males, with a male to female ratio 
of 4.4:1 (Kabbash et al. 2012). 
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Illiteracy was noted in about quarter of all patients, which emphasises 
the education challenges to implementation of HIV/AIDS prevention 
strategies, including safe sex education. A recent study published by Al-
Othman et al. (2010) confirmed that new HIV case notification is 
increasing every year in the Kingdom. They suggested that the lack of 
detailed education about safe sex was contributing to this annual 
increase (Al-Othman et al. 2010).  
Improving education should help to decrease HIV transmission, even in 
such a conservative society. Educational programmes and strategies 
should focus on young adults, especially males, as they represent the 
majority of Saudi HIV positive patients.  Even though extramarital sexual 
relations are strictly prohibited in Saudi law and regulation, more than 
half of the HIV positive patients in Jeddah are single. Again, this 
emphasizes the reality of individual behaviours despite standard 
expectation of societies, and shows the need to educate single men and 
women despite cultural norms. 
This study is useful because data on the probable route of acquiring HIV 
are much more complete than national studies using central notification 
data. Only 11% of patients had no identified route, compared to 41% in 
2004 and 46% in 2012 reports (Madani et al 2004; Kabbash et al. 2012)  
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As expected as it is one of the most common modes of HIV 
transmission globally, this study showed that heterosexual transmission 
of HIV was noted in about half (709/1383) of the Saudi patients in the 
Jeddah HIV clinic, compared to about 40% in 2004 (Madani 2004). As 
expected, it was the main route of transmission in women, statistically 
more common than in men. In men, male sex with men accounted for 
26% of all cases, much higher than previous estimates but similar to 
recent data from some neighbouring countries like Israel (Zohar et al. 
2014). This is a problem as homosexual activity is not legal and it is 
difficult to provide education and support for this group in Arabic 
societies (Shawky, Soliman et al 2009; Mumtaz et al. 2011). 
 
Travelling abroad is also an important concern in HIV positive patients 
and was found in 179 (13%) patients. In Saudi Arabia and by Islamic 
law, sexual practice is prohibited except through marriage. No sex 
workers are allowed in the Kingdom by law and this is strictly controlled 
by the Saudi authorities. Under such circumstances, travelling abroad 
provides an important opportunity to acquire and import HIV infection 
into the country. It is important to emphasise the use of  protection 
(condoms) as about 301(22%) of patients admit practicing sexual 
activities with their HIV positive partner without using protection. 
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In Saudi Arabia blood and blood products are strictly checked for 
infectious disease including HIV. Cases of HIV infection transmitted via 
blood or blood products have hardly occurred since 2001 and all 
remaining cases are from previous blood or blood products transfusion 
before 1986. Patients who had acquired HIV from transfusion of blood 
products account for about 25% of cases in Madani’s study (Madani 
2004). In this study about 10% of patients had a history of blood 
product transfusion at least once in their past medical history. This is 
probably because most of the cohort acquired HIV later than 1990 by 
which time the blood transfusions were recognized and prevented in 
the Kingdom. National data collected from the period 2012-2013 
showed that blood or blood products related HIV transmission had 
declined to 0.019% in Saudi Arabia (UNAIDS 2014). This decline is 
expected and expected to decrease more in future due to strict blood 
bank control. 
This study showed a larger proportion of other high risk groups than 
previous studies in KSA. 
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However, a past medical history of STI was rarely reported in HIV 
positive Saudi patients, being found in only 88 (6.4%) of patients. This 
suggest a large amount of underdiagnoses, as many studies from the 
West and from other Regions such as Africa show rates of STI 
infections of about 15% and 50% respectively (Hegazi et al. 2015; 
Winston et al. 2015) 
In this cohort only 60% had records of any syphilis serology being 
performed and there was no specific protocol to encourage routine 
examination and testing for STI in the clinic. As STI are important 
coinfections in transmission of HIV to others, this aspect of HIV care 
needs more prominence in the national HIV programme, despite the 
cultural difficulties of such issues.   
The VDRL test was positive in 128 (15%) but there was no statistically 
significant difference between males and females, except in men who have 
sex with men MSM (24.2%, 41/170) compared to other men (15%, 
129/856) (X2=8.3, P=0.003, OR 1.79, CI 95% 1.2-2.6) as expected from 
many studies elsewhere (Maek-a-nantawat 2014). The tests used in clinics 
were very basic and the difficulties of interpretation test like VDRL in a 
country where endemic syphilis is also present have already being 
discussed (Marks, Solomon & Mabey 2014). This study suggests that, 
along with improving protocols for testing HIV positive patients regularly 
for STI’s as in other countries (BHIVA 2013), the methodologies for 
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screening for syphilis should be reviewed  to include more modern 
serological test such as Treponema pallidum particle agglutination assay 
(TPPA) or Treponema pallidum hemagglutination assay (TPHA) and more 
vigorously implemented. This is particularly important in MSM and other 
patients for whom risky sexual practices and more frequent partner 
change may be a feature.    
A past history of IDU was found in 97 patients (7%), compared to 
1.3% a decade ago (Madani 2004). As expected in a conservative 
community, IDU in HIV positive patients was significantly associated 
with male gender. It is a concern that HIV is being spread this way as 
Jeddah is known to have a substantial larger population of IDU than 
elsewhere in the Kingdom, but in whom previous studies had shown 
very little HIV infection. However, more recent studies confirm that this 
is changing in Saudi Arabia with 10% of heroin users in Riyadh recently 
reported to be HIV positive (Al-Shomrani 2014). In Iran HIV is well 
known to be associated with IDU as an important risk group, and this is 
difficult to access for education as IDU activity is illegal. If rates 
continue to raise this could become a major public health problem in 
KSA. 
98 (7%) of HIV/AIDS Saudi patients had a history of being in prison. 
This is may be a chance association but probably suggests that being in 
prison should be considered as an important risk for HIV. It may be an 
independent risk factor for HIV than IDU, as only (12/98, 12.2%) IDU 
had been in prison. This ratio is less than might be expected, as in 
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many countries up to 50% of IDU have a history of being in prison 
(Hope et al. 2013). 
One of the important national programmes in Saudi Arabia is the 
premarital testing programme for certain inherited and infectious 
diseases. This programme is compulsory for all Saudi couples who are 
intending to get married. In this cohort about 3% of cases had been 
diagnosed to have HIV infection through this programme. This 
screening programme should be enhanced to lead to early detection of 
cases, particularly in antenatal care where HIV screening is not yet 
routinely applied despite the benefits in reducing mother to child 
transmission (Ross et al. 2015).   
 
57% of patients were clinically suspected to have HIV infection after a 
visit to a medical centre, which reflects the importance of keeping all 
medical centres and their personnel alert to maintain this high quality 
level of practice. Most of the patients included in this study presented 
to the clinics with respiratory symptoms (44%) and gastrointestinal 
(GI) symptoms (22%), while about 30% were asymptomatic. In 2004 
Madani et al found that asymptomatic presentations were more 
common and represented about 70% of HIV positive patients in the 
whole Kingdom (Madani 2004). This may be explained by the 
improvement in patient’s awareness of HIV symptoms and supports the 
presence of well-developed HIV/AIDS national programmes; so that 
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patients may they seek medical advice immediately for minimal 
symptoms rather than ignoring these and presenting later.     
All other presenting syndromes including central nervous system (CNS), 
skin and musculoskeletal system, cardiovascular system (CVS), and 
genitourinary system (GU) symptoms were presenting feature in only a 
small minority of patients, accounting for less than 4% (56/1383) of 
the whole cohort. 
The HIV clinic in Jeddah plays an important role in supporting HIV 
positive individuals and improving their health as the median of HIV 
infection duration was about 6 years and the highest duration of HIV 
infection was 18 years among patients who were being following at this 
clinic.  
After this study was performed in 2011, another HIV cohort review was 
performed at King Faisal Specialist Hospital in Riyadh, including all 
patients following in their clinics or admitted to the hospital between 
1984 and 2012 (Al-Mozaini et al. 2014). Some features of that smaller 
cohort are compared to those in Jeddah cohort in Table 3-10.  
There are interesting differences as the King Faisal Hospital cohort is in 
a different city and is a tertiary referral centre for the Kingdom, while 
our study looked at the whole population attending a local major centre 
in Jeddah. For example, I found more IDU in Jeddah than in Riyadh as 
expected from the known larger number of IDU in Jeddah (Berger 
2015). However, HCV coinfection was more common in Riyadh, 
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probably because it included early patients infected by blood products 
in the 1980’s and despite there being more IDU in Jeddah, a known risk 
factor for HCV/HIV coinfection (Berger 2015).  
Character  Riyadh study  This study  Remarks  
Place  Riyadh  Jeddah Most of HIV patient are 
in Jeddah  
Hospital King Faisal Hospital  King Saud Hospital KFSH is a tertiary 
referral hospital for 
whole of KSA. 
 
KSH is MOH and open 
to public  
Patients 602 patients 1383 patients  
Period 1984-2012 2000-2010 Jeddah more recent 
cohort overall 
Male/females 69% male 74% male Similar results  
Mean age (SD) at 
HIV diagnosis 
30 (14) years 36 (11) years Similar results 
Married  48% 52% Similar results 
Heterosexual  54% 57% Similar results 
Bisexual & MSM 3.3% +1.66% MSM 26% More MSM in Jeddah 
IDU 2.82% 7% More IDU in Jeddah  
Blood transfusion 14% 10.7% Similar results 
HCV coinfection 12.9% 6% More HCV in Riyadh 
Treated (HAART) 71% 75% Similar results 
 
Table (3-10) Comparison with a recently published report in cohort of HIV positive patients in 
Riyadh (Al-Mozaini et al. 2014) 
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Chapter 4 
HIV coinfections 
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4.1 Introduction  
As elsewhere in the Region, Saudi Arabia has obvious gaps in 
epidemiological data about HIV and even less information about clinical 
features related to HIV infection. Coinfections with TB, HCV and/or HBV 
are particularly important for HIV patients for different reasons, but 
very few data are available about these in KSA.  
Moreover, data about risk factors and assessment of the actual 
situation for high risk and hard to reach groups of patients are poor 
and need to be improved.   
This section focuses on the prevalence of key coinfections in the HIV 
cohort in Jeddah, and the behavioural risk factors associated with 
them. The aim was to provide data on efficiency of the service for 
detecting coinfection, to provide an estimate of patients who might 
need further specific treatment and recommendations on whether hard 
to reach groups need further specific services or education in harm 
reduction.      
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4.2. Results 
4.2.1. Past and present coinfections  
 
The mean (SD) age for HIV cases with no coinfection, was 41 (12) 
years and 61% were males. The mean (SD) log viral load was 3.33 
(1.5) with a mean (SD) of CD4 cell count of 444 (335) cells/mm3. Most 
of the non coinfected patients were in stage 1 (51%) or 2 (26.5%) of 
the WHO classification of HIV at the time of diagnosis.  
The hypothesis is that coinfection with TB, HCV or HBV might be 
associated with reduced CD4+ cell counts or later stage presentation, 
either as a cause or effect. This is examined in this section. TB 
coinfection was present in 15% of the whole cohort (208/1383). Most 
of those patients were males 82% (172/208), with a significant 
predominance of men compared to non TB coinfected patients in the 
cohort (P=0.002, X2 9.2, OR 1.7, 95% CI 1.2-2.6). There was no 
substantial difference in stage, CD4+ counts or HI viral load at 
presentation in the TB or non-TB groups (Table 4-1) 
 TB coinfection  No TB coinfection  
Age mean (SD) 42 (12) 41 (12) 
 
Gender  
Male 172/208 (82.3%) 854/1175 (72.7%) 
Female 36/208 (17.3%) 321/1175 (27.3%) 
Missing data  None 
Baseline CD4  
mean (SD) 
402 (362) 444 (335) 
Baseline viral load log 
mean (SD) 
3.44 (1.5) 3.61 (1.5) 
WHO Stage at 
presentation 
1 113/208 (54%) 706/1175 (60%) 
2 74/208 (35.5%) 367/1175 (31.3%) 
3 20/208 (9.6%) 98/1175 (8.4%) 
4 1/208 (0.4%) 4/1175 (0.3%) 
Table (4-1) Comparison of key clinical data in groups with and without TB in this study 
(n=1383) 
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Hepatitis C (HCV) tests were performed at least once in about 80% 
(1101/1383) of the whole cohort. 7.4% (82/1101) were anti-HCV 
antibody positive, of whom 90% (76/82) were males. This was highly 
significant compared to non HCV positive patients. (P < 0.005, X2 147, 
OR 33.4, 95% CI 14.3-77.6).  There was no substantial difference in 
stage, CD4+ counts or HI viral load at presentation in the HCV 
coinfected patients or non-HCV coinfected  groups (Table 4-2) 
 HCV coinfection No HCV coinfection 
Age mean(SD) 41 (11) 40 (12) 
 
Gender 
Male 76/82 (92.6%) 739/1019 (72.5%) 
Female 6/82 (7.4%) 280/1019 (27.5%) 
Missing data 282/1383 (20%) 
Baseline CD4 
mean (SD) 
415 (306) 444 (337) 
Baseline viral load log 
mean (SD) 
4.02 (1.48) 3.32 (1.51) 
WHO Stage at 
presentation 
1 49/82 (59.8%) 590/1019 (57.9%) 
2 29/82 (35.4%) 333/1019 (32.7%) 
3 4/82 (4.8%) 92/1019 (9%) 
4 0 4/1019 (0.4%) 
 
Table (4-2) Comparison of key clinical data in groups with and without HCV in this 
study (n=1101, missing for 282/1383=20%)  
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Hepatitis B serology was missing for 19% (262/1383) of the whole 
cohort. 5.3% (59/1121) of patients were HBsAg positive, predominantly 
males 86.4% (51/59), significantly different from the rest of the cohort 
(P-value 0.02, X2 5.04, OR 0.43, 95% CI 0.2-0.91). There was no 
substantial difference in stage, CD4+ counts or HI viral load at 
presentation in the HBV coinfected patients or non-HBV coinfected  
groups (Table 4-3) 
HBV coinfected patients had a mean age of 42 years and mean CD4+ 
of 396 with a viral log of 3.82 WHO staging results were not different 
from non coinfected patients or from other coinfected patients. 
 HBV coinfection No HBV coinfection 
Age mean(SD) 44 (11) 42 (12) 
 
Gender  
Male 51/59 (86.4%) 778/1062 (73.3%) 
Female 8/59 (13.6%) 284/1062 (26.7%) 
Missing data 262/1383 (19%) 
Baseline CD4  
mean (SD) 
396 (249) 446 (350) 
Baseline viral load log mean 
(SD) 
3.8 (1.2) 3.3 (1.5) 
WHO Stage at 
presentation 
1 36/59 (61.1%) 616/1062 (58%) 
2 19/59 (32.2%) 351/1062 (33%) 
3 4/59 (6.7%) 91/1062 (8.5%) 
4 0 4/1062 (0.5%) 
 
Table (4-3) Comparison of key clinical data in groups with and without HBV in this 
study (n=1062, missing for 262/1383=19%)  
 
 
 
174 
 
 
4.2.2. IDU and HCV infection: 
Hepatitis C (HCV) tests were performed in about 80% (1101/1383) of 
the whole cohort, of those patents 7.5% (83/1101) were IDU, and 
25.3% (21/83) of IDU patients were HCV antibody positive, with a 
significant statistical different compared to non HCV IDU patients 
(P<0.05, X2 41.5,  OR 5.3, 95% CI 3-9.2). 
   
 HCV 
positive Negative 
IDU  Yes 21/83 (25.3%) 62/83(74.7%) 
No 61/1018(6%) 957/1018 (94%) 
 
Table (4-4) IDU and HCV coinfection 
 
 
 
4.2.5. TB coinfection and IDU: 
 
1.7% (23/1383) patients were coinfected with TB and were also IDU. 
Those were 11% of the TB coinfected patients and about 24% of the 
IDU patients. 
There was a significant statistical difference increase in TB coinfection 
in IDU compared to non-IDU (P<0.01, RR 1.76, 95% CI 1.13-2.41). 
The coinfection rates and key risk factors are summarized in table (4-
5). 
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Table (4-5) Summary of Coinfections and key risk factors (TB, N=1383, HCV, 
N=1101, HBV, N=1121, Syphilis, N=830 and MSM, N=264) 
 
 
There was 47/264 (17.8%) MSM individuals had been coinfected with 
TB. 27/209 (13%) of MSM patient had been anti-HCV IgG AB positive 
where 11/130 (8.5%) of MSM patients were HBsAg positive. 
 
 
 
 
 
 
 
Co-infection rates and key risks  
  IDU Prison     MSM 
Coinfection Overall 
prevalence 
RR (95% CI) 
P value 
RR (95% CI)  
P value 
RR (95% CI)  
P value 
TB   208/1383 (15%) 1.67 (1.13-2.41) 
0.01 
1.83 (1.18-2.85) 
0.01  
1.2 (0.92-1.6) 
0.16 
HCV  82/1101 (7.4%) 4.22 (2.71-6.57)  
<0.05 
1.94 (1.04-3.63) 
0.07  
3.1 (1.9-5.04) 
0.00 
HBV 
 
59/1121 (5.3%) 1.89 (0.93-3.85) 
0.08 
2.38 (1.25-4.54) 
0.01  
0.62 (0.27-1.42) 
0.23  
Syphilis 
 (VDRL)   
128/830 (15%) 0.89 (0.41-1.93) 
0.4 
1.85 (1.04-3.26) 
0.03 
1.8 (1.3-2.5) 
0.000 
MSM 264/1026 (26%) 1.03(0.6-1.6) 
0.5 
1.08 (0.6-1.8) 
0.4 
--------------------- 
--------------------- 
176 
 
 
 
 
 
 
 
Prisoners  Yes  No  P X2 OR 95% CI 
TB 24/98 
 (24.4%) 
184/1285 
(14.3%) 
0.006 7.3 1.9 1.1-3.1 
HBV* 8/82  
(9.8%) 
51/1039 
(4.9%) 
0.058 3.5 2.1 0.9-4.5 
HCV** 7/79 
 (8.8%) 
75/1022 
(7.3%) 
0.6 0.24 1.2 0.5-2.7 
STI 14/98  
(14.3%) 
74/1285  
(5.8%) 
0.0008 11.1 2.7 1.4-5 
 
Table 4-6 Prisoner as a risk factor for TB, HBV, HCV and STI (N=98) *N=82, HBV missing data=16 ** 
N=79, HCV missing data=19 and prisoners=98 ) 
 
MSM Yes  No  P X2 OR 95% CI 
TB 47/264 
 (17.8%) 
161/762  
(21.1%) 
0.24 1.3 0.8 0.6-1.15 
HBV* 5/225 
 (2.2%) 
46/801 
(5.7%) 
0.03 4.6 0.37 0.1-0.9 
HCV** 26/221 
 (11.7%) 
50/805  
(6.2%) 
0.0005 7.8 2 1.2-3.3 
STI 22/264  
(8.3%) 
66/762 
(8.6%) 
0.86 0.02 0.95 0.5-1.5 
 
Table 4-7 MSM as a risk factor for TB, HBV, HCV and STI (N=88) *N=51, HBV males ** N=76, HCV 
males and MSM 264) 
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4.3. Discussion  
TB coinfection rates were expected to be high and 208 (15%) of the 
patients in this HIV positive cohort found to have active TB co infection. A 
study published in 2010 have shown that the incidence rate of TB 
coinfection in HIV positive individuals is at least 30 times higher than it is 
in the general Saudi population (Al Rajhi et al 2010). TB co infection was 
significantly more common in males and this is also expected in Saudi 
society where males are at higher risk for TB infection than females (Al 
Rajhi et al 2010). However, data collected for HIV/AIDS patients in the 
year 2012-2013 by the Ministry of Health showed that TB coinfection in 
HIV/AIDS Saudi patients is 2.16% (UNAIDS 2014). These discrepancies 
are hard to explain, but emphasize the need for a more systematic 
approach in both the TB and HIV national programmes, as HIV infection is 
a very important risk factor both for itself and for drug resistant forms of 
TB (Bruchfeld, Correia-Neves & Källenius 2015). This is particularly 
relevant in Jeddah, where this study shows significant association of TB 
coinfection with IDU and/or being in prison. These hard to reach groups 
may have poor access to treatment and more difficulty in adhering to 
treatment and prevention programmes once they have enrolled. 
As discussed in chapter one (Table 1-9), the diagnosis of chronic HBV 
infection can be established based on serum serological and virological 
markers of HBV. In addition biochemical and histological markers are also 
used.  
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Histological evaluation of liver biopsy specimens is a sensitive and 
accurate indicator of liver disease, however, liver biopsy is an invasive 
procedure and was reserved for only a few patients (data not shown) 
(Abaalkhail et al. 2014). Therefore, it is not possible to comment on the 
severity of liver disease in coinfected patients in this study.  
 
HIV infection increases the risk of liver cirrhosis in HBV patients. 
In several cohort studies, the risk of liver-related mortality has 
been found to be 2-3 times higher in HIV/HBV-coinfected 
patients than in HIV positive individuals with no coinfection 
(Group 2006).  
 
HIV accelerates HBV viral infection leading to liver damage, so 
HIV infection significantly increases hepatitis morbidity and 
mortality. However, most studies have not found HBV coinfection 
to have a substantial impact on HIV virological responses to ART 
or on the development of AIDS-defining illness or HIV-related 
death (Konopnicki et al. 2005; Piroth et al. 2015).HBV 
coinfection does not appear to influence the rate of HIV 
progression but may be a surrogate for factors associated with 
HIV seroconversion. Patients receiving HIV treatment should 
receive fully active HBV treatment as well. Monotherapy is not 
recommended while it is recommended to give fully active ART 
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in conjunction with HBV therapy, as there are limited options for 
effective HBV treatment thats lack any anti-HIV activity (UCSF 
2010). Recent data from West Africa confirm that inadequate 
HBV cover as part of ART for HIV results in increase of resistant 
HBV in coinfected patients (Geretti et al. 2010) 
 
In this study patients were only screened for hepatitis B infection by 
looking for HBsAg. This may occasionally be false negative in some 
patients and HBV PCR is required (detailed in chapter 1 table 1-9) and this 
is a limitation of the clinic performance and of the study. Further, because 
antiHBc or other antigens results were not available, this study can only 
show rates of current coinfection rather than report rates of past infection 
with hepatitis B, and thus the lack of serology limits interpretation of 
exposure risks. 
 
Coinfection with HCV was found in 82/1101 (7.4%) patients, most of 
whom were men. This may be explained because patients most at risk are 
IDU especially if they share needle, and MSM. This was supported by a 
strong link between IDU and HCV in this study. On the other hand HBV co 
infection was found in only 59 (4%) of the Saudi HIV/AIDS patients. HBV 
co infection is expected to be lower than HCV co infection in Saudi Arabia, 
because most HBV transmission occurs in childhood with a different 
epidemiological  pattern then acquiring HIV later in life, when HCV 
infection is also more likely.   
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The risk of progression to HCV related liver disease is increased in 
HIV/HCV coinfected people, with more likely to progress to fibrosis and 
poor treatment response. In addition, HCV clearance is likely lower than in 
HIV negative individuals and coinfected individuals have higher HCV viral 
loads and weaker immune responses against HCV (Sterling et al. 2010). 
 
Sterling and colleagues from Virginia Commonwealth University examined 
paired liver biopsies from 56 HIV/HCV coinfected patients and matched 
participants with HCV alone. Samples from coinfected patients showed 
more necrosis and inflammation. Although the frequency of fibrosis 
progression was statistically similar, coinfected individuals were twice as 
likely to progress by two stages (Sterling et al. 2010).  
 
There is evidence that ART in HIV patients can slow hepatitis C 
progression and should be recommended for HCV/HIV coinfected persons, 
including those with liver cirrhosis. Therefore, regardless of CD4 cell count 
it is recommended to start ART for HCV/HIV coinfection, while recognising 
the possibility of drug interactions (NAT 2012). 
 
 
HCV genotype has a large effect on the outcome of HCV therapy in 
HIV/HCV coinfected patients and similar to HCV mono-infected patients. 
Medrano et al studied the annual prevalence of HCV genotypes/subtypes 
and their influence on HCV clearance with ART in cohort of HIV/HCV 
181 
 
coinfected patients in Madrid since 2000. HCV genotypes were as follows: 
57.1% HCV-1, 1.3% HCV-2, 25.4% HCV-3 and 15.9% HCV-4. They also 
found that the prevalence of HCV-1 and HCV-4 has increased over the last 
decade in HIV/HCV-coinfected patients, whereas conversely it has 
declined for HCV-3, in association with the wider use of HCV therapy 
(41%) in this population (Medrano et al. 2011). 
In our study diagnosing HCV depended on only anti HCV antibody 
serology which may be false negative in up to 10% of HIV positive 
patients, so HCV PCR is also indicated. This was a limitation of the clinic 
performance and probably led to underestimation of the number of patiets 
with HCV/HIV coinfection in Jeddah. 
Stricter guidelines are required in the clinics as only 77% of patients had 
been tested for HBV and only 80% for HCV at the same stage, although 
this should be standard practice (BHIVA 2013). 
Those found to be HCV positive should have further investigation initially. 
Finally HIV management guidelines globally recommend that all HIV 
positive people should be tested for hepatitis A, B and C, and be 
vaccinated against hepatitis A and B if not already immune (BHIVA 2013). 
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Chapter 5 
  
Antiretroviral resistance in the 
Region 
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A systematic literature review was performed of large databases 
(PubMed, Scopus, Google scholar and CINAHL) using a wide search 
strategy for the period 2000 to 2014.  Combinations of keywords 
included HIV, AIDS, drug misuse, ART, ARV, coinfections, TB, 
hepatitis, HIV treatment naïve, resistance together with geographical 
terms such as Middle East, Saudi Arabia and each country in the 
Middle East and North Africa (MENA) WHO Region. The WHO website 
and UNAID websites were also consulted for any reference to HIV and 
to ART resistance. All relevant papers and reviews were obtained and 
the reference lists were consulted to identify further sources. Regional 
scientific journals were also reviewed including the Saudi Medical 
Journal, Annals of Saudi Medicine and Journal of Infection and Public 
Health. The review started at the beginning of work and was repeated 
in March 2015 to include the latest publications. 
259 results were found in the following databases: PubMed (102), 
Google scholar (92), Scopus (41) and CINAHL (24). 184 of the total 
results were excluded after reading the abstract, leaving 75. 53 were 
not relevant to this study, leaving 22 papers that were included (Table 
5-1) 
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259 total review results 
 
 
 
 
 
 
 
 
 
 
 
PubMed (102) , Google  
Scholar (92) Scopus (41)  
and CINAHL (24) 
 
 
 
 
 
 
 
 
184 of the total results were 
excluded 
 
 
 
 
 
 
 
 
 
 
184 of the total results were  
excluded after reading the  
abstract mostly because they  
were individual case reports 
or did not contain relevant  
epidemiological or virological 
data 
 
 
 
 
 
75 remaining results  
 
 
 
 
 
 
 
53 were not suitable or 
relevant to  
this review study 
 
 
 
22 studies were included 
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Country or region Year of publication  Authors 
Developing countries 1998 Palella et al  
Developing countries 2004 Moatti et al.  
Developed countries  2004 Mocroft et al.  
Developed countries 2005 Sabin et al.  
Developed countries 2005 Vella et al 
Developing countries 2007 Shekelle  et al.  
Europe and United States 1996 Yerly et al.  
Europe  2000 Paredes et al 
India 2008 Lall et al.  
India  2011 Deshpande er al.  
Iran  2014 Baesi et al. 
Global 2006 Young et al 
Oman 2004 Al Dhahry et al.  
Romania  2013 Temereanca et al  
Saudi Arabia 2010 Badahdah  
Saudi Arabia 2010 Jamjoom et al.  
Saudi Arabia (Paediatric)  2011 Al Hajjar et al. 
South Africa 2009 Orrell et al  
Turkey 2013 Sayan et al.  
United States 2005 Hammer  
United States 2005 Novak et al.  
United States 2008 Huang et al.  
 
Table (5-1) HIV publications used in this study 
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5.1. ART resistance in developing countries:  
 
Antiretroviral transmitted drug resistance is an important issue all over 
the world, but there are variations in prevalence different and pattern 
in countries and regions. 
A number of studies have described prevalence rates of transmitted 
drug resistance (TDR). They range from 0-25 % in different countries. 
It is as high as 12.9% in North America and 10.9% in Europe and lower 
in Latin America (6.3%), Africa (4.7%), and in Asia (4.2%)(Frentz, 
Boucher & Van De Vijver 2012). 
With the development of international collaborations, patients with 
HIV/AIDS patients can nowadays access antiretroviral medications 
in many developing countries more easily than in the past. It has 
been estimated that 13 million HIV/AIDS patients were on HAART a 
decade ago (Young et al. 2006). In 2010, about 5 million HIV 
positive individuals were receiving ART in Sub-Saharan Africa which 
represented a 20% increase in ART coverage compared to 2009 
(Abo et al. 2015). At the same time, more HIV patients are at risk 
of developing resistance to ART. This includes those in developing 
countries, which in turn may lead to an increase in acquired drug 
resistance in developed countries (Palella et al. 1998) 
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The problem is increasingly recognised in developing countries that 
have expanded ART access in recent years, and is especially 
significant where the supply of antiretroviral drugs (ARVs) is 
intermittent (Palella, Delaney et al. 1998). While HIV drug-resistance 
testing is not available in routine care in many resource-limited 
settings, large surveillance programmes are on-going to monitor 
regional trends and inform management strategies.  
ART resistance was more common when patients were taking single 
or dual antiretroviral agent therapy (Paredes, Mocroft et al. 2000).  
More recently, although ARV’s have been improved and are easier to 
take with simpler dosage regimens, the development of resistance is 
still a major challenge in the management of HIV (Mocroft, 
Ledergerber et al. 2004; Sabin, Hill et al. 2005).  
 
In addition, ARV resistant virus may transmit to patients with treated 
non-resistant HIV, or to ART naïve patients. Earlier reports showed 
that up to 30% of patients in Europe or United States might acquire a 
virus with drug resistance conferring mutations (Yerly, Rakik et al. 
1996). In developed countries, Vella and Palmisano found that about 
10% of the naïve patients who started on ART for the first time had 
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developed ART resistance before they started on the treatment (Vella, 
Palmisano 2005) 
 
In the USA several studies on ART resistance in treatment naïve 
HIV/AIDS patients showed resistance to different ART classes. A study 
of resistance to ART in treatment naïve patients in 2005 by Novak et 
al showed that resistance for NRTI was present in 7.8% while 
resistance to NNRTI was present in 3% and to PI in 0.7% (Novak, 
MacArthur et al. 2005). In 2008 Huang et al found that 9.8% of HIV 
treatment naïve patients had resistance to NRTI, 4.5% had resistance 
to NNRTI and about 1.8% showed resistance to PI (Huang, Daar et al. 
2008). These two studies showed that the resistance to ART in 
HIV/AIDS treatment naïve patients had increased over short period 
between from 2005 to 2008. 
 
Moatti et al. showed in their study in 2004 that ARV drug resistance 
was also problem in developing countries, although it was then more 
common in developed countries. To avoid this problem developing the 
relationship between adherence and ART needed to be addressed. 
They emphasised the strong link between poor adherence to ART and 
the increasing likelihood that the patient would develop resistant HIV 
(Moatti, Spire et al. 2004).  
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The availability of ART resistance testing is limited in developing 
countries, potentially leading to a serious problem in management of 
HIV patients in these countries. Moreover increasing ART resistance in 
the developing countries may result in acquired ART resistance being 
transmitted to HIV/AIDS patients in the developed countries (Hammer 
2005).  Limited data from some studies about ARV resistance in 
addition to WHO reports from developing countries, have already 
showed an increase in ARV resistance in these countries. 
 
Two studies were done in India in 2008 and 2011. Lall et al tested 
newly diagnosed treatment naïve patients in Pune western India in 
2008. Resistance to NRTI was present in 5% and resistance to NNRTI 
and to PI was present in 2.5% each (Lall et al. 2008). In 2011 
Deshpande et al. performed genotypic resistance tests on 68 
treatment naïve patients in Mumbai, India. No resistance was reported 
for NRTI but resistance mutations were found to NNRTI in 5.8% and 
about 3.8% of patients had resistance to PI (Deshpande, Karki, er al. 
2011). Temereance et al performed genetic resistance testing on 61 
treatment naïve Romanian patients in 2013 and found that 13.1% had 
resistance to NRTI, 3.3% showed resistance to NNRTI and about 
1.6% had resistance mutations to PI (Temereanca., Ene et al 2013).    
 
 
190 
 
ARVs have available in Europe and North America for many years and 
patients can easily access treatment. This may explain the higher 
prevalence of TDR in developed countries. In Africa, different patterns 
of resistance to antiretroviral drug classes were seen than in other 
parts of the world. On the past 5 years there has been an increase in 
TDR in continent. This may be explained by the wider availability of 
antiretroviral drugs following efforts by the WHO and international 
AIDS groups, complicated by intermittent availability of ART at clinic 
level. In a study in South Africa, Orrel et al tested for ART resistance 
in 2009 and they found that for 120 HIV patients resistance was 
minimal: no resistance was recorded for PI, only 1.7% resistance to 
NNRTI and 3.3% resistance was documented to NRTI (Orrell., et al 
2009). 
In addition, the differences in TDR rates worldwide, developing 
countries and developed countries can partially be explained by the 
use of different methods to define drug resistance. More international 
efforts and surveillance is needed to monitor the circulating HIV TDR 
rates and to ensure that ART is adjusted to take into account the 
evolution of drug resistance (Frentz, Boucher & Van De Vijver 2012) 
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Country  
 
Author   
 
year 
 
Sample 
size 
Resistance mutations (%) 
NRTI NNRTI PI 
Greece Skoura., Metallidis., et al 2013 238 14.3% 18.9 1.2% 
India (West, Pune) Lall., et al 2008 40 5% 2.5% 2.5% 
India (Mumbai) Deshpande, Karki. et al 2011 68 0 5.8% 3.8% 
Romania Temereanca., Ene et al 2013 61 13.1% 3.3% 1.6% 
South Africa Orrell., et al 2009 120 3.3% 1.7% 0 
Turkey Sayan et al. 2013 2013 117 4.2% 1.7% 1.7% 
USA Novak., MacArthur., et al  2005 491 7.8% 3% 0.7% 
USA Huang., Daar et al 2008 228 9.8% 4.5% 1.8% 
 
 
Table (5-2) ART resistance reported in HIV treatment naïve patient in 
selected countries 
 
5.2 ART resistance the Region and KSA  
ART resistance is a rising medical problem for HIV/AIDS patients 
worldwide. In the region of Saudi Arabia the lack of sufficient data for 
ART resistance is critically affecting the future of patient 
management. At the regional level only few studies have been 
published. These studies were heavily biased regarding patient 
selection.  Therefore the current prevalence and patterns of ART 
resistance in KSA are unknown. This information is essential for 
defining appropriate therapies for HIV in the Kingdom, especially as 
resistance may emerge in neighbouring countries (Shekelle et al. 
2007). 
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Al Dhahry et al published the first ART resistance study in the Region 
in 2004. Blood samples were collected from 93 HIV positive patients 
from Oman (April - July 2001) for ART resistance testing. Tests were 
successfully processed for 47/51 treatment naïve patients of whom 
3/47 (6.4%) had resistance mutations to reverse transcriptase 
inhibitors (RTI) and 6/47 (13%) showed resistance to protease 
inhibitors (PI).  Treatment experienced patients showed higher 
resistance to ART as expected.  24/32 (75%) had resistance to RTI 
and 7/32 (21.8%) showed resistance mutations to PI (Al Dhahry, 
Scrimgeour et al. 2004). The study showed the resistance rate for RTI 
in common but did not define the resistance to NRTI or NNRTI 
specifically. 
There were no other ART resistance publications in the Region until 6 
years later when Jamjoom et al tested 63 treatment experienced 
Saudi patients for ART resistance (2004 - 2009). 26/63 (41%) had 
mutations conferring resistance to NRTI, 10/63 (16%) showed 
resistance to NNRTI and 8/63 (13%) had resistance to PI. 2/63 (3%) 
had resistance to all three ART class (NRTI, NNRTI and PI). The study 
was performed in Jeddah at King Abdulaziz University and selected 
only treatment failure patients; no data were available for treatment 
naïve patients (Jamjoom, Azhar et al. 2010). 
Al Hajjar et al in 2011 reviewed genotypic resistance test results for 
22 Saudi HIV positive children at a tertiary care centre in Riyadh. They 
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collected data retrospectively (July 2006 to January 2009). All 22 
children were treatment failures and had HIV RNA > 1000 copies/mL. 
Resistance to any drug was present in 86.4%. There were 24 
mutations in protease coding region and 14 in the reverse 
transcriptase (RT) coding region. M184V was detected in 70% of the 
isolates (Al Hajjar, Frayha & Althawadi 2011). This study showed high 
resistance rate in ART failing children in Saudi Arabia.  
All these studies were heavily biased regarding patient selection, as 
they predominantly included patients who had failed one or more 
switches of ARV therapy.  As would be expected, there was a high 
prevalence of resistance to NRTI, NNRTI and PIs in these studies.  
ART has been available for over 10 years, but treatment failures are 
sometimes observed due to drug resistance (either primary or 
acquired) and problems with treatment adherence. Access to 
resistance testing has only become available recently and tends to be 
used only for patients failing therapy (Jamjoom, Azhar et al. 2010). 
In order to improve clinical care and to improve treatment outcome, 
ART resistance testing was highly recommended. In addition standard 
ART genotypic resistance testing should be considered in all HIV 
positive patients including treatment naïve and at diagnosis.   
 
The current prevalence and patterns of resistance in ART-naïve and 
treated patients in the Region and in Saudi Arabia are unknown. This 
information is essential for defining appropriate first-line and salvage 
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therapies for HIV in the Kingdom for the future, especially as 
especially as ART resistance testing is not yet routinely available and 
resistance may emerge in neighbouring countries (Shekelle, Maglione 
et al. 2007; Bawah, Bongaarts et al. 2006; Moore, Beadsworth et al. 
2010). 
 
For example, a recent Turkish study by Sayan et al. tested 117 
treatment naïve patients for ART resistance. The samples were 
collected from June 2009 to February 2012. Resistance to NRTI was 
found in 5/117 (4.2%), resistance to NNRTI was found in 2/117 
(1.7%) and PI resistance was found in in 9/117 (1.7%) (Sayan et al. 
2013).  
Baesi et al. published a study in 2014 of ART resistance in both 
treatment naïve and treatment experienced patients Iran. They 
collected samples from 92 patients over a one year period (2013). 30 
patients were treatment naïve and 62 had been taking ART. Results 
for the treatment naïve patients showed 2/30 (6.7%) resistance to 
NNRTI and 4/30 (13.3%) had mutations conferring resistance to PI. 
Results for treatment experienced patients showed that 36/62 (58%) 
had resistance to treatment; 7/62 (11.3%) had resistance to one class 
of ART, 27/62 (43.5%) had resistance to two classes of ART and 2/62 
(3.2%) had resistance to all three classes (Baesi et al. 2014). 
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Therefore, this is the first study in the Kingdom and in the whole 
Region to look for the prevalence and types of ART resistance in 
treatment naïve HIV patients. This will inform the Saudi authority in 
the Saudi Ministry of Health (MOH) and the Saudi programme of 
HIV/AIDS about appropriate first and second line ARV regimens. 
 
Country Oman KSA Turkey Iran  
Reference  (Al Dhahry et al. 
2004) 
(Jamjoom et 
al. 2010) 
(AlHajjar et 
al.2011) 
(Sayan et 
al. 2013) 
(Baesi et al. 2014) 
 
 
Study period April - July 2001 Aug. 2004 –
Jun 2009  
July 2006 -
January 2009 
June 
2009 –  
Feb. 2012 
One year (2013) 
 
Number of 
patients  
93 63 22 (Paediatrics) 117 92 (including IDU 
patients) 
Treatment 
Experience  
Naïve  ART Naïve  ART Naïve  ART Naïve  Naïve  ART 
51 37 (current) 
5 (stopped) 
0 63 0 22 117 30 62 
Treatment 
regimen  
One  - 3/37  
(8%) 
- - - 3/22 
(13%) 
- - 36/62 
(58%) 
Two  - 0 - - - 5/22 
(22%) 
- - - 
Three  - 5/37 
(13.5%) 
- - - 14/22 
63% 
- - - 
Resistance  RTI 3/47 
(6.4%) 
24/32 
(75%) 
- 36/63 
(57%) 
- - 7/117 
(5.9%) 
2/30 
(6.7%) 
- 
NRTI - - - 26/63 
(41%) 
- - 5/117 
(4.2%) 
- - 
NNRTI - - - 10/63 
(16%) 
- 19/22 
(86.4%) 
2/117 
(1.7%) 
2/30 
(6.7%) 
- 
PI 6/47  
(13%)  
7/32 
(21.8%) 
- 8/63 
(13%) 
- - 9/117 
(1.7%) 
4/30 
(13.3%) 
- 
Resistance 
by class  
One  - - - - - - - - 7/62 
(11.3%) 
Two  - - - - - - - - 27/62 
(43.5%) 
Three  - - - 2/63 
(3%) 
- - - - 2/62 
(3.2%) 
 
Table (5-3) – Summary of all ART resistance studies in the Region 
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Chapter 6 
 
Antiretroviral resistant in 
treatment naïve patients 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
 
 
6. ART resistance in Jeddah  
6.1 Introduction 
The introduction of combination antiretroviral therapy revolutionised the 
management of HIV patients (Palella et al. 1998;  Flepp et al. 2001). 
Today, patients with HIV should expect a similar life expectancy to HIV 
negative individuals if their diagnosis is made early and the viral load is 
well controlled (May et al. 2014). Key factors are the availability of ART, 
acceptance and treatment adherence by patient, influenced by side-
effects (Romanelli & Pomeroy 2000).  
The number of HIV patients with "treatment emergent resistance" will 
increase if an inadequate regimen is chosen or adherence to therapy is 
poor (Romanelli & Pomeroy 2000). "Primary resistance” may occur in an 
ART naïve-patient to whom resistance virus is transmitted. 
Most international guidelines for HIV treatment programmes include 
assessment of the presence of resistance in all patients prior to 
therapy and regular monitoring of HIV viral load during therapy to 
detect treatment failure early (Johnson et al. 2006). The possibility of 
resistance would be investigated with molecular methods to 
characterise the virus for resistance patterns.  
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In choosing the first choice ART for HIV treatment programme and for 
description of the likely "standard" regimen for treatment failure 
patients, it is essential to know the presence of primary ART resistance 
and the types of secondary resistance that are found. Antiretroviral 
therapy has been readily available in the Kingdom since the late 1990's, 
but no studies of primary resistance have been performed in the 
Kingdom or any other countries in the Region. Only two studies had 
been published from Oman (Al Dhahry et al. 2004) and KSA (Jamjoom et 
al. 2010) of resistance in patients who have failed multiple ART 
combination; they showed high resistance rates. 
6.2 Aims          
The aim of this study was to determine the prevalence and the pattern 
of ART resistance in ART naïve patients attending the largest HIV 
treatment centre in the Kingdom of Saudi Arabia, in Jeddah. 
6.3 Methods 
These have been discussed in detail on page 124. In brief, sequentially 
presenting ART naïve patients were identified in the Jeddah clinic 
between November 2013 and February 2014, and instructed to give an 
extra sample of blood, which was used for genotypic resistance testing 
by Sanger and Next Generation Sequencing methods in the UK. 
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6.4. Demographic details 
Over the period of 4 months (November 2013 – February 2014) blood 
samples were collected from HIV treatment naïve cases followed at King 
Saud Hospital in Jeddah. Out of all 664 patients 117 were treatment 
naïve patients and of them 109 were eligible to be enrolled in this study 
(see page 141). 
Of the 109 patients, 71 (65%) were male with a median (range) age of 
33 (18-59) years. Overall, 52 (48%) had first received their HIV 
diagnosis within 6 months prior to attending. The demographic and 
clinical profile of the patients is compared to that of the ART naïve 
patients identified in the review of the 2010 patient cohort (Chapter 5) in 
Table (6-1). The prospective cohort was younger and proportionally 
more women, in keeping with national trends. CD4+cell counts were 
lower in the prospective group overall, but HIV viral loads were similar. 
The proportions of gender and the ages of the two patient groups were 
similar although there were more women in the prospective sample. No 
further risk factor data were allowed 
ART naïve patients  2010 Cohort  2013/14 Cohort  
Sex male 248/334 (74%) 71/109 (65%) 
Age Median 
(range) 
35 years ( 18-78 years) 33 years (18-59 years) 
Mean (SD) 37 (11) years 32 (10.6) years 
 CD4+ Mean (SD) 524 (320) 327 (296) cells/mm3 
HIV Viral load(log)  Mean (SD) 3.8 (1.15) 3.7 (1.6)copies/ml 
 
Table (6-1) comparing our data from 2010 and 2013/14 cohorts 
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6.5. Genotypic resistance tests.  
 
Of the 109 samples obtained from ART naïve patients, 87 (80%) were 
successfully amplified and screened for mutations associated with 
resistance to NNRTI and NRTI, and 93 (85%) were examined for 
mutations associated with PIs (Sanger method). The most common HIV-
1 subtype is C (41.3%) and the second most common subtype was G 
(19.3%).  
Resistance mutations for all 3 classes of antiretroviral agents were 
successfully examined in 86 (79%) and conversely, no results at all were 
could be obtained for 23 (21%) samples. All 22 individual patients with 
at least one potential resistance mutation detected are summarised in 
Table 6-2.  
Resistance to NNRTI was the most common 9/87 (10.3%) . Resistance 
to NRTI was only found in 1/87 (1.1%). Resistance to PI was found in 
6/93 (6.5%). Moreover 4.5% of the samples showed resistance to EFV 
and NPV. In addition 1.1% of samples showed resistance to 3TC, FTC, 
DDI and ABC (M184MV). 
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Table (6-2) ART resistance (Sanger) according to ART class 
 
 
 NNRTI NRTI PI 
Sample # Mutations Resistance Mutations Resistance Mutations Resistance 
KSH101 None   None   L33F minor yes  
KSH104 None   None   K43T minor yes  
KSH011 E138EG yes  None   None   
KSH017 None   None   L10IL minor yes  
KSH019 V179E yes  None   None   
KSH002 V90I  No None   L10IV minor  No 
KSH022 None   M184MV yes  None   
KSH003 E138A yes  None   A71T minor  No 
KSH035 None   None   L10I minor  No 
KSH040 V106I  No None   None   
KSH042 Y188DY  No None   None   
KSH049 V90I  No None   None   
KSH057 E138A yes  None   None   
KSH060 None   None   L10I minor yes  
KSH063 V1061V  No None   None   
KSH066 V106M +V179D yes  None   None   
KSH067 E138A yes  None   None   
KSH068 E138EG yes  None   None   
KSH069 K103N + V106I yes  None   None   
KSH071 None   None   L10IL minor yes  
KSH073 None   None   A71V minor  No 
KSH078 V179IT  No None   None   
KSH079 V106IV  No None   None   
KSH084 V179DV yes  None   L33IV minor  No 
KSH085 None   None   L10I minor yes  
Total 9/87 (10.3%) 9 7 1/87 (1.1%) 1 0 6/93 (6.5%) 6 5 
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6.6. Resistance to Reverse Transcriptase Inhibitors 
(RTI)(Sanger): 
 87 samples from treatment naïve Saudi HIV recently diagnosed 
patient were successfully sequenced and tested for resistance to 
reverse transcriptase inhibitors. The majority 70 (80.5%) were 
sensitive to RTI. Resistance to at least one RTI was noted in 10 
(11.5%) of the cases. Some mutations were noted in 3 (3.4%) which 
are weakly selected by RTI but if present with another mutation 
(V179D) will cause significant resistance to RTI. 
 
6.7. Resistance to NNRTI and NRTI (Sanger): 
Resistance to NNRTI was detected in 9/87 (10.3%) and in 1/87 
(1.1%) in NRTI. The majority of samples showed sensitive 
sequences with no mutation or non-resistant mutations (88.5%).  
6.8. Resistance to PI (Sanger): 
 
93 samples were processed successfully and sequenced for 
resistance. 6 (6.5%) samples showed significant mutations which 
can cause resistance to PI. 
The frequency of different mutations detected and interpretation 
of their significance is summarised in table (6-3). 
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NNRTI Sample  Resistance mutation N (%) Resistance to (ARV) 
Total  
9/87 
(10.3%) 
KSH003, KSH057, KSH067 E138A 3 (3.4) RPV 
KSH011, KSH068 E138EG 2 (2.3) ETR and RPV 
KSH066, KSH084 V179D 2 (2.3) EVF and NVP 
KSH066 V106M 1 (1.2) EVF and NVP 
KSH069 K103M 1 (1.2) EVF and NVP 
KSH019 K179E 1 (1.2) EVF and NVP 
KSH069 V106I 1 (1.1) EVF and NVP 
NRTI Sample  Resistance mutation  N (%) Resistance to (ARV) 
Total 1/87 (1.1%) KSH022 M184MV 1 (1.1) 3TC, ABC, DDI and FTC 
PI Sample  Resistance mutation  N (%) Resistance to (ARV) 
Total  
6/93 
(6.5%) 
KSH101 L33F 1 (1.1) FPV/r and NFV 
KSH104 K43T 1 (1.1) NFV and TPV 
KSH017 and KSH071 L10IL 2 (2.2) NFV 
KSH085 and KSH060 L10I 2 (2.2) NFV 
 
Table (6-3) ART resistance and mutations by drug class (Sanger) 
 
6.9. ART resistance by next generation sequencing (NGS)  
Following testing for ART resistance by the Sanger sequencing method, 
105/109 (96.3%) HIV treatment naïve patient samples were successfully 
tested for ART resistance by using deep sequencing and next generation 
sequencing (NGS) techniques. 
Resistance to NNRTI was reported in 24/105 (22.9%) of the total samples, 
while in the original sequencing method resistance to NNRTI was detected in 
9/87(10.3%). Mutations that confer resistance to NRTI were found in 6/105 
(5.7%) when samples were processed by deep sequencing (NGS). NRTI 
resistance with the original sequencing technique resistance was found in 
only 1/93 (1.1%). Minor HIV sequence mutations to PI were noted in 34/105 
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(32.4%), whereas by using the original sequencing method there were minor 
mutations in only 6/93 (6.5%) of the samples. 
NRTI 
KSH035 T6MT KSH034 K219R 
KSH057 M41LM KSH018 T69A,T69N, M184V 
KSH105 M184I KSH011 L210R, L210W 
Total 6/105 (5.7%) 
NNRTI 
KSH002 V90I KSH084 V179DV 
KSH003 V90I, E138A KSH105 V106I, V108I, M230I 
KSH019 V179EV,E138A KSH104 V106I, V106M, V108I 
KSH040 V106I KSH074 V106I 
KSH049 V90IV KSH070 V106I, V179I 
KSH057 E138A KSH055 V90I 
KSH062 V106I KSH053 V90I 
KSH066 V106M, V179D KSH052 E138A 
KSH067 E138A KSH048 E138A 
KSH069 K103N, V106I KSH033 E138A 
KSH078 V179I KSH002 E138A 
KSH079 E138A,V106IMV KSH019 E138A 
Total 24/105 (22.9%) 
PI  
KSH002 L10LV KSH056 K20I 
KSH003 A71T KSH060 K20I, L10I 
KSH007 T74S KSH061 K20I 
KSH014 T74S KSH064 K20I 
KSH018 K20I KSH065 K20I 
KSH019 K20I KSH071 K20I, L10IL 
KSH025 K20I KSH073 A71V 
KSH031 K20I KSH074 K20I 
KSH035 L10I KSH075 K20I 
KSH037 K20I KSH077 M46I 
KSH039 K20I KSH078 K20I, M46I 
KSH041 K20I KSH079 K20I, T74S 
KSH044 K20I KSH080 K20I 
KSH045 K20IK KSH084 L33IV 
KSH049 K20I KSH085 K20I, L10I 
KSH053 K20I KSH088 T74ST 
KSH055 K20I KSH089 T74S 
Total 34/105 (32.4%) 
 
Table (6-4) Summary of all ART resistance mutations (NGS) 
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Table (6-5) comparison between ART resistance by Sanger and NGS methods 
(n=109) 
*20% cut-off was used in NGS to compare results with Sanger methods which had 
threshold of 20%.    
 
 
 
 
 
 Genotypic Testing (Sanger) Genotypic testing (NGS 20%)* 
Sample Subtype  Mutation/ART class Remarks Subtype Mutation/ART class  Remarks 
  NNRTI NRTI PI   NNRTI (%) NRTI (%) PI (%)  
KSH001 C None  None  None   C None  None  None   
KSH002 C None  None  None   C V90I(84%) None L10LV(35%)  
KSH003 C E138A None  None   C E138A(23%) None  A71T(96%)  
KSH004 C None  None  None   C None  None  None   
KSH005 Unable None  None  None   CRF01_AE None  None  None   
KSH006 D None  None  None   D None  None  None   
KSH007 C None  None  None   C None  None  T74S(99%)  
KSH008 C None  None  None   C None  None  None   
KSH009 CRF02_AG None  None  None   CRF02_AG  None  None  None   
KSH010 C None  None  None   C None  None  None   
KSH011 Unable E138EG None  None   C None  L210R(2%), 
L210W(2%) 
None   
KSH012 Unable None  None  None   Unable None  None  None   
KSH013 B None  None  None   B None  None  None   
KSH014 A None  None  None   A None  None  T74S(35%)  
KSH015 Unable     Not 
processed 
Unable None  None  None   
KSH016 Unable    Not 
processed 
Unable None  None  None   
KSH017 Unable None  None  L10IL  Unable     Not 
processed 
KSH018 G None  None  None   G T69A(10%), 
T69N(7%), 
M184V 
(11%) 
None  K20I(100%)  
KSH019 G K179E None  None   G V179E(57&%), 
E138A(3.6%) 
None  K20I(100%)  
KSH020 C None  None  None   C None  None  None   
KSH021 CRF01_AE None  None  None   CRF01_AE None  None  None   
KSH022 G None  M184MV None   G None  None  None   
KSH023 C None  None  None   C None  None  None   
KSH024 C None  None  None   C None  None  None  
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Table (6-5) comparison between ART resistance by Sanger and NGS methods 
(n=109) 
 
*20% cut-off was used in NGS to compare results with Sanger methods which had 
threshold of 20%.     
 Genotypic Testing (Sanger) Genotypic testing (NGS 20%)* 
Sample Subtype  Mutation/ART class Remarks Subtype Mutation/ART class Remarks 
  NNRTI NRTI PI   NNRTI (%) NRTI (%) PI (%)  
KSH025 Unable Not processed None   Unable None  None  None   
KSH026 G None  None  None   G None  None  None   
KSH027 A None  None  None   A None  None  None   
KSH028 Unable    Not 
processed 
Unable None  None  None   
KSH029 Unable    Not 
processed 
Unable None  None  None   
KSH030 C None  None  None   C None  None  None   
KSH031 G None  None  None   G None  None  K20I(96%)  
KSH032 Unable None  None  None   A/B None  None  None   
KSH033 C None  None  None   C E138A 
(21%) 
None  None   
KSH034 C None  None  None   C None  K219R 
(3.4%) 
None   
KSH035 K None  None  None   K None  T69NT 
(21%) 
L10I(100%)  
KSH036 C None  None  None   C None  None  None  
KSH037 G None  None  None   G None  None  K20I(90%)  
KSH038 C None  None  None   C None  None  None  
KSH039 G None  None  None   G None  None  K20I(90%)  
KSH040 D None  None  None   D V106IV 
(63%) 
None  None  
KSH041 G None  None  None   G None  None  K20I(90%)  
KSH042 CRF01_AE None  None  None   CRF01_AE None  None  None  
KSH043 Unable    Not 
processed 
Unable None  None  None  
KSH044 CRF02_AG None  None  None   CRF02_AG None  None  K20I(99%)  
KSH045 G None  None  None   G None  None  K20IK(70%)  
KSH046 C None  None  None   C None  None  None  
KSH047 D None  None  None   D None  None  None  
KSH048 C None  None  None   C E138A 
(5.1%) 
None  None  
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Table (6-5) comparison between ART resistance by Sanger and NGS methods 
(n=109) 
 
*20% cut-off was used in NGS to compare results with Sanger methods which had 
threshold of 20%.    
 
 
 Genotypic Testing (Sanger) Genotypic testing (NGS 20%)* 
Sample Subtype  Mutation/ART class Remarks Subtype Mutation/ART class Remarks 
  NNRTI NRTI PI   NNRTI (%) NRTI (%) PI(%)  
KSH049 G None  None  None   G V90IV(63%) None  K20I(99%)  
KSH050 C    Not 
processed 
C None  None  None   
KSH051 D    Not 
processed 
D None  None  None   
KSH052 Unable None  None  None   D/G E138A(14.6%) None  None   
KSH053 G None  None  None   G V90I (5%) None  K20I(99%)  
KSH054 Unable None  None  None   Unable None  None  None  
KSH055 G None  None  None   G V90I(4.8%) None  K20I(99%)  
KSH056 G None  None  None   G None  None  K20I(99%)  
KSH057 C E138A None  None   C E138A(85%) M41LM(21%) None   
KSH058 Unable None  None  None   J/D None  None  None   
KSH059 C None  None  None   C None  None  None  
KSH060 CRF02_AG None  None  L10I  CRF02_AG None  None  K20I(100%) 
L10I(99%) 
 
KSH061 G Not processed None   G None  None  K20I(99%)  
KSH062 D None  None  None   D V106I(99%) None  None  
KSH063 G None  None  None   G    Not 
processed 
KSH064 G None  None  None   G None None  K20I(99%)  
KSH065 CRF02_AG None  None  None   CRF02_AG None None  K20I(99%)  
KSH066 D V179D,V106M None  None   D V106M(78%) 
V179D(88%) 
None  None   
KSH067 C E138A None  None   C  E138A(99%) None  None   
KSH068 C E138EG None  None   C None None  None   
KSH069 D K103N,V106I None  None   D K103N(99%) 
V106I(98%) 
None  None   
KSH070 D None  None  None   D V179I(75%) M41LM(22%) None   
KSH071 G None  None  L10IL  G None None  L10IL(59%) 
K20I(99%) 
 
KSH072 C None  None  None   C None  None None  
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Table (6-5) comparison between ART resistance by Sanger and NGS methods 
(n=109) 
 
*20% cut-off was used in NGS to compare results with Sanger methods which had 
threshold of 20%.    
  Genotypic Testing (original)   Genotypic testing (NGS 20%)*  
Sample Subtype  Mutation/ART class Remarks Subtype Mutation/ART class Remarks 
  NNRTI NRTI PI   NNRTI  (%)  NRTI(%) PI (%)  
KSH073 B  Not 
processed 
None   B None  None  A71V(99%)  
KSH074 CRF02_AG None  None  None   CRF02_AG V106I(6.2%) None  K20I(94%)  
KSH075 CRF02_AG None  None  None   CRF02_AG None  None  K20I(99%)  
KSH076 Unable None  None  Not 
processed 
 C None  None  None  
KSH077 J None  None  None   J None  None  M46I(3.2%)  
KSH078 G None  None  None   G V179T(48.5%) None  K20I(91%) 
M46I(13.6%) 
 
KSH079 G None  None  None   G V106I(24%) None  K20I(99%) 
T74S(87%) 
 
KSH080 G None  None  None   G None None  K20I(99%)  
KSH081 Unable  Not 
processed 
None       Not 
processed 
KSH082 C None  None  None   C None  None  None   
KSH083 C None  None  None   C None  None  None   
KSH084 D V179D None  None   D V179D(33%) None  L33IV(53%)  
KSH085 Unable None  None  L10I  G/K None  None  L10I(90%) 
K20I(93%) 
 
KSH086 C None  None  None   C None  None  None   
KSH087 C None  None  None   C None  None  None   
KSH088 C Not processed None  C  None  T74S(77%)  
KSH089 C None  None  None   C None  None  T74S(98%)  
KSH090 C None  None  None   C None  None  None   
KSH091 C None  None  None   C None  None  None   
KSH092 C None  None  None   C None  None  None   
KSH093 Unable     Not 
processed 
Unable None  None  None   
KSH094 Unable    Not 
processed 
Unable None  None  None   
KSH095 Unable    Not 
processed 
Unable None  None  None   
KSH096 C    Not 
processed 
C None  None  None   
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 Genotypic Testing (original) Genotypic testing (NGS 20%)* 
Sample Subtype  Mutation/ART class Remarks Subtype Mutation/ART class Remarks 
  NNRTI NRTI PI   NNRTI (%) NRTI(%) PI (%)  
KSH097 C None  None  None   C None  None  None   
KSH098 C None  None  None   C None  None  None   
KSH099 G    Not 
processed 
G None  None  K20I(100%)  
KSH100 C    Not 
processed 
C None  None  None   
KSH101 G Not processed L33F  G None  None  None   
KSH102 C None  None  None        Not 
processed  
KSH103 C None  None  None   C None  None  None  
KSH104 G None  None  K43T  G V106I(9%), 
V106M(2%), 
V108I(7%) 
None  K20I(44%)  
KSH105 K None  None  None   K V106I(97%)
V108I(97%) 
M184I(3%) None   
KSH106 C None  None  None   C None  None  None   
KSH107 D None  None  None   D None  None  None   
KSH108 C    Not 
processed 
C None  None  None   
KSH109 C    Not 
processed 
C None  None  None   
 
 
Table (6-5) comparison between ART resistance by Sanger and NGS methods 
(n=109) 
 
*20% cut-off was used in NGS to compare results with Sanger methods which had 
threshold of 20%.    
 
 
 
 
210 
 
 
6.10. Discussion  
 
6.10.1 ART resistance: 
Blood samples were collected from 109/116 (94%) patients 
approached to join the study. 71 (65%) were male and 52 (48%) had 
been diagnosed with HIV within the last 6 months. HIV RNA was 
successfully amplified from 96, and sequence data obtained from 93 
Prot amplicons and 87 RT amplicons. Mutations at putative resistance 
sites were detected in 25/96 (26%). Those with significant potential 
to confer resistance to NNRTI were found in 9/87 (10.3%), with 
resistance to NRTI in 1/87 (1.1%) and PI in 6/93 (6.5%). 4.5% of the 
samples showed resistance to efavirenz and nevirapine. In addition, 
1.1% of samples showed resistance to lamivudine, emtricitabine, 
didanosine and abacavir (M184MV).  
To confirm and extend findings, the samples were tested using next 
generation sequencing (deep sequencing technique) to look for more 
mutations conferring resistance to ART. This is a recently introduced 
technique which can examine in more depth the nucleic acid sequence 
and therefore gives a better comparison with the wild type HIV virus. 
No studies have been performed in the Region or in KSA on ART 
resistance using next generation sequencing. This is the first study to 
look systematically for ART resistance in treatment naïve patients and 
211 
 
to compare the results obtained by using both sequencing techniques 
(deep sequencing and the original Sanger sequencing technique). 
Using NGS genotypic resistance testing, revealed mutations conferring 
resistance to protease inhibitors (PI) in 34/105 (32.4%) and to 
reverse transcriptase inhibitors (RTI) in 24/105 (22.9%).  
 
ART resistance Results Summary  
Sanger  NGS* 
 Total sample size was 109 samples.  Total sample size was 105 samples 
 Resistance to NNRTI was the most common 
9/87 (10.3%)  
 Resistance to NNRTI was the most common 
24/105 (22.9%) 
 Resistance to NRTI was only 1/87 (1.1%)  Resistance to NRTI was 6/105 (5.7%) 
 Resistance to PI was 6/93(6.5%)  
  
 Resistance to PI was 34/105 (32.4%)  
 
 
Table (6-6) ART resistance Results Summary (n=109) 
*20% cut-off was used in NGS to compare results with Sanger methods which had 
threshold of 20%.    
 
Several protease inhibitors have been introduced for HIV treatment. It 
is important to know how the effect of each protease inhibitor 
mutation impacts on resistance to other PI. Boosted PI regimens 
(often using low dose raltegravir) have been found to be more 
effective at decreasing viral replication than unboosted protease 
inhibitor regimens (Rhee et al. 2010) 
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Protease inhibitors reduce HIV viral replication but some residual viral 
activity remains. This activity may lead to mutations which produce 
resistance. In addition, many of the PIs have poor oral bioavailability 
or short half-lives. This may affect adherence to treatment because 
doses will be given in higher amount and more frequently. Moreover, 
the side effects of PIs may be increased by prescribing higher doses. 
Such toxic effects may include gastrointestinal side effects 
(diarrhoea), rash, renal colic and dry skin. These factors may further 
increase the likelihood of inadequate adherence and subsequently 
induce resistance (Walmsley 2007). Thus, protease inhibitor use can 
result in high levels of resistance and numerous side effects (Kožíšek 
et al. 2014). 
Other factors may be considered and may affect resistance to ART, 
including HIV exposure mode, pre-treatment viral load and CD4 cell 
count, content of first ART regimen, hepatitis B/C co-infection, prior 
AIDS diagnosis, HIV subtype, and adherence to treatment. 
Transmitted drug resistance is also significant for drug-specific or drug 
class–specific resistance to treatment outcome and its significance 
requires further study.  
Sirivichayakul et al recently studied transmitted drug resistance and 
ART outcomes in non-subtype B HIV-1–infected patients in South East 
Asia (Sirivichayakul et al. 2014).  1471 patients were included from 12 
sites in Thailand, Malaysia, Hong Kong, the Philippines and Indonesia. 
All patients were ART-naïve. The common subtype in this region is 
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HIV-1 CRF01_AE. In our study in Saudi Arabia about 8% of patients 
were HIV 1 subtype CRF02_AG (see chapter 7). Drug mutations that 
confer resistance for HIV treatment were found in 4.1% before ART 
initiation. They found that patients taking ART with resistance to least 
one drug class will have a 3.12-fold higher chance of virological failure 
compared to those without resistance (Sirivichayakul et al. 2014) 
 
Country Oman KSA Turkey Iran  
Reference  (Al Dhahry et al. 2004) (Jamjoom et 
al. 2010) 
This study  (Sayan et 
al. 2013) 
(Baesi et al. 2014) 
 
 
Study period April - July 2001 Aug. 2004 –
Jun 2009  
Nov.2013 –Feb.2014 June 
2009 –  
Feb. 2012 
One year (2013) 
 
Number of patients  93 63 109 117 92 
Treatment 
Experience  
Naïve  ART Naïve  ART Naïve  ART Naïve  Naïve  ART 
51 37 (current) 
5 (stopped) 
0 63 109 0 117 30 62 
Treatment 
regimen  
One  - 3/37  
(8%) 
- - Sanger NGS - - - 36/62 
(58%) - - 
Two  - 0 - - - - - - - - 
Three  - 5/37 
(13.5%) 
- - - - - - - - 
Resistance  RTI 3/47 
(6.4%) 
24/32 
(75%) 
- 36/63 
(57%) 
10/87 
(11.4%) 
30/105 
(28.6%) 
- 7/117 
(5.9%) 
2/30 
(6.7%) 
- 
NRTI - - - 26/63 
(41%) 
(1/87) 
1.1% 
6/105 
(5.7%) 
- 5/117 
(4.2%) 
- - 
NNRTI - - - 10/63 
(16%) 
9/87 
(10.3%) 
24/105 
(22.9%) 
- 2/117 
(1.7%) 
2/30 
(6.7%) 
- 
PI 6/47  
(13%)  
7/32 
(21.8%) 
- 8/63 
(13%) 
6/93 
(6.5%) 
34/105 
(32.4%) 
- 9/117 
(1.7%) 
4/30 
(13.3%) 
- 
Resistance 
by class  
One  - - - - 16/93 
17.2 
64/105 
60% 
- - - 7/62 
(11.3%) 
Two  - - - - 0 4/105 
3.8% 
- - - 27/62 
(43.5%) 
Three  - - - 2/63 
(3%) 
0 0 - - - 2/62 
(3.2%) 
 
Table (6-7) This study results compared to ART resistance studies results in the 
Region 
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As expected, more mutations that confer resistance to ART were 
discovered by NGS sequencing. Resistance to NNRTI was found in 
22.9% compared to 10.3% detected using the original sequencing 
technique. 5.7% mutations that confer resistance to NRTI were found 
using deep sequencing technique (next generation sequencing) while 
only 1.1% resistance to NRTI was found using the original technique. 
The study showed that the rate of minor mutations that may confer PI 
resistance is 32.4% using the deep sequencing and only 6.5% using 
the original sequencing. 
To put this in context the finding of Sanger and NGS sequencing in 
this study have been compared with other studies of ART in adults in 
Table 6-7. Although the numbers in each study are small, there is a 
lot of similarity in the findings in ART naïve patients in Oman (2004) 
and Iran (2014) where there was RT resistance in 6.4% and 6.7% 
respectively, compared to 11.4% in this study in KSA. Similarly, these 
studies revealed 13% and 13.3% PI resistance respectively, compared 
to 6.5% this study.  
NNRTI resistance was found in 6.7 % of patients in Iran compared to 
10.3% in this study. 
Thus, there seem to be 5-15% transmitted resistance to each class, 
with a trend towards higher levels of NNRTI resistance in this more 
comprehensive study in KSA.   
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6.10.2 Low dose efavirenz 
 
Efavirenz is one of the most commonly used and recommended 
NNRTI in first line regimen for HIV treatment naïve patients. 
Advantages of efavirenz include a low pill burden (once daily), 
multiple clinical trials have shown good drug potency with few 
metabolic effects, and it is not known to have long term side effects. 
On the other hand, efavirenz is associated with increased frequency of 
transmitted drug resistance, cross class resistance, rash and CNS side 
effects (Stone et al. 2009). 
In 2014 the ENCORE1 study group published a randomised, double-
blind, placebo-controlled study comparing the eﬃcacy of low dose 
efavirenz (400 mg) versus standard 600 mg dose in HIV treatment 
naïve patients. Participants were recruited from centres in 13 different 
countries include Argentina, Australia, Chile, Germany, Hong Kong, 
Israel, Malaysia, Mexico, Nigeria, Singapore, South Africa, Thailand 
and the UK. The study included 311 patients on reduced 400mg dose 
and 295 patients on regular 600mg dose followed for 48 weeks. The 
study showed that a reduced dose of 400 mg efavirenz is non-inferior 
to the standard dose of 600 mg, when combined with tenofovir and 
emtricitabine during 48 weeks in ART-naïve adults with HIV-1 
infection. In addition reducing the dose will also improve the cost and 
reduce the side effects (Group 2014) 
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This result of efavirenz efficacy was also supported by earlier 
published reports describing the efficacy and potency of efavirenz-
containing regimens in first line antiretroviral therapy (Puls et al. 
2010). 
In Saudi Arabia the most common first line ART prescribed to HIV 
treatment naïve patents is a combination of tenofovir and 
emtricitabine in addition to the regular dose of 600mg efavirenz. Dose 
reduction should be considered in the future because of the reduction 
of cost and side effects. However, it will be important to monitor the 
effect of this on acquired resistance, and patients should be tested for 
TDR, as 4.5% have resistance to EFV and NVP by Sanger sequencing 
and a higher proportion of 9.5% was detected by NGS method.   
6.10.3 Etravirine and rilpivirine Resistance: 
Rilpivirine resistance-associated-mutations (RAMs) were found in 5 
(5.7%) of treatment naïve HIV patients. Mutations were noted in 
E138A (3.4%) and E138EG (2.3%). 80% were HIV-1 subtype C. 
Etravirine only RAMs detected in 2 (2.3%). The mutation noted was 
E138EG. These drugs have hardly been used in KSA so their presence 
is a cause for concern. 
In 2013 Asahchop and colleagues studied etravirine and rilpivirine 
resistance in viruses containing NNRTI mutations at base line. The 
study showed that in wild type viruses E138K or E138G mutations 
were detected following pressure with etravirine or rilpivirine, prior to 
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the appearance of other NNRTI resistance mutations. Etravirine and 
rilpivirine are likely to select for E138K as major RAMs (Asahchop et al 
2013) 
Geretti and colleagues examined both sensitive methods of testing for 
of HIV-1 RNA in plasma and Sanger sequencing to detect drug 
resistance prior to starting first-line ART with etravirine or efavirenz. 
They found that 13.9% of the patients had polymorphic RAMs to 
etravirine of V90I, V106I and E138A (Geretti et al 2014) 
Gallien and colleagues studied the resistance mutations to rilpivirine 
and etravirine in successfully treated HIV patients pre-exposed to 
efavirenz or nevirapine. The study showed RAMs for rilpivirine in 41 
(32%) individuals. 6% of the mutations were in E138A/G/K/Q/R/S. 
Etravirine mutations were detected in 5 (4%) individuals. They 
concluded that switching to rilpivirine-based regimens should not be 
recommended (Gallien et al 2014).  
These emerging resistances are significant and can probably be 
generalized over the Saudi Kingdom. Therefore, future plans for Saudi 
programme for HIV/AIDS fighting should include routine ART 
resistance test for HIV treatment naïve patients. 
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6.10.4 Pre-exposure and post exposure prophylaxis  
Pre-exposure prophylaxis (PrEP) describes the prescription of an 
antiretroviral drug for a person who does not have HIV infection, as a 
strategy for prevention of acquisition of the virus (CDC 2014). 
Post-exposure prophylaxis (PEP) with ART has long been recommended 
for people who experience exposures to HIV through accident, assault, 
rape, accidental injury, occupational and other sources. This is now well 
accepted and is a standard of care (Ford et al. 2015), as is perinatal 
and prenatal prescription of ART to mother and infant to reduce the 
chance of mother to child transmission of HIV (Hurst et al. 2014). The 
use of PrEP was a logical extension of these polices for individuals at 
reported high risk of infection but has been controversial.  
It is an optional treatment for people who are HIV negative but with 
high risk of getting the infection, such as MSM with frequent partner 
change. Currently, the only drug which any health organization 
recommends for PrEP is the combination of tenofovir/emtricitabine. 
Daily oral PrEP with the fixed-dose combination of tenofovir (TDF) 300 
mg and emtricitabine (FTC) 200 mg has been shown to be safe and 
effective in reducing the risk of sexual HIV acquisition in adults.The 
Centers for Disease Control recommends PrEP as it is a powerful HIV 
prevention tool and can be combined with condoms and other 
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prevention methods to provide even greater protection than when used 
alone (CDC 2014).  
The only medication regimen approved by the Food and Drug 
Administration and recommended for PrEP with all the populations 
specified in this guideline is daily TDF 300 mg co-formulated with FTC 
200 mg (Truvada) (CDC 2014). 
However, there are concerns about promoting ART resistance when 
PrEP is recommended. Daily oral PrEP using emtricitabine/tenofovir 
(FTC/TDF) or even TDF alone is safe and effective for preventing HIV 
acquisition by MSM but adherence remains an important factor in 
resistance development. Moreover this regimen does not achieve 
sufficient activity for full HIV virus suppression, so PrEP in people 
already infected with HIV will probably induce drug resistance. 
Therefore, recommendations for PrEP emphasize the importance of HIV 
testing prior to starting or restarting PrEP (Grant & Liegler 2015) 
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Chapter 7 
 
HIV subtypes and phylogenetic 
analysis 
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7.1 Virus Clade 
At least three separate zoonotic transmissions resulted in the formation 
of three distinct HIV-1 groups: M (main), O (outlier), and N (non-M/non-
O). About 90% of HIV-1 infections are classified as group M and these 
are distributed worldwide. Group O infections are endemic to several 
west central African countries and represent 1 to 5% of all HIV-1 
infection in those areas. The M group is further divided into different 
subtypes, the geographical distributions of which are shown in figure (7-
1). Almost 50% of global HIV-1 infection is subtype C which is the 
dominant subtype in Africa, Ethiopia and India. About 12% of HIV 
infection worldwide is subtype A. Subtype B is most commonly found in 
Americas, Europe and Australia. Circulating recombinant forms (CRF) are 
commonly found in East Asia, West and Central Africa, and the Middle 
East and North Africa regions (Peters et al. 2013). 
 
Figure (7-1) HIV-1 subtypes global map (Peters et al. 2013) 
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In a recent Turkish study, looking at 117 newly diagnosed HIV positive 
patients, CRFs were the most common subtypes (CRF 02_AG, CRF 
01_AE, CRF 12_BF and CRF 03_AB; 47%, 55/117) and B (33.3%, 
39/117) (Sayan et al. 2013). A similar study in Iran looking at 50 HIV 
positive ART naïve patients, revealed that 95.7% of sequenced samples 
were CRF35_AD, 2.1% and CRF01_AE 2.1% (Jahanbakhsh et al. 2013). 
As in most studies from Iran, many patients were IDU and there is 
clearly spread of limited clades of HIV in this population due to syringe 
sharing.  
Previous phylogenetic analysis in Saudi patients showed that the most 
common HIV-1 subtypes are C (39.3%) G (25%), B (17.9%), D (3.6%), 
A (1.8%) and CRF02_AG (1.8%) (Badreddine et al. 2007), and similar 
results were obtained in two other studies in the Kingdom (Jamjoom et 
al. 2010; Alzahrani 2008). 
In this study, it was not possible to identify the virus clade in 20 (18%) 
of the samples. The results of the whole cohort of 109 are detailed in 
table 7-1 and summarised in Figures 7-2 and 7-3.  
The most common clade by Sanger method was C (41/89, 46%), 
followed by subtype G (23/89, 26%). A cluster of CRF02_A and 
CRF01_AE was present in (8/87, 9%). Other subtypes included D (10/89, 
11%), A (2/89, 2.2%), B (2/89, 2.2%), K (2/89, 2.2%) and J (1/89, 
1.2%).   
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A representative phylogenetic tree derived from sequences is shown in 
Figure 7.2. This tree illustrates high levels of HIV-1 strain diversity within 
the Saudi study population. 
The most common clade by NGS method was C (42/95, 44.2%), 
followed by subtype G (23/95, 24.2%). A cluster of CRF02_A and 
CRF01_AE was present in (9/95, 9.5%). Other subtypes included D 
(10/95, 10.5%), A (2/95, 2.1%), B (2/95, 2.1%), K (2/95, 2.1%) and J, 
J/D, D/G, G/K and A/B (1/95, 1.1%).   
Thus, the results were very similar by both Sanger and NGS methods 
(Table 7-1). Results when both were successful were concordant, with 
6/109 samples identified by NGS methods but not by Sanger.   
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(Figure 7-2) HIV-1 subtypes in this study (Sanger method N=109) 
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Table (7-1) HIV -1 Subtypes by Sanger and NGS methods (N=109) 
 
 
 
 
 
Sample subtype sample subtype sample Subtype 
sanger NGS sanger NGS sanger NGS 
KSH001 C C KSH038 C C KSH075 CRF02_AG CRF02_AG 
KSH002 C C KSH039 G G KSH076 Unable C 
KSH003 C C KSH040 D D KSH077 J J 
KSH004 C C KSH041 G G KSH078 G G 
KSH005 Unable CRF01_AE KSH042 CRF01_AE CRF01_AE KSH079 G G 
KSH006 D D KSH043 Unable Unable KSH080 G G 
KSH007 C C KSH044 CRF02_AG CRF02_AG KSH081 Unable Unable 
KSH008 C C KSH045 G G KSH082 C C 
KSH009 CRF02_AG CRF02_AG  KSH046 C C KSH083 C C 
KSH010 C C KSH047 D D KSH084 D D 
KSH011 Unable C KSH048 C C KSH085 Unable G/K 
KSH012 Unable Unable KSH049 G G KSH086 C C 
KSH013 B B KSH050 C C KSH087 C C 
KSH014 A A KSH051 D D KSH088 C C 
KSH015 Unable Unable KSH052 Unable D/G KSH089 C C 
KSH016 Unable Unable KSH053 G G KSH090 C C 
KSH017 Unable Unable KSH054 Unable Unable KSH091 C C 
KSH018 G G KSH055 G G KSH092 C C 
KSH019 G G KSH056 G G KSH093 Unable Unable 
KSH020 C C KSH057 C C KSH094 Unable Unable 
KSH021 CRF01_AE CRF01_AE KSH058 Unable J/D KSH095 Unable Unable 
KSH022 G G KSH059 C C KSH096 C C 
KSH023 C C KSH060 CRF02_AG CRF02_AG KSH097 C C 
KSH024 C C KSH061 G G KSH098 C C 
KSH025 Unable Unable KSH062 D D KSH099 G G 
KSH026 G G KSH063 G G KSH100 C C 
KSH027 A A KSH064 G G KSH101 G G 
KSH028 Unable Unable KSH065 CRF02_AG CRF02_AG KSH102 C C 
KSH029 Unable Unable KSH066 D D KSH103 C C 
KSH030 C C KSH067 C C  KSH104 G G 
KSH031 G G KSH068 C C KSH105 K K 
KSH032 Unable A/B KSH069 D D KSH106 C C 
KSH033 C C KSH070 D D KSH107 D D 
KSH034 C C KSH071 G G KSH108 C C 
KSH035 K K KSH072 C C KSH109 C C 
KSH036 C C KSH073 B B    
KSH037 G G KSH074 CRF02_AG CRF02_AG    
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Figure (7-3) HIV-1 subtypes (NGS N=109) 
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There was no difference in prevalence of the most common subtypes C, 
G or D in patients diagnosed with HIV within the last 6 months, 
compared to those diagnosed for longer than 6 months (table 7-2)  
 
 HIV duration 
HIV-1 Subtype n/N <6 months 
n/N 
>6 months 
n/N 
Unable  14/109 9/51 5/58 
CRF02_A 8/95 5/42 3/53 
C 42/95 18/42 23/53 
G 23/95 10/42 13/53 
A 2/95 1/42 1/53 
D 10/95 4/42 6/53 
K 2/95 0 2/53 
J 1/95 1/42 0 
B 2/95 0 2/53 
J/D 1/95 1/42 0 
D/G 1/95 0 0 
G/K 1/95 0 1/53 
A/B 1/95 1/42 0 
 
Table (7-2) HIV subtypes (NGS method) and infection duration (N=95) 
 
7.2. HIV-1 Subtypes and Resistance of ART classes  
One patient 1/87 (1.1%) was noted to have significant mutations that 
confers resistance to NRTI. Most of the isolates were subtype C 41/109 
(38%) and the mutations conferring resistance to NRTI was seen in 1/41 
(2.4%) of these subtype C cases. 
On the other hand we could not detect the subtype of 20/109 (18%) of 
the cases. Only 1/20 (5%) of these cases showed mutations conferring 
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resistance to NNRTI. 8/109 (7%) of the cases were CRF02_A subtype 
and 1/8 (12.5%) of these showed significant mutations that may lead to 
resistance to NNRTI. 4/41 (9.7%) of subtype C cases had mutations 
conferred resistance to NNRTI and 3/23 (13%) of subtype G showed 
mutations conferring resistance to NNRTI. 1/8 (12.5%) of CRF2_A 
subtype showed resistance to PI. Subtype C was the most common 
subtype with mutations to PI at 3/41 (7.3%) C. Only 1/23 (4.3%) of G 
subtypes cases showing a resistance mutation to PI. The proportion of 
resistant isolates in each clade is similar, although numbers are too small 
for statistical comparison.   
 
 
Table (7-3) HIV-1 Subtypes and resistance to ART classes (Sanger, N=89) 
 
   Resistance to 
NNRTI 
resistance to 
NRTI 
Resistance to 
PI 
 n/N % n/N % n/N  % Count  % 
HIV-1 
Subtype 
Unable 20/109 18% 1/20 5 % 0 0.0% 0 0% 
CRF02_A 8/89 9% 1/8 12.5% 0 0.0% 1/8 12.5% 
C 41/89 46% 4/41 9.7% 1/41 2.4% 3/41 7.3% 
G 23/89 26% 3/23 13% 0 0.0% 1/23 4.3% 
A 2/89 2.2% 0 0.0% 0 0.0% 0 0.0% 
D 10/89 11% 0 0% 0 0.0% 0 0% 
K 2/89 2.2% 0 0.0% 0 0.0% 0 0% 
J 1/89 1.2% 0 0.0% 0 0.0% 0 0% 
B 2/89 2.2% 0 0.0% 0 0.0% 1/2 50% 
 total 109  9/87 10.3% 1/87 1.1% 6/93 6.5% 
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Table (7-4) HIV-1 Subtypes and resistance to ART classes (NGS, N=95) 
 
7.3 Discussion  
Detecting the HIV subtype is important for epidemiology and determining 
the infection origin. In this study subtype C was the most common (38%) 
followed by subtype G (21%). CRF02_A was found in 8% of the cases.  
Previous phylogenetic analysis in 62 HIV positive Saudi patients, showed 
diversity of HIV subtypes in Saudi Arabia. The most common HIV-1 subtypes 
in the 2007 study were C (39.3%) G (25%), B (17.9%), D (3.6%), A (1.8%) 
and CRF02_AG (1.8%) (Badreddine et al. 2007). 
   Resistance to 
NNRTI 
resistance to 
NRTI  
Resistance to 
PI 
 n/N % n/N % n/N  % Count  % 
HIV-1 
Subtype 
Unable 14/109 12.8% 1/14 7.14% 0 0.0% 1/14 7.14% 
CRF02_A 8/95 8.4% 1/8 12.5% 0 0.0% 5/8 62.5% 
C 42/95 44.2% 6/42 14.3% 3/42 7.1% 5/42 11.9% 
G 23/95 24.2% 8/23 34.8% 0 0.0% 18/23 78.2% 
A 2/95 2.1% 0 0.0% 0 0.0% 0 0.0% 
D 10/95 10.5% 4/10 40% 1/10 10% 1/10 10% 
K 2/95 2.1% 1/2 50% 2/2 100% 1/2 50% 
J 1/95 1.1 % 0 0.0% 0 0.0% 1/1 100% 
B 2/95 2.1% 0 0.0% 0 0.0% 1/2 50% 
J/D 1/95 1.1 % 0 0.0% 0 0.0% 0 0.0% 
D/G 1/95 1.1 % 1/1 100% 0 0.0% 0 0.0% 
G/K 1/95 1.1 % 0 0.0% 0 0.0% 1/1 100 
A/B 1/95 1.1 % 0 0.0% 0 0.0% 0 0.0% 
 total 109  24/105 22.9% 6/105 5.7% 34/105 32.4% 
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In 2008 Al-Zahrani showed that HIV subtype C was the most common 
subtype in the Kingdom (58%). Other subtypes were B (17%) and A, D and 
G (8%) each. This study was performed in 39 HIV positive patients in 
Dammam, KSA (Alzahrani 2008).       
In 2010 Jamjom et al studied 60 samples from HIV patients at King 
Abdulaziz University Hospital in Jeddah. The study was carried out using 
blood samples from treatment failure patients. The most frequent HIV-1 
genotypes were type C (35%), G (38%), while type B (14%). All these 
studies favour an African or Asian source for most infections in Saudi 
patients. Genotype C of HIV-1 is the most frequent genotype in Africa and 
India, while genotype B is more prevalent in North America and Western 
Europe (Jamjoom et al. 2010). 
In this study the most common HIV-1 group M subtype by using NGS 
method was subtype C (38%). Subtype G accounted for (21%) and subtype 
D for (9%). In addition, subtypes B (2%), A (2%), and CRF02_AG (8%) 
were present, and the subtype could not be identified in 13% of the cases. 
Other diversity of mixed recombinant strains consisted of CRF subtypes A/B, 
G/K, D/G, J/D (1% each). Considering the low prevalence of HIV in the 
Kingdom (0.1%) the diversity of HIV-1 phylogenetic subtypes is quite high.  
The high diversity of subtypes suggests that the sources of HIV infection in 
the Kingdom are variable and indicates multiple sources. 
These results were similar to previous HIV subtype studies in the Kingdom, 
but different from other studies in the Region (Table 7-5). 
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As the most common HIV-1 subtype in Saudi Arabia, identifying the 
geographical origin of the subtype C infections is important. HIV-1 subtype C 
is the most common worldwide and is the predominant strain circulating in 
India, South Africa, and countries along the east coast of Africa (Hu, 
Pieniazek & Mastro 2013).  
The geographical proximity of Saudi Arabia to Africa and the common 
commercial interests explain the predominance of subtype C in the Kingdom. 
Subtype G has been found in the west central African countries of Nigeria, 
Cameroon, and Democratic Republic of Congo and patients with subtype G 
accounted for 21% of isolates in Jeddah. Again, CRF02_AG is the 
predominant HIV-1 strain circulating in west and west central Africa (Hu, 
Pieniazek & Mastro 2013) and accounted for 8% of our isolates.  
Only 2% of cases in Jeddah had subtype B, which commonly circulates in the 
Americas and Europe including in MSM. In the study cohort (chapter 3) more 
than 10% of the cases had a past history of travelling abroad. This may also 
contribute to this diversity of HIV-1 phylogenetic subtypes.   
A study in the neighbouring Yemen, showed that subtype B was the most 
common (47.3%) followed by subtype C (31.6%) and D (10.5%)(Saad et al. 
2005). Moving round the Arabian region anticlockwise, there is a further shift 
in predominant subtype in Oman where the predominant subtype is B (56%) 
and A (12.5%)(Al Dhahry et al. 2004). 
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In Oman, other subtypes C, D and CRF01_AE were 8% each (Al Dhahry et 
al. 2004). This is surprising given the close historical and trading links with 
East Africa and one would expect there to be a larger proportion of clade C 
isolates. In this study 37% of HIV patients were treatment experience and 
54% were treatment Naïve HIV patients. It is not known if this study results 
would be generalised to all of Oman, as it was done in Muscat. 
Country Selection ways Author Year Subtype 
A  B C G D CRFs 
Iran N 50 
(51% IDU) 
Jahanbakhsh et al. 2013 - - - - - CRF35_AD (95.7%) 
CRF01_AE (2.1%) 
patients ART naïve  
Lebanon 
 
  
N 26 Pieniazek et al. 1998 44% 40% 4% 4% 4% - 
patients On ART 
Oman N 88 Al Dhahry et al.    2004 12% 56% 8% - 8% CRF01_AE (8%) 
patients 37 on ART 
51 ART naïve  
Saudi 
Arabia 
N 62 Badreddine et al. 2007 1.8% 17.9% 39% 25% 3.6% CRF02_AG(1.8 %)  
patients On ART 
N 39 Alzahrani  2008 8% 17% 58% 8% 8%  
patients On ART 
N 60 Jamjoom et al. 
 
 
2010 - 14% 35% 38% % - 
patients On ART 
N 109 This study 2014 2% 2% 38% 21% 9% CRF02_A (8%) 
patients ART naïve  
Turkey N 117 Sayan et al.  2013 - 33% - - - CRF 02_AG, CRF 
01_AE, CRF 12_BF  
and CRF 03_AB; 
47%, 55/117 
patients ART naïve  
N 190 Araştırılması et al.  2014 - 31% - - - CRF 02_AG, CRF 
01_AE, CRF 12_BF,  
CRF 03_AB; (47% ) 
CRF02_G (7.8%) 
patients ART naïve  
Yemen  N 19 Saad et al.  2005 5.3% 47.3% 31%  10.5%  
patients On ART 
 
 Table (7-5) HIV-1 Subtypes in Iran, Lebanon, Oman, Saudi Arabia, Turkey 
and Yemen 
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There is considerable genetic HIV variation in other countries in the Region. 
Phylogenetic relationships and transmission dynamics were analysed in 26 
HIV-infected patients from Lebanon. One isolate was HIV-2 subtype B and 
the 25 HIV-1 isolates subtype were A (44%), B (40%), C (4%), D (4%) and 
G (4%)(Pieniazek et al. 1998). The predominance of subtype A and B 
suggest that most infection had been imported from Europe or North 
America, but the number of patients was very small and dates back nearly 2 
decades. 
In two reported Turkish studies, HIV-1 subtypes and CRFs were identified 
and the most common occurring subtypes were CRFs (CRF 02_AG, CRF 
01_AE, CRF 12_BF and CRF 03_AB; 47%, 55/117) and B (33.3%, 39/117) 
(Sayan et al. 2013). A second study also showed that the most prevalent 
HIV-1 subtypes were subtype B (31%); recombinant B/CRF02_AG (10.5%) 
and CRF02_G (7.8%) (Araştırılması et al 2014). The studies were done in 
similar groups of ART naïve HIV positive patients from different Turkish 
cities. These different distributions of subtypes suggest a mixed importation 
of isolates from Europe and North America (subtype B) and other CRFs from 
Asia. 
CRFs are more prominent in Iran where almost all strains were CRF35_AD, 
the study included 50 newly diagnosed with HIV infection from different 
Iranian centres, more than half of the patients were injecting drug users and 
needle sharing was common (Jahanbakhsh et al. 2013) 
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Unfortunately in this study permission was not granted to collect data on risk 
factors for acquiring HIV in Jeddah. As the regional variations in Table 7-5 
show, it would be valuable to study this in more detail across the Kingdom to 
identify the probable sources of HIV infection imported by different risk 
groups in several cities. 
The limited number of samples in the current study did not allow statistically 
significant comparison of ARV resistance rate in different HIV subtypes 
(Tables 7-3 and 7-4)    
It is uncertain whether some subtypes are associated with resistance, and 
this deserves further study. 
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Chapter 8 
Conclusions and recommendation 
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8. Conclusions and recommendations: 
This study provides a more accurate picture of a large group of 
HIV patients attending a non-selective HIV clinic in Jeddah. The 
clinical and risk details are more complete compared to previous 
epidemiological reports from the Kingdom because details were 
obtained directly from patient notes. Details about coinfection 
were included as well as about clinical presentation and WHO 
staging details. Results differ from a very recent report from a 
tertiary reference centre in Riyadh. These are the only two such 
reports in the Arabian Peninsula. 
However, data were not available consistently for all patients and this 
could be improved by regular quality checks and audits on operational 
performance in the clinic. 
The sensitivity of HIV/AIDS subject in Saudi culture was one of the 
important difficulties we had to overcome with proper collaborations 
and close coordination with the Saudi authority and Ministry of Health 
in the Kingdom. Homosexuality (MSM) is considered as criminal action 
in Saudi Arabian law and if proved in court, sentence of death is the 
plenty. This made data collection about such very sensitive issue very 
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difficult and extra caution and absolute confidentiality is a must. It 
was one of the difficulties we had to tackle in this study.  
8.1 Clinic Limitations 
Data were collected retrospectively from patients’ records, therefore, 
some key and important data could not be found (missing data). With 
retrospective studies, there is no control of accuracy on the available 
data because it depends on the quality of record keeping in the past. 
This was a particularly important limitation because some of the 
missing data were impossible to locate. For this study, all missing data 
were clearly labelled and excluded from all statistical calculations.  
Hepatitis A (HAV) was not tested or it was not recorded in patients’ 
medical notes at all in this study cohort. Moreover HAV vaccination 
was not recorded.   
In addition, hepatitis B surface antigen (HBsAg) was not tested 
(missing) in 19% (262/1383) of the study cohort. HBsAg positive 
patients require further evaluation (HBV DNA) but this was not 
available in the records. There was no anti-HBV antibody testing so 
exposure to HBV could not be investigated. Data on HBV vaccination 
was not available 
Hepatitis C (HCV IgG) was not tested (missing) in 20% (282/1383). 
Negative anti-HCV antibody results may be false negative in HIV 
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patients and HCV PCR is indicated both in this situation and in anti-
HCV Ab positive cases. No HCV PCR results were available. 
Hepatitis C coinfection may be missed if molecular methods are not 
used and hepatitis C coinfection needs early treatment. This should be 
reviewed prospectively in this cohort. 
The recording of past infections e.g. toxoplasmosis and hepatitis B 
and VDRL results was highly variable and often deficient.  
 
 test n/N % 
Hepatitis A  anti HAV IgG 1383 100% 
Hepatitis B HBsAg 321/1383 23.2% 
HBV PCR 1383 100% 
anti HBV antibodies 1383 100% 
Hepatitis C  anti HCV antibodies 282/1383 20% 
HCV PCR 1383 100% 
Toxoplasma IgG antibody 699/1383 50.5% 
CMV IgG antibody  486/1383 35% 
EBV IgG antibody 595/1383 43% 
VZV IgG antibody 767/1383 55.5% 
Syphilis VDRL 553/1383 40% 
 
Table 8-1 Summary of missing results in 1383 HIV positive patients in Jeddah 
 
The clinic still uses out-moded VDRL tests to look for syphilis. 
These tests are non- specific and may be altered by past bejel 
exposure. STI testing and screening protocols including 
introducing of modern syphilis serological methods need to be 
introduced as routine. 
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There is no clear protocol for detection or prevention of TB 
coinfection although this was common. This needs to be changed.  
This study has provided very important data for public health services 
in the Kingdom and should help to improve the future HIV/AIDS plans 
in the country. This will reflect on the general Saudi population and 
particularly on HIV patients. Moreover, care of HIV patients will be 
improved to match (as much as possible) the best possible services in 
other countries. 
Overall the study showed that clinical presentations and the rates 
of hepatitis and TB co infection are similar to those reported in 
many Western HIV patient cohorts. A substantial proportion of 
men acquire infection through sex with other men and this 
proportion is much higher than past reports from the Kingdom 
and Region. More patients were injecting drugs users than in 
previous reports from the Kingdom. This might be expected in 
Jeddah, where IDU has long been acknowledged to be present 
but is a concern in light of recent findings of increasing rates of 
HIV in IDU in Riyadh (Al-Shomrani 2014)  
Coinfection rates are highest in difficult to reach groups such as 
drug users and those who have been in prison. This has difficult 
implications for the HIV control and treatment programmes in 
Jeddah and elsewhere in KSA. 
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HIV control strategies in the Middle East countries have challenges 
and difficulties. In Saudi Arabia, as in many other countries in the 
Region many social and public health issues should be considered.  
Although there has been a significant improvement in case 
notification of HIV/AIDS cases in the Kingdom, there are still 
serious challenges including social challenges facing the Saudi 
National Program for HIV Control. However, the Saudi national 
HIV prevention programme is one of the most comprehensive and 
transparent HIV control programmes in the Region, and needs to 
use data from studies such as these studies in the futures to 
respond to changes in this rising medical problem.   
 
The best prevention approach is to improve the public health 
education and increase public awareness of HIV/AIDS. Political, 
financial, and social barriers have often restricted the most 
effective prevention and treatment strategies. These studies 
should also focus on detection and prevention in the high risk 
groups or difficult to reach groups such as IDU, MSM and 
prisoners. There is a need to ensure continuous access for high 
risk groups in order to ensure availability of treatment and all 
related services to control and prevent HIV/AIDS in such groups. 
Careful collaboration in the community between religious and 
social groups is very important to overcome these barriers.  
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For high risk groups including prisoners, HIV education should be 
provided.  
HIV testing is indicated more frequently for those at increased risk of 
acquiring HIV (MSM, IDU, STI and Hepatitis/TB clinics). HIV testing 
should be encouraged at all clinics whenever HIV is suspected.  
HIV patients should be screened more vigorously and systematically 
for possible coinfections and opportunistic infections (OI) using 
protocols adapted from other international standards eg BHIVA, CDC. 
Clinics in the Kingdom should have standard proformas for clinical 
data collection and guidelines for CD4 and viral load monitoring. For 
hepatitis screening we recommend that HAV to be included.  
This study did not examine the success of ART regimen, but this 
should be audited routinely in future.  Use of correct HIV treatment 
protocols for coinfected patients needs to be checked by clinical audit. 
8.2 Antiretroviral resistance 
Clinically significant ART resistance is emerging (16%) in this 
population. A variety of other markers included some clustering 
suggest local transmission of primary resistance. The results are 
probably generalizable in KSA and we recommend the introduction 
of routine resistance testing for all HIV positive patients in 
resource rich countries in the Region before starting ART. The 
WHO guidelines for HIV/AIDS which includes Saudi Arabia within 
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the MENA region should be revised, considering that the Kingdom 
and other GCC are resource rich. Local and national management 
protocols should include the best HIV/AIDS management 
standards rather than following recommendations for resource 
poor countries in Africa.  
The deep sequencing method was more accurate and a sensitive and 
has high reproducibility of test results compared to the original 
(standard) sequencing technique. It is suggested that this should be 
available for use in selected cases and specific prospective population 
studies are needed to provide more accuracy in identifying pattern of 
ART resistance in the Kingdom. 
Regimens of ART should be selected based on resistance test results 
with consideration of dosing frequency, pill burden, toxicity profiles, 
comorbidities, and drug-drug interactions for each patient individually.  
As future work we recommend that similar studies be carried out 
simultaneously in all Saudi provinces, and that collaborations with 
international AIDS organizations be developed in order to improve 
epidemiological and clinical data in the Kingdom. 
Moreover, future studies of a larger cohort from Saudi Arabia 
including ART naïve HIV patients are indicated to reveal the changing 
real state of the transmitted drug resistance in the country. This is the 
only study of treatment naïve patients in the Kingdom.  
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For this study we only collected limited epidemiological data and 
were not able to look for clustering of resistance in groups of 
patients. Further studies about epidemiological risk for primary 
and drug induced ART resistance are needed to help predict 
future ART resistance in HIV patients in the Kingdom, and to 
improve or adapt treatment protocols. 
HIV phylogenicity and subtyping in Saudi Arabia showed high 
diversities in four studies (including ours) in Saudi Arabia. These data 
about HIV-1 genetic origin and possible HIV geographical sources of 
infection help to inform for future plans and for control of HIV/AIDS in 
the Kingdom. As a future work we recommend wider scale studies and 
more research projects to explore HIV strain diversity in Saudi Arabia, 
and use the data to focus prevention effects on specific high risk area 
or newly emerging foci of transmission. 
8.3 Conclusion  
This work was carried out within the social and administrative climate 
several years ago, and I thank all those who contributed and helped 
to overcome a number of obstacles.  The work described in this thesis 
has successfully addressed the aims at the outset  
 It has provided a clear picture of clinical presentations of a 
large cohort of patients in Jeddah. 
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 It has provided a more complete picture of risk factors for 
infection including the  hard to reach groups such as MSM, 
IDU and prisoners, and confirmed the expected links of these 
groups to coinfections such as HBV, HCV, TB and syphilis. 
 It has revealed a lack of consistency of approach to screening 
and recording opportunistic infections and interventions to 
prevent these.   
 In the face of lack of the specific management protocols it 
could not assess the success of therapy in this cohort.  
 The study is the first comprehensive and study of transmitted 
drug resistance in unselected ART- naïve patients in the 
Region and the first to compare results of Sanger genoptypic 
sequencing with next generation sequencing. 
 These molecular methods revealed rates of primary resistance 
of 5-15% against several classes of antiretroviral drugs, 
including etravirine and rilpivirne, while have hardly been used 
in the Kingdom until now. 
 The results suggest that all patients should have resistance 
testing as a routine prior to starting therapy and whenever 
there is treatment failure. 
 The study confirms the broad pattern of heterogeneity of HIV 
isolates in KSA described in previous studies. These are 
different from the countries in the Region, highlighting their 
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use in identifying risk groups for importation of HIV infection 
into the Kingdom. 
The Ministry of Health and other officials have established an 
innovative programme for HIV in the Kingdom, against a backdrop of 
social complexities. Standards of care are already well established 
and have been upgraded since the first part of this work was 
completed. The work described in this thesis suggests that the clinic 
and management  protocols should be reviewed regularly in 
comparison to other international standards of care and protocols in 
resource rich countries, and adapted to match these. Regular clinical 
and operational audit of care holding, treatment initiation and 
success and similar outcomes, should be instituted to monitor the 
effectiveness of the programme. 
These efforts will cause benefit not only for patients who currently 
live with HIV/AIDS in the Kingdom, but also reduce the risks of 
onward transmission of potentially resistant HIV within Saudi Arabia, 
and benefit the country as a whole.      
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Appendix A 
Patients log. During data collection (Clinical features and epidemiology of HIV/AIDS in KSA) 
 
# Code Name File 
# 
DOB Sex Age Date 
Let. Numbers 1st 2nd family Mother’s 
name 
1  
 
            
2  
 
            
3  
 
            
4  
 
            
5  
 
            
6  
 
            
7  
 
            
8  
 
            
9  
 
            
10  
 
            
11  
 
            
12  
 
            
13  
 
            
14  
 
            
15  
 
            
16  
 
            
17  
 
 
 
           
...   
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Appendix B 
Data collection sheet(Clinical Features and Epidemiology HIV KSA) 
Section Patient's     Remarks 
A Data  Code:    Letter Numbers  
         
 Age  A.(   )18-25       B. (   )26-35 C.(     )36-45 D.(    )46-60      E.(   )60+ 
      
 Sex 1. (   )female  2. (  )Male    
      
      
      
 Education  A.(  )Illiterate    B(   ).R&W C.(  )High School  D.(  ) University   E.(   )PG 
      
 Marital 
Status 
1.(   )Single  2.(   )Married 3.(   )Divorced   
  4.(  )Widow    
section      
B History     
 HIV Dx date Duration A.( ) 1y or less  B.( )2-5y    C.( )5-10 D.(  )>10y  
  Age at Dx  (       )years     
 Presenting  
history 
    
      
 HIV Dx  Clinical suspicion 
    1.(  )yes.         2.( ) no 
Pre-marital test 
1.(   )yes       2.( ) no 
Routine serology 
1.(  )yes     2.( )no 
 
  pre-occupation 
1.(  )yes                  2.(  ) no 
   
 History of  1.(   )Hetero sexuality  2.( )Homosexuality  3.(  )IDU   
  4.(  )Blood Transfusion  5.(  ) Unprotected 
sex  
6.(   )Contact w/ 
HIV 
 
  7.(  ) History of prison 8.(  )STI 9.(  )Psychotic 
history.  
 
  10.(  ) travel history    
 Co 
infections 
HBV  
A.(   )yes  B.(  )no 
 C.( )not tested       
HCV 
A.(   ) yes B.(  )no    
C. (  )ND  
TB   
A.(   )yes    
B (  )no  
C. (  )treated   
D. (  )not treated 
 
section Lab.     
C  WBC    
  Hb    
268 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CD4+    % Absolute CD8 + count  
  Lymphocyte   %  Absolute    
  Esinophils       % Absolute   
  HBsAg 
 
1. (   )yes   2.( )no 
 3.(  )ND 
HCV  Ag (PCR) 
 
1.(   )yes  .(  ) no 
 3.( )ND 
Toxo 
 
1.(  )yes      2.(  ) no 
3.(  ) ND 
 
  CMV 
 
1.(  ) yes    2.(  ) no 
3.(  ) ND  
Cryptococcal 
 
1.(  )yes   2.(  )no 
3.(  )ND 
EBV 
 
1.(  )yes   2.(  )no 
3.(  )ND 
 
  VZV 
 
1.(  )yes   2.(  )no 
3.(  )ND 
VDRL 
 
1.(  )yes   2.(  )no 
3.(  )ND 
Other STI 
 
 
      
  Viral Load:    
  Log  Copies /ml   
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 CDC/WHO 
Staging at 
presentation 
A.(  ) stage 1 B.(  ) stage 2   
   
 
C.(  ) stage 3  
 
 
D. (  ) stage 4 
  
section Medication     
D ART Used in the 
Past 
1. (    )Yes  2. (     )No   
      
 Regimen      
      
      
      
      
 ART resistance  A. (  )Done  B.(  )ND    
 Resistance 
detected  
A. (  )Yes  B.(   )No   
      
 Currently on 
ART 
1. (    )Yes  2. (     )No   
      
 Regimen      
      
      
      
      
 ART resistance  A. (  )Done  B.(  )ND    
 Resistance 
detected  
A. (  )Yes  B.(   )No   
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 Latter use of 
ART 
1. (    )Yes  2. (     )No   
      
 Regimen      
      
      
      
      
 ART 
resistance  
A. (  )Done  B.(  )ND    
 Resistance 
detected  
A. (  )Yes  B.(   )No   
 
 
 
 
Dr.Wail Bajhmom  
Dr. Nick Beeching          16.07.2010 
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Appendix C 
Dr.Bajhmom 
Consent (ART resistance Jeddah) 2012 
 
CONSENT ةقفاوملاب رارقا 
 
I________________________ 
 
انأ__________________________  
 
 
 
I understand and consent to take extra  
samples of my blood. I acknowledge that 
these samples will be stored for research 
purposes (ART resistance). 
 
يمد نم ةيفاضا ةنيع ذخلا يتقفاوم يطعاو مهفتأ . يننا امك
 ثحبلا ضرغل مختستو نزخت فوس ةنيعلا هذه نأب مات ملع ىلع 
يملعلا(ةيسوريفلا تاداضملا ةمواقم)  
 
I consent to this sample to be used to 
provide extra information to my doctor at 
the clinic to guide the best treatment to 
myself. 
 
 لضفلا يلوصحل دعاستو جلاعملا يبيبطلل تامولعم يطعتسو
 لكل ةنيعلا هذه ليلحتو مادختسا ىلع قفاوا هيلعو نكمم جلاع 
ةساردلاب ةقلاع هلام.  
 
I understand that the samples will be 
sent to Liverpool UK for analysis related 
to the research at the University labs. 
 
 ةكلمملاب لوبرفيل ىلا لسرتس ةنيعلا هذه نأب ملع ىلع اناو
ةعماجلا تاربتخم يف ةمزلالا تارابتخلاا لمعل ةدحتملا.  
 
 
I understand that confidentiality will be 
assured and I will not be identified if the 
results are published. 
 
 مت دقو ا دقو فرعتلا متي نل هنأو ةساردلا ةيرس ىلع ديكاتلا
جئاتنلا رشن لاح يف يتيصخش ىلع.  
Signature of 
participant:____________________ 
 عيقوت
كراشملا______________________________  
 
Signature of interviewer 
(witness):______________________ 
 
 
 
 عيقوتلباقملا(دهاشلا)________________________  
 
 
Date __________________________. 
 
خيراتلا__________________________  
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Appendix D 
Questionnaire (data collection ART resistance) 
Dr.Bajhmom (ART resistance Jeddah) 2012 
 
 
# Pt code   
Age     
Sex    1.(   ) male 2.(    ) female  
HIV 
duration: 
   
    
On ART 1.(     ) yes 2.(      ) no  
    
Adherence  1.poor (     ) 2.reasonable (   ) 3.Excellent (   ) 
     
Duration of 
ART 
1.(      )< 6 months 2. (     )>6 months  
Total years    
ART 
regimen 
   
How many 
different 
regimen  
0 1 2 more Unknown  
 A. (NRTI) no
w 
previou
s 
B. (NNRTI) now previo
us 
C. (PI) no
w 
Previou
s 
 1. 
Zidovudine 
ZDV 
  1. efavirenz  
EFV 
  1.Atazanavir, 
ATV 
  
 2. 
Lamivudine 
3TC 
  2.nevirapin
e, NVP 
  2. Lopinavir 
LPV 
  
 3. Combivir   3.etravirine   3.Ritonavir   
RTV 
  
 4.Tenofovir   4.   4.Kalerta 
 
  
 5.Emtricitabi
ne FTC 
 
        
 6.Truvada 
 
        
          
    
CD4+ Viral load 
  Absol
ute  
%   Absolut
e  
Log 
 Nadir     Nadir    
 Peak     Peak    
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Copy of e-mail Ethical Approval from Saudi MOH  
RE: 12-159 Clinical and laboratory features of HIV/AIDS in KSA 
From: Omar H. Kasule <okasule@kfmc.med.sa> > > To: "zmemish@yahoo.com" <zmemish@yahoo.com> > > Cc: malakita al 
masri malouk22@hotmail.com  
>> Cc: bajhmoum@hotmail.com  
>> Cc: nbeeching@blueyonder.co.uk > > Sent: Tuesday, August 14, 2012 1:05 PM  
> > Subject: 12-159 Clinical and laboratory features of HIV/AIDS in the Kingdom 
> > of Saudi Arabia (Antiretroviral Resistance in Jeddah)  
IRB Registration Number with KACST, KSA: H-01-R-012 > > IRB Registration Number with 
OHRP/NIH, USA : IRB00008644 > > Approval Number Federal Wide Assurance NIH , USA : 
FWA00018774 > > August 14, 2012 > > IRB > > Log Number: 12-159  
 
I am pleased to inform you that your study titled: 'Clinical and > > 
laboratory features of HIV/AIDS in the Kingdom of Saudi Arabia 
(Antiretroviral Resistance in Jeddah)' > > was reviewed and was 
approved.  
 
> > > > Please > > be informed that in conducting this study, you as the Principal 
Investigator > > are required to abide by the rules and regulations of the Government of > 
> Saudi Arabia > > and KFMC/IRB. Further, you are required to submit a Progress Report 
before > > July > > 14, 2013; it can be reviewed by the IRB without lapse of approval. The 
> > approval > > of this proposal will automatically be suspended on August 14, 2013 
pending > > the > > acceptance of the Progress Report. You also need to notify the IRB as 
soon as possible in the case of: 
1. Any amendments to the project; > > 2. Termination of the study; > > 3. Any serious 
unexpected adverse events (within two working days). > > 4. Any event or new information 
that may affect the benefit/risk ratio of > > the proposal. > > > > Please > > observe the 
following: > > > > 1. Personal identifying data should only be collected when necessary for 
> > research; > > 2. The data collected should only be used for this proposal; > > 3. Data 
should be stored securely so that a few authorized users are > > permitted access to the 
database; > > 4. Secondary disclosure of personal identifiable data is not allowed. > > 5. 
Copy of the Consent Form should be kept in the Research Subject’s > > Medical Record and 
the consent process should be documented in the medical > > record. > > 6. Blood 
samples send overseas will not be used for any human genetic > > studies > > > > We > 
> wish you every success in your research endeavor. > > > > If > > you have any further 
questions feel free to contact me. 
Sincerely  
yours,  
Prof. Omar H. Kasule  
Chairman  Institutional Review Board--IRB.  
KingFahd Medical City, 
 Riyadh , KSA.  
Tel: + 966 1 288 9999 Ext. 7540 
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Appendix F 
 
List of presentations and publication 
 
 LSTM presentation, Marriott Hotel, Liverpool Friday 14th May 2010 
(poster) 
 LSTM PG Presentation Day May 2011 (poster) 
 University of Liverpool Presentation Day March 2011 (poster) 
 LSTM PG presentation 21 May 2012 Liverpool (talk) 
 British Infection Association 15th Annual Meeting Friday 25th May 2012 
London (poster) 
 Royal Society of Tropical Medicine and Hygiene Research in Progress 
2012 poster presentation, at School of Oriental and African Studies 
(SOAS) London Dec 2012 (poster). 
 LSTM postgraduate presentation day May 2013 (talk) 
 LSTM postgraduates presentation (May 2013 and 2014)) 
 Both project phases were published in HIV Medicine volume 15 April 
2014 and presented in third BHIVA and BASHH joint conference April 
2014. 
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